<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hydroxyurea (hydroxycarbamide) for sickle cell disease - Rankine-Mullings, AE - 2022 | Cochrane Library</title> <meta content="Hydroxyurea (hydroxycarbamide) for sickle cell disease - Rankine-Mullings, AE - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002202.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hydroxyurea (hydroxycarbamide) for sickle cell disease - Rankine-Mullings, AE - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002202.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002202.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Hydroxyurea (hydroxycarbamide) for sickle cell disease" name="citation_title"/> <meta content="Angela E Rankine-Mullings" name="citation_author"/> <meta content="Caribbean Institute for Health Research, University of the West Indies" name="citation_author_institution"/> <meta content="angela.rankinemullings@uwimona.edu.jm" name="citation_author_email"/> <meta content="Sarah J Nevitt" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD002202.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/09/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002202.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002202.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002202.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Acute Chest Syndrome [chemically induced, complications, drug therapy]; *Anemia, Sickle Cell [complications, drug therapy]; Antisickling Agents [adverse effects]; Hemoglobin, Sickle [therapeutic use]; Hydroxyurea [adverse effects]; Pain [drug therapy]; *Stroke [prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002202.pub3&amp;doi=10.1002/14651858.CD002202.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="0TJL4CWK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002202\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002202\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","ko","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002202.pub3",title:"Hydroxyurea (hydroxycarbamide) for sickle cell disease",firstPublishedDate:"Sep 1, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002202.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002202.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002202.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002202.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002202.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002202.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002202.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002202.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002202.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002202.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8691 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002202.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/supinfo/CD002202StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/supinfo/CD002202StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hydroxyurea (hydroxycarbamide) for sickle cell disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/information#CD002202-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Angela E Rankine-Mullings</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002202.pub3/information#CD002202-cr-0005">Sarah J Nevitt</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/information/en#CD002202-sec-0119">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 September 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002202.pub3">https://doi.org/10.1002/14651858.CD002202.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002202-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002202-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002202-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002202-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002202-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002202-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002202-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002202-abs-0001" lang="en"> <section id="CD002202-sec-0001"> <h3 class="title" id="CD002202-sec-0001">Background</h3> <p>Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. It is associated with lifelong morbidity and a reduced life expectancy. Hydroxyurea (hydroxycarbamide), an oral chemotherapeutic drug, ameliorates some of the clinical problems of SCD, in particular that of pain, by raising foetal haemoglobin (HbF). This is an update of a previously published Cochrane Review. </p> </section> <section id="CD002202-sec-0002"> <h3 class="title" id="CD002202-sec-0002">Objectives</h3> <p>The aims of this review are to determine through a review of randomised or quasi‐randomised studies whether the use of hydroxyurea in people with SCD alters the pattern of acute events, including pain; prevents, delays or reverses organ dysfunction; alters mortality and quality of life; or is associated with adverse effects. </p> <p>In addition, we hoped to assess whether the response to hydroxyurea in SCD varies with the type of SCD, age of the individual, duration and dose of treatment, and healthcare setting. </p> </section> <section id="CD002202-sec-0003"> <h3 class="title" id="CD002202-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Haemoglobinopathies Register, comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also searched online trial registries. The date of the most recent search was 17 February 2022. </p> </section> <section id="CD002202-sec-0004"> <h3 class="title" id="CD002202-sec-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised controlled trials (RCTs and quasi‐RCTs), of one month or longer, comparing hydroxyurea with placebo or standard therapy in people  with SCD. </p> </section> <section id="CD002202-sec-0005"> <h3 class="title" id="CD002202-sec-0005">Data collection and analysis</h3> <p>Authors independently assessed studies for inclusion, carried out data extraction, assessed the risk of bias and assessed the quality of the evidence using GRADE. </p> </section> <section id="CD002202-sec-0006"> <h3 class="title" id="CD002202-sec-0006">Main results</h3> <p>We included nine RCTs recruiting 1104 adults and children with SCD (haemoglobin SS (HbSS), haemoglobin SC (HbSC) or haemoglobin Sβºthalassaemia (HbSβºthal) genotypes). Studies lasted from six to 30 months. </p> <p>We judged the quality of the evidence for the first two comparisons below as moderate to low as the studies contributing to these comparisons were mostly large and well‐designed (and at low risk of bias); however, the evidence was limited and imprecise for some outcomes such as quality of life, deaths during the studies and adverse events, and the results are applicable only to individuals with HbSS and HbSβºthal genotypes. We judged the quality of the evidence for the third and fourth comparisons to be very low due to the limited number of participants, the lack of statistical power (both studies were terminated early with approximately only 20% of their target sample size recruited) and the lack of applicability to all age groups and genotypes. </p> <p>Hydroxyurea versus placebo </p> <p>Five studies (784 adults and children with HbSS or HbSβºthal) compared hydroxyurea to placebo; four recruited individuals with only severe disease and one recruited individuals with all disease severities. Hydroxyurea probably improves pain alteration (using measures such as pain crisis frequency, duration, intensity, hospital admissions and opoid use) and life‐threatening illness, but we found no difference in death rates (10 deaths occurred during the studies, but the rates did not differ by treatment group) (all moderate‐quality evidence). Hydroxyurea may improve measures of HbF (low‐quality evidence) and probably decreases neutrophil counts (moderate‐quality evidence). There were no consistent differences in terms of quality of life and adverse events (including serious or life‐threatening events) (low‐quality evidence). There were fewer occurrences of acute chest syndrome and blood transfusions in the hydroxyurea groups.  </p> <p>Hydroxyurea and phlebotomy versus transfusion and chelation </p> <p>Two studies (254 children with HbSS or HbSβºthal also with risk of primary or secondary stroke) contributed to this comparison. There were no consistent differences in terms of pain alteration, death or adverse events (low‐quality evidence) or life‐threatening illness (moderate‐quality evidence). Hydroxyurea with phlebotomy probably increased HbF and decreased neutrophil counts (moderate‐quality evidence), but there were more occurrences of acute chest syndrome and infections. Quality of life was not reported. In the primary prevention study, no strokes occurred in either treatment group but in the secondary prevention study, seven strokes occurred in the hydroxyurea and phlebotomy group (none in the transfusion and chelation group) and the study was terminated early.  </p> <p>Hydroxyurea versus observation </p> <p>One study (22 children with HbSS or HbSβºthal also at risk of stoke) compared hydroxyurea to observation. Pain alteration and quality of life were not reported. There were no differences in life‐threatening illness, death (no deaths reported in either group) or adverse events (very low‐quality evidence). We are uncertain if hydroxyurea improves HbF or decreases neutrophil counts (very low‐quality evidence). </p> <p>Treatment regimens with and without hydroxyurea </p> <p>One study (44 adults and children with HbSC) compared treatment regimens with and without hydroxyurea. Pain alteration, life‐threatening illness and quality of life were not reported. There were no differences in death rates (no deaths reported in either group), adverse events or neutrophil levels (very low‐quality evidence). We are uncertain if hydroxyurea improves HbF (very low‐quality evidence). </p> </section> <section id="CD002202-sec-0007"> <h3 class="title" id="CD002202-sec-0007">Authors' conclusions</h3> <p>There is evidence to suggest that hydroxyurea may be effective in decreasing the frequency of pain episodes and other acute complications in adults and children with sickle cell anaemia of HbSS or HbSβºthal genotypes and in preventing life‐threatening neurological events in those with sickle cell anaemia at risk of primary stroke by maintaining transcranial Doppler velocities. However, there is still insufficient evidence on the long‐term benefits of hydroxyurea, particularly with regard to preventing chronic complications of SCD, or recommending a standard dose or dose escalation to maximum tolerated dose. There is also insufficient evidence about the long‐term risks of hydroxyurea, including its effects on fertility and reproduction. Evidence is also limited on the effects of hydroxyurea on individuals with the HbSC genotype. Future studies should be designed to address such uncertainties. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002202-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002202-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002202-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002202-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002202-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002202-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002202-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002202-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002202-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002202-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002202-abs-0002" lang="en"> <h3>Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease</h3> <p><b>Review question</b> </p> <p>What is the effect of hydroxyurea on clinical outcomes (changes in pain crises, life‐threatening illnesses, survival, haemoglobin levels, quality of life and side effects) in people with sickle cell disease (SCD) of any genotype? </p> <p><b>Background</b> </p> <p>Sickle cell disease (SCD) is an inherited genetic disorder that creates problems with haemoglobin (the substance in red blood cells that carries oxygen around the body). The disease can be inherited in different ways; people can inherit two sickle genes (HbSS genotype) or they can inherit the sickle gene from one parent and a different haemoglobin gene such as haemoglobin C, resulting in the HbSC genotype, or a beta thalassaemia gene from the second parent, which gives rise to HbSβ+ or HbSβºthal.  </p> <p>In people with SCD the abnormal sickle haemoglobin forms long polymers (chains) within the red blood cells when they become de‐oxygenated. This damages the red blood cells and makes them stickier, leading to blockages and reduced blood flow, causing pain and organ damage. Foetal haemoglobin (HbF) stops these polymers forming in the sickle haemoglobin within the red blood cell. The drug hydroxyurea is used to increase HbF and can reduce the effects of the disease. </p> <p>This is an update of a previously published Cochrane Review.</p> <p><b>Search date</b> </p> <p>The evidence is current to 17 February 2022.</p> <p><b>Study characteristics</b> </p> <p>We included nine randomised studies (1104 adults and children with SCD (HbSS, HbSC or HbSβºthal genotypes)). Studies lasted from six to 30 months. </p> <p><b>Key results and quality of the evidence</b> </p> <p>In five studies, 784 adults and children with SCD were randomly selected to receive hydroxyurea or placebo. In two studies, 254 children with SCD, who were also at an increased risk of having a first or second stroke, were randomly selected to receive hydroxyurea and phlebotomy (collection of blood) or blood transfusion and chelation (administration of agents to remove excess iron from the body). These seven studies only recruited people with HbSS or HbSβºthal genotypes so the results do not apply to people with the HbSC genotype. </p> <p>There was moderate‐quality evidence from these seven studies that hydroxyurea may reduce the frequency of pain crises, may increase HbF and may decrease neutrophil (white blood cell) counts compared to the comparator treatment. We found no difference between people receiving hydroxyurea or other treatments in terms of quality of life, deaths during the studies and adverse effects (including serious and life‐threatening effects). However, there is less information about these outcomes in the studies, so the quality of this evidence is low. </p> <p>Two further studies were included in the review. In one study, 22 children with SCD, who were also at increased risk of having a stroke, were randomly selected to receive hydroxyurea or no treatment (observation only) and in one study 44 adults and children were randomly selected to receive treatments with or without adding hydroxyurea. In both studies we are unsure if hydroxyurea led to an increase in HbF compared to the comparator treatment. There were no deaths during the studies. There was no difference between people receiving hydroxyurea or other treatments in terms of pain crises and adverse effects (including serious or life‐threatening effects) and neither study measured quality of life. The quality of the evidence from these studies is very low, given the studies were very small and only recruited around 20% of the intended number of people, and the results do not apply to all people with SCD (different genotypes). </p> <p><b>Conclusions</b> </p> <p>The evidence shows that hydroxyurea is likely to be effective in the short term at decreasing the frequency of painful episodes and raising HbF levels in the blood in people with SCD. Hydroxyurea is also likely to be effective in preventing first strokes for those at an increased risk of stroke and does not seem to be associated with an increase in any adverse effects (including serious and life‐threatening effects). </p> <p>There is currently little evidence from the studies that we examined on whether hydroxyurea is beneficial over a long period of time, what the best dose to take is, or whether treatment causes any long‐term or serious side effects. More studies are needed to answer these questions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002202-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002202-sec-0106"></div> <h3 class="title" id="CD002202-sec-0107">Implications for practice</h3> <section id="CD002202-sec-0107"> <p>The initial randomised studies showed efficacy of hydroxyurea in decreasing pain episodes and other acute complications in adults and children with haemoglobin SS (HbSS) and haemoglobin Sβºthalassaemia (HbSβºthal) (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). This led to recommendations that hydroxyurea should be offered to this group of individuals. The evidence of similar efficacy in a group of infants not selected for severity is suggestive that all infants with sickle cell anaemia may benefit from hydroxyurea (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). This has led to recommendations that it should be offered to all children with sickle cell anaemia regardless of clinical severity (<a href="./references#CD002202-bbs2-0086" title="Evidence Based Management of Sickle Cell Disease. Expert Panel Report. National Institute of Health. 2014. www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/sickle-cell-disease-report%20020816.pdf (accessed 19 September 2016).">NIH 2014</a>), and has led to an increased use of hydroxyurea, particularly in children. There is still insufficient evidence on the long‐term benefits of hydroxyurea, particularly in the prevention of the chronic complications of sickle cell disease (SCD) and also insufficient evidence about the long‐term risks of hydroxyurea including its effects on fertility and reproduction. The efficacy of hydroxyurea in reducing the acute complications of the disease and potential risks of use should be discussed with all individuals with SCD and the families of children with SCD, allowing them to take an informed decision about its use. </p> <p>There is insufficient evidence to recommend its routine use in those individuals with genotypes other than sickle cell anaemia, but its potential benefits and risks of use should be discussed with those with a severe disease phenotype. </p> <p>Randomised comparisons of hydroxyurea and transfusion showed that hydroxyurea seems to be as effective as transfusion in preventing stroke in children with sickle cell anaemia and abnormal transcranial Doppler (TCD) velocities who have received at least one year of transfusion therapy and have no evidence of vasculopathy on magnetic resonance angiography (MRA). Hydroxyurea does not seem to be as effective as transfusion therapy in preventing stroke in children with sickle cell anaemia who have already experienced a stroke. Hydroxyurea should be offered to children in the former group (sickle cell anaemia, abnormal TCD velocity, normal MRA, received at least one year of transfusion therapy) as an alternative to long‐term transfusion therapy. </p> <p>There is insufficient evidence on whether to prescribe a standard dose or dose escalation to the maximum tolerated dose. All individuals treated with hydroxyurea should remain in long‐term follow‐up, which should include regular blood monitoring. </p> </section> <h3 class="title" id="CD002202-sec-0108">Implications for research</h3> <section id="CD002202-sec-0108"> <p>Many questions remain unanswered relating to the role of hydroxyurea in SCD (as discussed below). All of these questions need to be addressed by appropriately structured, randomised controlled studies. However, there is a need for international agreement on a baseline common data set that should be collected in such studies so that they can be analysed later using meta‐analysis techniques, as well as the need for standardised and validated measures for sickle painful crisis and quality of life in people with SCD. </p> <p>The continued long‐term follow‐up of the participants of the MSH and BABY HUG studies, with regular reporting of outcomes, is welcomed (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). Particular issues for future studies include: </p> <p> <ol id="CD002202-list-0011"> <li> <p>the impact of hydroxyurea on the chronic complications of SCD;</p> </li> <li> <p>the role of hydroxyurea in the management of specific hard to treat complications of SCD of all ages; </p> </li> <li> <p>study of the long‐term toxicity profile of hydroxyurea in SCD;</p> </li> <li> <p>the impact of low (15 mg/kg per day) or medium (20 mg/kg per day) hydroxyurea dosage in SCD versus dose escalation to maximum tolerated dose; </p> </li> <li> <p>the role of hydroxyurea in low‐ and middle‐income countries;</p> </li> <li> <p>the impact of hydroxyurea in genotypes other than HbSS.</p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002202-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002202-sec-0008"></div> <div class="table" id="CD002202-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea compared with placebo for sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Hydroxyurea compared with placebo for sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population</b>: adults and children with sickle cell disease </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: hydroxyurea </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain alteration<sup>a</sup> </b> </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All studies showed a significant advantage to hydroxyurea compared to placebo (different measures of pain alteration presented)<b><sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>784</p> <p>(5 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life‐threatening illness</b> </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Significantly fewer occurrences of ACS (3 studies) and transfusions (4 studies) on hydroxyurea compared to placebo. No significant differences in terms of stroke, hepatic or splenic sequestration (2 studies). </p> <p>In 1 study, 6 serious adverse events of bacteraemia/sepsis were reported in each of the hydroxyurea and placebo groups and 1 serious adverse event of anaemia was reported in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>759</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during the study</b> (all deaths) </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> <p>(3 to 36 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65 (0.19 to 2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>784</p> <p>(5 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was also no significant difference between groups in terms of deaths related to SCD. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of HbF</b> (%) </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant increase in HbF(%) in the hydroxyurea group compared to the placebo group in all studies (different measures presented).<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>784</p> <p>(5 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>e,f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of ANC</b> </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant decrease in ANC in the hydroxyurea group compared to the placebo group in all studies (different measures presented).<b><sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724</p> <p>(4 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b>: 'Health Status Survey', the 'Profile of Mood States' and the 'Ladder of Life' </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant difference in terms of any domain of any scale except for pain recall at 18 months (MD 0.70, 95% CI 0.11 to 1.29, P = 0.02).<b><sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 277</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>e,g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events or toxicity</b>: differences in rates of specific adverse events </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Significantly fewer events of hospitalisation, dactylitis, sepsis or bacteraemia, anaemia and gastroenteritis, and significantly more events of thrombocytopenia and ANC raised to between 500 to 1250 in the hydroxyurea compared to the placebo group. </p> <p>No significant differences between groups in terms of all other events.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>784</p> <p>(5 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>e,h</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study also reported statistically significantly fewer composite SCA‐related events (vaso‐occlusive pain crisis, dactylitis, acute chest syndrome, splenic sequestration or blood transfusion) in the hydroxyurea group compared to the placebo group: RR 0.66 (95% CI 0.51 to 0.84). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>The basis for the <b>assumed risk</b> is the event rate in the control group unless otherwise stated in the comments and footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ACS</b> : acute chest syndrome; <b>ANC</b> : absolute neutrophil counts; <b>CI</b> : confidence interval; <b>HbF</b> : foetal haemoglobin; <b>MD</b> : mean difference;<b>NA</b> : not applicable; <b>RR</b> : risk ratio; <b>SCA</b> : sickle cell anaemia; <b>SCD</b>: sickle cell disease. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b><sup>a</sup> </b>Pain alteration measured by mean annual pain crisis rate, time from initiation of treatment to first, second or third crisis, number of vaso‐occlusive crises, proportion of participants experiencing pain, proportion of hospitalisations for painful episodes. </p> <p><b><sup>b</sup> </b>One study of 25 participants is of a cross‐over design and participants are counted only once in this total (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). These results are not included in the meta‐analysis, but they provide relevant information and so contribute to the outcome. </p> <p><b><sup>c</sup> </b>Different measures presented ‐ change from baseline or post intervention measures ‐ therefore, data from all studies could not be pooled. </p> <p><b><sup>d</sup> </b>Within the study (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>, reported in <a href="./references#CD002202-bbs2-0050" title="BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59.">Ballas 2006</a>), to allow for multiple statistical testing of the quality of life domains, a P value &lt; 0.01 was considered significant. Therefore this result is not interpreted as significant in the study publication. </p> <p><b><sup>e</sup> </b>Downgraded once due to applicability: only individuals with HbSS or HbSβº‐thalassaemia genotypes were included therefore the results are not applicable to individuals with the HbSC genotype. </p> <p><b><sup>f</sup> </b>Downgraded once due to inconsistency: substantial heterogeneity present in the analyses of HbF (%) (I² &gt; 90%), indicating uncertainty in the pooled result due to the difference in the results of the individual studies. </p> <p><b><sup>g</sup> </b>Downgraded once due to imprecision/uncertainty: caution is encouraged regarding the interpretation of these results as not all participants contributed data to all quality of life domains and the study publication defines statistical significance differently to this review. </p> <p><b><sup>h</sup> </b>Downgraded once due to imprecision/uncertainty: caution is encouraged regarding the interpretation of these results due to the number of separate outcomes considered in analysis and the increased probability of a statistical type I error. Also, where data were pooled, the individual study proportions of some adverse events were very different. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002202-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea and phlebotomy compared to transfusion and chelation for people with sickle cell disease and an increased risk of stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Hydroxyurea and phlebotomy compared to transfusion and chelation for people with sickle cell disease and an increased risk of stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population</b>: adults and children with sickle cell disease and an increased risk of stroke </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: hydroxyurea and phlebotomy </p> <p><b>Comparison</b>: transfusion and chelation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Transfusion and chelation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea and phlebotomy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain alteration</b>: proportion experiencing serious VOC or sickle‐related pain events </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>718 per 1000</p> <p>(339 to 1000 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.37 (95% CI 1.59 to 7.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>d,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference between treatment groups in terms of all pain events (serious and non‐serious) in 1 study (RR 1.03, 95% CI 0.81 to 1.30). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life‐threatening illness</b> </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant difference between groups in life‐threatening neurological events, hepatobiliary disease and splenic sequestration; significantly more ACS and infections and infestations in the hydroxyurea and phlebotomy compared to the transfusion and chelation group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during the study</b> (all deaths) </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 death occurred in the transfusion and chelation group of 1 study<b><sup>a</sup> </b>. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 death occurred in the hydroxyurea and phlebotomy group of 1 study<b><sup>a</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99 (95% CI 0.06 to 15.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>d,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of HbF</b> (%) </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant increase in HbF(%) in the hydroxyurea and phlebotomy group compared to the transfusion and chelation group for both studies (different measures presented)<b><sup>b</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of ANC</b> </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant decrease in ANC in the hydroxyurea and phlebotomy group compared to the transfusion and chelation group for both studies (different measures presented)<b><sup>b</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported<b><sup>c</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events or toxicity</b>: differences in rates of specific adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a statistically significant difference in terms of immune disorders (more in transfusion and chelation group), reticulocytopenia, neutropenia and anaemia (more in hydroxyurea and phlebotomy group) in 1 study and the rate of adverse events was balanced across groups in the other study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>d,f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>The basis for the <b>assumed risk</b> is the event rate in the control group unless otherwise stated in the comments and footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ACS</b> : acute chest syndrome; <b>ANC</b> : absolute neutrophil counts; <b>CI</b> : confidence interval; <b>HbF</b> : foetal haemoglobin; <b>NA</b> : not applicable; <b>RR</b> : risk ratio; <b>VOC</b>: vaso‐occlusive crisis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b><sup>a</sup> </b> Absolute data presented for number of deaths as the confidence interval of the relative effect is very large due to the small number of events.<br/><b><sup>b</sup> </b> Different measures presented ‐ mean or median change from baseline ‐ therefore data from all studies could not be pooled.<br/><b><sup>c</sup> </b>Quality of life data were collected in <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>; to date, the primary results of this study have been published but not the quality of life data. When available, quality of life data will be included in an update of this review.<br/><b><sup>d</sup> </b> Downgraded once due to applicability: only children with HbSS or HbSβº‐thalassaemia were included therefore the results are not applicable to adults or individuals with the HbSC genotype.<br/><b><sup>e</sup> </b> Downgraded once due to imprecision: small number of events and large CI around the relative effect.<br/><b><sup>f</sup> </b>Downgraded once due to imprecision/uncertainty: caution is encouraged regarding the interpretation of these results due to the number of separate outcomes considered in analysis and the increased probability of a statistical type I error. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002202-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea compared with observation for people with sickle cell disease and an increased risk of stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Hydroxyurea compared with observation for people with sickle cell disease and an increased risk of stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population</b>: adults and children with sickle cell disease and an increased risk of stroke </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: hydroxyurea </p> <p><b>Comparison</b>: observation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Observation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain alteration</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life‐threatening illness</b> </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant differences between groups in terms of ACS, blood transfusions required or acute splenic sequestration. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during the study</b> </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of HbF</b> </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant increase in HbF in the hydroxyurea group compared to the observation group<b><sup>a</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of ANC</b> </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant decrease in ANC in the hydroxyurea group compared to the observation group<b><sup>a</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported<b><sup>b</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events or toxicity:</b> differences in rates of specific adverse events </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant differences between groups in terms of transient neutropenia, reticulocytopenia, parasite infestation, headache and dizziness. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>The basis for the <b>assumed risk</b> is the event rate in the control group unless otherwise stated in the comments and footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ACS</b> : acute chest syndrome; <b>ANC</b> : absolute neutrophil counts; <b>CI</b> : confidence interval; <b>HbF</b> : foetal haemoglobin; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Median values reported so data cannot be entered into analysis.<br/><sup>b</sup>Outcome was not collected or presented due to early termination of study.<br/><sup>c</sup>Downgraded twice due to serious imprecision: study terminated early with only 22 of target 100 participants recruited. Small number of participants included in final analyses, which are likely to be underpowered.<br/><sup>d</sup>Downgraded once due to applicability: only children with HbSS or HbSβº‐thalassaemia were included therefore the results are not applicable to adults or individuals with HbSC genotype. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002202-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea compared with no hydroxyurea for people with sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Hydroxyurea compared with no hydroxyurea for sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population</b>: adults and children with sickle cell disease </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: hydroxyurea </p> <p><b>Comparison</b>: no hydroxyurea </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No hydroxyurea</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain alteration</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life‐threatening illness</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during the study</b> </p> <p>Follow‐up: 11 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 44</p> <p>(1 study)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of HbF</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant increase in HbF in the hydroxyurea group compared to the no hydroxyurea group<sup>1</sup>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 44</p> <p>(1 study)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of ANC</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no significant difference in ANC between treatment groups<b><sup>a</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 44</p> <p>(1 study)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events or toxicity</b> </p> <p>Follow‐up: 11 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Vaso‐occlusive pain crises, headache/migraine, upper respiratory infection, skin rash diarrhoea and abdominal pain were the most common adverse events during the trial and these events were evenly distributed across treatment groups (not separated by group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 44</p> <p>(1 study)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>The basis for the <b>assumed risk</b> is the event rate in the control group unless otherwise stated in the comments and footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ANC</b> : absolute neutrophil counts; <b>CI</b> : confidence interval; <b>HbF</b> : foetal haemoglobin; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence.<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b><sup>a</sup> </b>Due to the factorial design of the study (22 participants randomised to a treatment arm including hydroxyurea and 22 randomised to a treatment arm without hydroxyurea), the results are not entered into analysis. All results of this trial are considered exploratory (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>).<br/><b><sup>b</sup> </b> Downgraded once due to indirectness: the factorial design of the study makes comparison of hydroxyurea to no hydroxyurea indirect.<br/><b><sup>c</sup> </b> Downgraded once due to imprecision and risk of bias: the study was terminated early with only 44 out of 188 participants recruited and outcome data are presented for only those who completed each follow‐up time.<br/><b><sup>d</sup> </b>Downgraded once due to applicability: participants with HbSC were included therefore the results are not applicable to individuals with HbSS or HbSβº‐thalassaemia genotypes. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002202-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002202-sec-0009"></div> <section id="CD002202-sec-0010"> <h3 class="title" id="CD002202-sec-0010">Description of the condition</h3> <p>Haemoglobinopathies, including sickle cell disease (SCD), are among the most common inherited disorders in the world. SCD affects people originating from sub‐Saharan Africa, Arab countries, the Mediterranean, the Indian subcontinent, the Caribbean and South America, as well as African‐Americans and descendants from immigrants from the above countries in other parts of the world. The genetic mutation gives carriers some advantage against malaria and for this reason has persisted. There is an estimated global birth rate of around 300,000 affected individuals per year, the majority of which are in Africa (<a href="./references#CD002202-bbs2-0089" title="PielFB , PatilAP , HowesRE , NyangiriOA , GethingPW , DewiM , et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet2013;381(9861):142-51.">Piel 2013</a>). There are an estimated 90,000 to 100,000 individuals with SCD in the USA and approximately 12,000 to 15,000 in the UK (<a href="./references#CD002202-bbs2-0057" title="BrousseauDC , A PanepintoJ , NimmerM , HoffmannRG . The number of people with sickle‐cell disease in the United States: national and state estimates. American Journal of Hematology2010;85(1):77-8.">Brousseau 2010</a>; <a href="./references#CD002202-bbs2-0072" title="HassellKL . Population estimates of sickle cell disease in the US. American Journal of Preventive Medicine2010;38(4):S512-21.">Hassell 2010</a>; <a href="./references#CD002202-bbs2-0085" title="National Institute of Clinical Excellence (NICE). Sickle cell acute painful episode: management of an acute painful sickle cell episode in hospital. www.nice.org.uk/guidance/cg143 (accessed 6 March 2017)2012.">NICE 2012</a>). </p> <p>Haemoglobin is responsible for transporting oxygen around the body packaged in red blood cells (RBCs). SCD is caused by the recessive inheritance of abnormal haemoglobins. People who inherit only one sickle gene and the normal gene for adult haemoglobin (HbA) are sickle cell carriers (sickle cell trait or AS) and are healthy. When people are homozygous, because they have inherited two sickle genes (SS), they have sickle cell anaemia, which is a variable clinical condition, with the vast majority of individuals suffering some pain attacks and a reduced life expectancy. Clinically significant SCD also arises when people inherit the sickle gene from one parent and another variant haemoglobin gene from the second parent such as haemoglobin C (SC) or a beta thalassaemia gene (Sβ+ or Sβ0). Under de‐oxygenated conditions, sickle haemoglobin polymerises, distorting the RBC into the classic 'sickle' shape. The clinical problems arise predominantly as a result of chronic anaemia and the blockage of small blood vessels, which stops oxygen delivery to the tissues, causing pain or organ damage, or both. </p> <p>The most frequent clinical problem is pain, which causes over 90% of acute hospital admissions (<a href="./references#CD002202-bbs2-0058" title="BrozovicM , DaviesSC . Management of sickle cell disease. Postgraduate Medical Journal1987;63:605-9.">Brozovic 1987</a>), and significant morbidity in the community (<a href="./references#CD002202-bbs2-0065" title="FuggleP , ShandPAX , GillLJ , DaviesSC . Pain, quality of life, and coping in sickle cell disease. Archives of Disease in Childhood1996;75:199-203.">Fuggle 1996</a>). Other acute complications include acute chest syndrome, stroke, splenic sequestration, priapism and an increased risk of infection. SCD is a multi‐organ disease with a high chronic disease burden, which increases with increasing age. The majority of individuals are anaemic, with haemoglobin levels of 60 g/L to 90 g/L in HbSS. Common chronic complications include chronic sickle lung damage, pulmonary hypertension, renal dysfunction, chronic bony damage (avascular necrosis), retinopathy and leg ulceration (<a href="./references#CD002202-bbs2-0075" title="HowardJ , TelferP . Sickle Cell Disease in Clinical Practice. London: Springer-Verlag, 2015.">Howard 2015</a>). </p> <p>Whilst the majority of persons affected used to die in childhood, and still do within parts of the developing world (<a href="./references#CD002202-bbs2-0059" title="ChakravortyS , WilliamsTN . Sickle cell disease: a neglected chronic disease of increasing global health importance. Archives of Disease in Childhood2015;100(1):48-53.">Chakravorty 2015</a>; <a href="./references#CD002202-bbs2-0069" title="GrosseSD , OdameI , AtrashHK , AmendahDD , PielFB , WilliamsTN . Sickle cell disease in Africa: a neglected cause of early childhood mortality. American Journal of Preventive Medicine2011;41(6):S398-405.">Grosse 2011</a>), death rates in children in higher‐income countries have fallen over the past decades and the majority of children (over 95%) now survive to adulthood (<a href="./references#CD002202-bbs2-0093" title="QuinnCT , RogersZR , McCavitTL , BuchananGR . Improved survival of children and adolescents with sickle cell disease. Blood2010;115:3447-52.">Quinn 2010</a>; <a href="./references#CD002202-bbs2-0103" title="TelferP ,  CoenP ,  ChakravortyS ,  WilkeyO ,  EvansJ ,  NewellH ,  et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica2007;92(7):905-12.">Telfer 2007</a>; <a href="./references#CD002202-bbs2-0106" title="van derPlasEM ,  van den TweelXW ,  GeskusRB ,  HeijboerH ,  BiemondBJ ,  PetersM ,  et al. Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening. British Journal of Haematology2011;155(1):106-10.">van der Plas 2011</a>). In fact, mortality among children younger than five years old, diagnosed at birth and treated at a comprehensive clinic, was no different to the general population (<a href="./references#CD002202-bbs2-0077" title="KingLG , Bortolusso-AliS , Cunningham-MyrieCA , ReidME . Impact of a Comprehensive Sickle Cell Center on early childhood mortality in a developing country: the Jamaican experience. Journal of Pediatrics2015;167(3):702-5.">King 2015</a>). Data from the USA reviewing national mortality data from 1979 to 2005 have confirmed this decrease in mortality in children, but showed an increased mortality rate in adults, with a median age of death of 42 years for women and 38 years for men (<a href="./references#CD002202-bbs2-0078" title="LanzkronS , CarrollCP , Haywood JrC . Mortality rates and age at death from sickle cell disease: US. 1979-2005. Public Health Reports2013;128:110-6.">Lanzkron 2013</a>). Earlier data from the USA showed a median survival for adults with HbSS in the USA of 42 years in men and 46 years in women and in HbSC of 60 years and 68 years, respectively (<a href="./references#CD002202-bbs2-0091" title="PlattOS , BrambillaDJ , RosseWF , MilnerPF , CastroO , SteinbergMH , et al. Mortality in sickle cell disease - life expectancy and risk factors for early death. New England Journal of Medicine1994;330:1639-43.">Platt 1994</a>). This contrasts with Jamaican figures, which show median survival for HbSS of 53 years for men and 58.5 years for women (<a href="./references#CD002202-bbs2-0110" title="Wierenga KJ,  HambletonIR ,  LewisNA . Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet2001;357(9257):680-3.">Wierenga 2001</a>), and recent single‐centre data from the UK have shown median survival of 67 years in people with HbSS and higher in those with HbSC (<a href="./references#CD002202-bbs2-0066" title="GardnerK , DouiriA , DrasarE , AllmanM , MwirigiA , AwogbadeM , et al. Survival in adults with sickle cell disease in a high income setting. Blood2016;128(10):1436-8.">Gardner 2016</a>). Data from the USA have also shown an increase in deaths following transition from paediatric to adult services (<a href="./references#CD002202-bbs2-0093" title="QuinnCT , RogersZR , McCavitTL , BuchananGR . Improved survival of children and adolescents with sickle cell disease. Blood2010;115:3447-52.">Quinn 2010</a>). Death is generally SCD‐related and is caused either by chronic organ failure consequent to the sickling process (e.g. renal failure, pulmonary hypertension, hepatic failure) (<a href="./references#CD002202-bbs2-0080" title="Manci EA,  CulbersonDE ,  YangYM ,  GardnerTM ,  PowellR ,  Haynes J Jr, et al. Causes of death in sickle cell disease: an autopsy study. British Journal of Haematology2003;123(2):359-65.">Manci 2003</a>), or as a result of an acute catastrophic event, such as stroke (<a href="./references#CD002202-bbs2-0092" title="PowarsD , OverturfG , TurnerE . Is there an increased risk of Haemophilus influenzae septicemia in sickle cell anaemia?Pediatrics1983;71:927-31.">Powars 1983</a>), acute sickle chest syndrome, splenic sequestration (<a href="./references#CD002202-bbs2-0095" title="RogersDW , ClarkeJM , CupidoreL , RamlalA , SparkeBR , SerjeantGR . Early deaths in Jamaican children with sickle cell disease. British Medical Journal1978;1:1515-6.">Rogers 1978</a>), sepsis (<a href="./references#CD002202-bbs2-0080" title="Manci EA,  CulbersonDE ,  YangYM ,  GardnerTM ,  PowellR ,  Haynes J Jr, et al. Causes of death in sickle cell disease: an autopsy study. British Journal of Haematology2003;123(2):359-65.">Manci 2003</a>; <a href="./references#CD002202-bbs2-0106" title="van derPlasEM ,  van den TweelXW ,  GeskusRB ,  HeijboerH ,  BiemondBJ ,  PetersM ,  et al. Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening. British Journal of Haematology2011;155(1):106-10.">van der Plas 2011</a>), or other complications (<a href="./references#CD002202-bbs2-0067" title="GrayA , AnionwuEN , DaviesSC , BrozovicM . Mortality in sickle cell disease: the experience of a British centre. Journal of Clinical Pathology1991;44:459-63.">Gray 1991</a>; <a href="./references#CD002202-bbs2-0078" title="LanzkronS , CarrollCP , Haywood JrC . Mortality rates and age at death from sickle cell disease: US. 1979-2005. Public Health Reports2013;128:110-6.">Lanzkron 2013</a>; <a href="./references#CD002202-bbs2-0088" title="PerronneV ,  Roberts-HarewoodM ,  BachirD ,  Roudot-ThoravalF ,  DelordJM ,  ThuretI , et al. Patterns of mortality in sickle cell disease in adults in France and England. Haematology Journal2002;3(1):56-60.">Perronne 2002</a>). These causes of death were still significant in a more recent study (<a href="./references#CD002202-bbs2-0096" title="SerjeantGR , ChinN , AsnaniMR , SerjeantBE , MasonKP , HambletonIR , et al. Causes of death and early life determinants of survival in homozygous sickle cell disease: the Jamaican cohort study from birth. PLOS One2018;13(3):e0192710.">Serjeant 2018</a>). The UK National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report reviewed UK mortality data over 48 months and found six child and 40 adult deaths. One child death was due to pneumococcal sepsis and two were due to subarachnoid haemorrhage. In adults the main causes of death were stroke, multi‐organ failure, acute chest syndrome, renal failure and non‐sickle causes (<a href="./references#CD002202-bbs2-0084" title="NCEPOD. ‘Sickle: A sickle crisis?’ A report of the national confidential enquiry into patient outcome and death. 2008. www.ncepod.org.uk.2008sc.html (accessed 19 September 2016).">NCEPOD 2008</a>). </p> <p>Improvements in paediatric outcomes are related to the introduction of neonatal screening, early enrolment in comprehensive paediatric care, penicillin prophylaxis, vaccination to decrease life‐threatening infection and primary stroke prevention with transcranial Doppler screening. The risk of  vaso‐occlusive crisis and acute chest syndrome among children presenting with these acute events was less among those who were registered early in specialist care (<a href="./references#CD002202-bbs2-0094" title="Rankine-MullingsAE , LoganTM , King L-G, Cunningham-MyrieCA , ScottCR , Knight-MaddenJM . The risk of acute events among patients with sickle cell disease in relation to early or late initiation of care at a specialist center: evidence from a retrospective cohort study. BMC Pediatrics2020;20(1):373.">Rankine‐Mullings 2020</a>). In adults, treatment has relied on the avoidance of factors that precipitate crisis (including dehydration, infection and cold), and symptomatic treatment of the acute painful episodes (<a href="./references#CD002202-bbs2-0061" title="DaviesSC , Roberts-HarewoodM . Blood transfusion in sickle cell disease. Blood Reviews1997;11:57-71.">Davies 1997a</a>; <a href="./references#CD002202-bbs2-0062" title="DaviesSC , OniL . The management of patients with sickle cell disease. BMJ1997;315:656-60.">Davies 1997b</a>; <a href="./references#CD002202-bbs2-0097" title="SteinbergMH . The management of sickle cell disease. New England Journal of Medicine1999;340:1021-30.">Steinberg 1999</a>; <a href="./references#CD002202-bbs2-0101" title="LeeMT , PiomelliS , GrangerS , MillerST , HarknessS , BrambillaDJ , et al. Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood2006;108(3):847-52.">STOP 2006</a>). Hydroxyurea is currently the only licensed treatment for SCD. Blood transfusion is often required and may be used to treat acute complications or in the long term to treat or prevent disease complications. Haemopoietic stem cell transplantation is the only currently available curative treatment option and is offered to children with severe disease phenotype and a human leukocyte antigen (HLA)‐matched sibling donor. Other donor transplant options and adult transplant are currently only available in the context of clinical trials. Gene therapy offers another potential curative treatment and is currently being investigated in clinical trials.  </p> </section> <section id="CD002202-sec-0011"> <h3 class="title" id="CD002202-sec-0011">Description of the intervention</h3> <p>Hydroxyurea (also known as hydroxycarbamide) is an anti‐neoplastic oral drug and an inhibitor of ribonucleotide reductase (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). The drug has been shown to have many beneficial effects for treating SCD, including increasing foetal haemoglobin (HbF) concentration in RBCs, improving nitric oxide metabolism, reducing red cell‐endothelial interaction and erythrocyte density (<a href="./references#CD002202-bbs2-0109" title="WareRE . How I use hydroxyurea to treat young patients with sickle cell anemia. Blood2010;115:5300-11.">Ware 2010</a>). Such disease‐modifying effects have been shown to decrease episodes of pain, acute chest syndrome, hospital admissions and the need for transfusions among people with SCD (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0102" title="StrouseJJ , LanzkronS , BeachMC , HaywoodC , ParkH , WitkopC , et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics2008;122(6):1332-43.">Strouse 2008</a>). However, monitoring of the person's blood count and other parameters are required to reduce the risk of toxicity. There are recognised, but mostly reversible, side effects of hydroxyurea, such as low neutrophil count, low platelet count, anaemia, rash, headache and occasionally nausea. Furthermore, it may have teratogenic effects and may have an effect on male fertility (<a href="./references#CD002202-bbs2-0102" title="StrouseJJ , LanzkronS , BeachMC , HaywoodC , ParkH , WitkopC , et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics2008;122(6):1332-43.">Strouse 2008</a>; <a href="./references#CD002202-bbs2-0111" title="ZimmermanSA , SchultzWH , DavisJS , PickensCV , MortierNA , HowardTA , et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood2004;103(6):2039-45.">Zimmerman 2004</a>). Long‐term or serious adverse effects (or both) of hydroxyurea are rare (<a href="./references#CD002202-bbs2-0099" title="SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8.">Steinberg 2010</a>; <a href="./references#CD002202-bbs2-0102" title="StrouseJJ , LanzkronS , BeachMC , HaywoodC , ParkH , WitkopC , et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics2008;122(6):1332-43.">Strouse 2008</a>), and observational data suggest a survival advantage for those treated with hydroxyurea (<a href="./references#CD002202-bbs2-0099" title="SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8.">Steinberg 2010</a>; <a href="./references#CD002202-bbs2-0108" title="VoskaridouE , ChristoulasD , BilalisA , PlataE , VarvagiannisK , StamatopoulosG , et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-centre trial (LaSHS). Blood2010;115:2354-63.">Voskaridou 2010</a>). </p> </section> <section id="CD002202-sec-0012"> <h3 class="title" id="CD002202-sec-0012">How the intervention might work</h3> <p>It has long been recognised that raised HbF levels can ameliorate the clinical effects of SCD (<a href="./references#CD002202-bbs2-0087" title="PerrineRP , PembreyME , JohnP , PerrineS , ShoupF . Natural history of sickle cell anaemia in Saudi Arabs: a study of 270 subjects. Annals of Internal Medicine1978;88:1-6.">Perrine 1978</a>; <a href="./references#CD002202-bbs2-0091" title="PlattOS , BrambillaDJ , RosseWF , MilnerPF , CastroO , SteinbergMH , et al. Mortality in sickle cell disease - life expectancy and risk factors for early death. New England Journal of Medicine1994;330:1639-43.">Platt 1994</a>). HbF levels are high at birth and decrease over the first year of life and hence clinical manifestations are often delayed until the HbF levels decrease. In addition, individuals who inherit high levels of HbF display a milder disease phenotype. This is because the HbF interferes with the polymer formation of the sickle haemoglobin within the RBC. This polymerisation is the underlying pathology in SCD. The more HbF there is, the greater the inhibition. Hydroxyurea was first shown to raise HbF levels in SCD in the 1980s (<a href="./references#CD002202-bbs2-0090" title="PlattOS , OrkinSH , DoverGJ , BeardsleyGP , MillerB , NathanDG . Hydroxyurea increases fetal hemoglobin production in sickle cell anemia. Transactions of the Association of American Physicians1984;97:268-74.">Platt 1984</a>; <a href="./references#CD002202-bbs2-0107" title="VeithR , GalanelloR , PapayannopoulouT , StamatoyannopoulosG . Stimulation of F-cell production in patients with sickle cell anaemia treated with cytarabine or hydroxyurea. New England Journal of Medicine1985;313:1571-5.">Veith 1985</a>). Its intermittent toxicity on the bone marrow leads to a stress response and enhanced erythropoiesis and levels of HbF. In addition to its effects on SCD via HbF enhancement, hydroxyurea also improves blood flow and reduces vaso‐occlusion via other mechanisms, including decrease of adhesion molecules and stimulation of nitric oxide production (<a href="./references#CD002202-bbs2-0068" title="GreenNS , BarralS . Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatric Research2013;75(1-2):196-204.">Green 2014</a>). </p> </section> <section id="CD002202-sec-0013"> <h3 class="title" id="CD002202-sec-0013">Why it is important to do this review</h3> <p>It is important to examine as a whole the body of work relating to the use of hydroxyurea in SCD, to evaluate the drug's effectiveness and tolerability in adults and children, and in the different types of SCD, the dosage regimens and whether the setting appears to influence the outcome, i.e. high‐income versus low‐ and middle‐income countries. We aim to review any evidence relating to the impact of hydroxyurea on the natural history of SCD and life expectancy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002202-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002202-sec-0014"></div> <p>The aims of this review are to determine through a review of randomised or quasi‐randomised studies whether the use of hydroxyurea in people with SCD: </p> <p> <ol id="CD002202-list-0001"> <li> <p>alters the pattern of acute events, including pain;</p> </li> <li> <p>prevents, delays or reverses organ dysfunction;</p> </li> <li> <p>alters mortality and quality of life;</p> </li> <li> <p>is associated with adverse effects.</p> </li> </ol> </p> <p>In addition, we hoped to assess whether the response to hydroxyurea in SCD varies with type of SCD, age of the individual, duration and dose of treatment and healthcare setting. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002202-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002202-sec-0015"></div> <section id="CD002202-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002202-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised or quasi‐randomised studies, irrespective of language. We included studies with quasi‐randomised methods, such as alternation, if there was sufficient evidence that the treatment and control groups were similar at baseline. </p> </section> <section id="CD002202-sec-0018"> <h4 class="title">Types of participants</h4> <p>This review is limited to studies of hydroxyurea in SCD only. In order to fully quantify the potential harm and toxicity of this drug, a further review may need to be undertaken in all patient groups treated with hydroxyurea. </p> <p>People of any age with SCD genotype (SS, Sβ₀, SC, Sβ+) proven by electrophoresis and sickle solubility test, with family studies or DNA tests as appropriate. </p> </section> <section id="CD002202-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Hydroxyurea, in any formulation at all doses, compared to either placebo or standard treatment (no placebo) for periods of one month or longer. </p> </section> <section id="CD002202-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We aimed to assess each of the following outcomes at three, six, 12 months and annually thereafter. </p> <section id="CD002202-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002202-list-0002"> <li> <p>Pain alteration</p> <ol id="CD002202-list-0003"> <li> <p>Frequency, duration, severity measured on self‐reported patient scales</p> </li> <li> <p>Health service utilisation (e.g. inpatient days, outpatient or accident and emergency department visits) </p> </li> <li> <p>Opioid use</p> </li> </ol> </li> <li> <p>Life‐threatening illness (e.g. acute chest syndrome, stroke and acute splenic sequestration)*</p> </li> <li> <p>Death during the study</p> </li> </ol> </p> <p>* In the 2017 update of the review, serious adverse events reported in included studies (whether treatment‐related or not) were included under the definition of 'Life‐threatening illness'. </p> </section> <section id="CD002202-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD002202-list-0004"> <li> <p>Measures of HbF (or F cells) and neutrophil counts</p> </li> <li> <p>Other surrogate markers of response (e.g. haemoglobin, mean cell volume, platelet count and growth) </p> </li> <li> <p>Quality of life, time lost to school or employment, integration into society, scales recording feeling of well‐being and global function (e.g. Karnofsky) </p> </li> <li> <p>Measures of organ damage (e.g. spleen (pitted red cells), chronic sickle lung disease (transfer factor), liver, chronic renal failure (creatinine), priapism, leg ulcer, neurological damage (e.g. intelligence quotient (IQ))) </p> </li> <li> <p>Any reported adverse effects or toxicity</p> </li> </ol> </p> </section> </section> </section> <section id="CD002202-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD002202-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Relevant studies were identified from the Cochrane Cystic Fibrosis and Genetic Disorders Haemoglobinopathies Trials Register using the terms: (sickle cell OR (haemoglobinopathies AND general)):kw AND hydroxyurea:kw </p> <p>The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (Clinical Trials) (updated each new issue of the Cochrane Library) and weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Public Health Agency Annual Scientific Meeting (formerly the Caribbean Health Research Council Meeting); and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>The date of the most recent search of the Haemoglobinopathies Trials Register was 17 February 2022. </p> <p>We also searched the following trials registries on 11 May 2022:</p> <p> <ol id="CD002202-list-0005"> <li> <p><a href="http://www.clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> using the following search terms: hydroxyurea AND sickle; </p> </li> <li> <p><a href="http://apps.who.int/trialsearch" target="_blank">WHO International Clinical Trials Registry Platform (ICTRP)</a> using the following search terms: hydroxyurea AND sickle. </p> </li> </ol> </p> </section> <section id="CD002202-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We assessed the bibliographic references of all retrieved studies and reviews for additional reports of studies. </p> </section> </section> <section id="CD002202-sec-0026"> <h3 class="title" id="CD002202-sec-0026">Data collection and analysis</h3> <section id="CD002202-sec-0027"> <h4 class="title">Selection of studies</h4> <p>For the initial review, two authors (SCD and AO) independently applied the inclusion criteria. For the updates to this review, two authors (AJ and SJN; and for the 2022 update ARM and SJN) performed this task. There were no discrepancies between the authors' assessments. </p> </section> <section id="CD002202-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For the initial review, two authors (SCD and AO) independently extracted the data. For the updates of the review, two authors (AJ and SJN; and for the 2022 update ARM and SJN) performed this task. There were no discrepancies between the authors' assessments. </p> <p>We intended to group outcome data into those measured at three, six, 12 months and annually thereafter. When outcome data were recorded at other time periods, we considered examining these as well. </p> </section> <section id="CD002202-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For the initial review, two authors (SCD and AO) independently assessed the methodological quality of each trial using the Cochrane risk of bias tool (<a href="./references#CD002202-bbs2-0074" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). For the updates of the review, two authors (AJ and SJN; and for the 2022 update ARM and SJN) performed these tasks. The authors assessed the risks of bias in the methods of concealment and generation of randomisation sequence, blinding, whether data were available to analyse on intention‐to‐treat basis and whether all randomised participants were included in the analysis. There were no discrepancies between the authors' assessments. </p> </section> <section id="CD002202-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, we aimed to calculate a pooled estimate of the treatment effect for each outcome across studies (the risk of an outcome among treatment‐allocated participants to the corresponding risk among controls). For each study, we calculated risk ratios (RR) with 95% confidence intervals (CI) for all important, dichotomous outcomes. We present RR in preference to odds ratios (OR), as ORs give an inflated impression of the size of effect where event rates are high, as is the case of these studies. For the continuous outcomes, we aimed to calculate a pooled estimate of treatment effect, using the mean difference (MD). </p> </section> <section id="CD002202-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>One study was cross‐over in design (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). We planned to analyse data from this study using the approach recommended by Elbourne (<a href="./references#CD002202-bbs2-0063" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>), extracting and analysing data from paired analyses if possible. </p> <p>Outcomes were measured at different time points throughout the course of the Multicenter Study of Hydroxyurea (MSH) study. Methods to analyse aggregate longitudinal data if individual patient data are not available are discussed by Jones (<a href="./references#CD002202-bbs2-0076" title="JonesAP , RileyRD , WilliamsonPR , WhiteheadA . Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clinical Trials2009;6(1):16-27.">Jones 2009</a>); however, the data presented did not allow the use of these methods, therefore we have carried out analysis at each individual time point reported. </p> </section> <section id="CD002202-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>In order to allow an intention‐to‐treat analysis, we collected data by allocated treatment groups, irrespective of compliance, later exclusion (regardless of cause) or loss to follow‐up. </p> </section> <section id="CD002202-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by reviewing the differences across trials in the characteristics of recruited participants and treatment protocols. We assessed statistical heterogeneity using a Chi² test for heterogeneity. We assessed heterogeneity using the Q test (P &lt; 0.10 for significance) and the I² statistic (greater than 50% indicating considerable heterogeneity; <a href="./references#CD002202-bbs2-0073" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327:557-60.">Higgins 2003</a>), and visually by inspecting forest plots. </p> </section> <section id="CD002202-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to reduce the risk of reporting bias by searching resources systematically for unpublished as well as published studies. Where available, we compared the results of every included study with its protocol and the methods section of the final publication to assess the risk of selective reporting. </p> <p>If we find a sufficient number of studies (at least 10) for future updates, we will try to identify any publication bias by generating a funnel plot. If the funnel plot is asymmetrical we will explore reasons for this including reasons other than publication bias. </p> </section> <section id="CD002202-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We analysed data using the fixed‐effect model. If we had found considerable heterogeneity (I² statistic &gt; 50%) then we would have examined it using a random‐effects model and subgroup analyses. </p> </section> <section id="CD002202-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to perform subgroup analyses according to age (infant, child, adult etc), type of SCD (SS, Sβ₀, SC, Sβ+), dosage regimen (study‐specific) and setting (community, hospital, outpatient, etc.), however the available data did not allow for these analyses. </p> </section> <section id="CD002202-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned a sensitivity analysis based on the methodological quality of the studies, including and excluding quasi‐randomised studies. However, no quasi‐randomised studies were included in the review, therefore we performed no sensitivity analyses. </p> </section> <section id="CD002202-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>In a post hoc change from the protocol, we have presented four summary of findings tables, one for each comparison of the review (<a href="./full#CD002202-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD002202-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002202-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD002202-tbl-0004">summary of findings Table 4</a>). </p> <p> <ol id="CD002202-list-0006"> <li> <p>Hydroxyurea compared to placebo for participants with SCD</p> </li> <li> <p>Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </p> </li> <li> <p>Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </p> </li> <li> <p>Hydroxyurea compared to no hydroxyurea for participants with SCD</p> </li> </ol> </p> <p>The following outcomes were reported in all tables (chosen based on their relevance to clinicians and consumers): pain alteration; life‐threatening illnesses; deaths during the study; measures of HbF or F cells and neutrophil counts; quality of life; and adverse events or toxicity. </p> <p>We determined the quality of the evidence using the GRADE approach and downgraded the evidence in the presence of a high risk of bias in at least one study, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results or high probability of publication bias. We downgraded the evidence by one level if we considered the limitation to be serious and by two levels if very serious. </p> <p>For clarity in the tables, where outcomes were presented using different measures (e.g. pain alteration) or different domains (e.g. quality of life or adverse events), a general statement is made in the table regarding the summary of findings for these outcomes and the evidence is graded based on all of the measures or subdomains combined. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002202-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002202-sec-0039"></div> <section id="CD002202-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD002202-sec-0041"> <h4 class="title">Results of the search</h4> <p>Please refer to the published notes section for details of previous searches (<a href="#CD002202-sec-0124">Published notes</a>).  </p> <p>Searches conducted for the 2022 update identified 312 references. Following removal of 88 duplicates, the authors screened 224 references and excluded 127 clearly irrelevant references based on title and abstract. We added multiple references to already included and excluded studies.  </p> <p>In total, we have included nine studies (reported in 156 references) in the review (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). We have excluded 35 studies (69 references), and listed two studies, each with single reference, as ongoing (<a href="./references#CD002202-bbs2-0045" title="NCT01389024. Hydroxyurea to prevent brain injury in sickle cell disease (HUPrevent). www.clinicaltrials.gov/ct2/show/NCT01389024 (first received 30 June 2011). ">NCT01389024</a>; <a href="./references#CD002202-bbs2-0046" title="NCT03806452. SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial). www.clinicaltrials.gov/ct2/show/NCT03806452 (first received 16 January 2019). ">NCT03806452</a>). </p> <p>Please see <a href="#CD002202-fig-0001">Figure 1</a> for the PRISMA study flow diagram containing further details. </p> <div class="figure" id="CD002202-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for this review (2022)" data-id="CD002202-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for this review (2022)</p> </div> </div> </div> </section> <section id="CD002202-sec-0042"> <h4 class="title">Included studies</h4> <p>We have included nine studies with a total of 1104 children and adults (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). </p> <section id="CD002202-sec-0043"> <h5 class="title">Hydroxyurea compared to placebo for participants with SCD</h5> <p>This comparison includes five studies with 784 randomised participants (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>The BABY HUG study was a multicentre, randomised, controlled study conducted in 13 centres in the USA (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). It enrolled children aged nine months to 18 months who had HbSS or HbSβºthal. Participants received liquid hydroxyurea (20 mg/kg per day) or matching placebo for two years administered as an oral syrup. A total of 193 children were randomised: 96 were randomised to the hydroxyurea group and 97 were randomised to the placebo group. Participants, caregivers and medical co‐ordinating centre staff were masked to treatment allocation and an unmasked "primary end‐point person" monitored laboratory values and assisted in clinical management. </p> <p>The Belgian Study was conduced in a single centre in Belgium and involved 25 children and young adults with HbSS genotype with the aim of reviewing the impact on pain events, hospitalisation and also on HbF reactivation (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). This randomised study was also placebo‐controlled and blinded to the participant but not to the caring physician. In addition, this was a cross‐over study which started at 20 mg/kg per day and, unless cytopenia developed, this was raised to a maximum of 25 mg/kg per day. Participants were randomised to either hydroxyurea or placebo for the initial six months and then crossed over to the other arm. There was no statistically significant period or carry‐over effect present for the outcomes of the number of hospitalisations and the number of days in hospital (period and carry‐over effects assessed by the Wilcoxon Rank Sum test). </p> <p>The Jain study was a double‐blind (participants, personnel and outcome assessors) randomised controlled study conducted in a tertiary hospital in Nagpur City, India (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>). The study enrolled children with sickle cell anaemia (proportion with each genotype not stated) between the ages of five and 18 years with three or more blood transfusions or vaso‐occlusive crises requiring hospitalisation per year despite high HbF. A total of 60 participants were randomised: 30 to hydroxyurea (fixed dose 10 mg/mg per day) and 30 to a matched placebo for 18 months. </p> <p>The MSH study was a multicentre, North American, randomised and double‐blind study, which compared hydroxyurea to placebo over two years in adults with sickle cell anaemia (SS genotype only) with the objective of reducing the frequency pain crises (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). A total of 299 participants were randomised: 152 to hydroxyurea and 147 to matching placebo. Hydroxyurea was started at a low dose (15 mg/kg per day) and increased at 12‐weekly intervals by 5 mg/kg per day until mild bone marrow depression, as judged by either neutropenia or thrombocytopenia; at that point the treatment was stopped (as reported for the MSH study) (<a href="./references#CD002202-bbs2-0070" title="HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the Multicentre Study of Hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S.">Handy 1996</a>). Once the blood count had recovered, treatment was restarted at 2.5 mg/kg per day less than the toxic dose. The study was therefore aiming for the maximum tolerated dose (MTD) for each individual within the study. The study was blinded and the study centre recorded and held the mean corpuscular volume (MCV) and HbF levels, which were not looked at by the caring physicians as the MCV and HbF levels rise in most people with SS taking hydroxyurea. As a result of the beneficial effects observed in terms of the primary pain outcome, as reported for the MSH study (<a href="./references#CD002202-bbs2-0052" title="BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in Sickle Cell Anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17:67S.">Barton 1996</a>), the study was stopped by the National Heart, Lung and Blood Institute of the USA at a mean follow‐up of 21 months, before the planned 24 months of treatment had been completed for all participants (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). Long‐term follow‐up continued for the study sample, with all participants offered treatment with hydroxyurea. </p> <p>The NOHARM study was a double‐blind (participants, personnel and outcome assessors), randomised, placebo‐controlled study conducted within a sickle cell clinic in Kampala, Uganda (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). The study was conducted in children between the ages of one and four years with documented HbSS and living in an area of meso‐endemic malaria transmission. A total of 208 children were randomised, 104 to either hydroxyurea (20 ± 2.5 mg/kg/day) or matched placebo. One randomised participant in the placebo group was later found to be ineligible so was excluded from the study and 207 children were included in the analyses. </p> </section> <section id="CD002202-sec-0044"> <h5 class="title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </h5> <p>This comparison includes two studies with 254 randomised participants (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). </p> <p>The SWiTCH study was a non‐inferiority study, comparing hydroxyurea and phlebotomy to standard treatment (transfusion and chelation) using a composite endpoint including secondary stroke prevention and improved management of iron overload. It included children with sickle cell anaemia (HbSS and HbSβºthal, HbSO<sup>Arab</sup>) and previous stroke, who had been receiving chronic transfusions for at least 18 months (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). It was conducted in 26 SCD centres across the USA and a total of 134 children were randomised (67 to the standard treatment and 67 to the hydroxyurea and phlebotomy group). Participants randomised to hydroxyurea and phlebotomy commenced hydroxyurea at 20 mg/kg with escalation to MTD (defined by dose causing mild myelosuppression). Transfusion continued for four to nine months during hydroxyurea dose escalation. Once MTD was reached and transfusion stopped, phlebotomy of 10 mL/kg monthly was performed, if haemoglobin was sufficient. </p> <p>The TWiTCH study was a multicentre, phase III, randomised, open‐label (partially masked) non‐inferiority study conducted at 26 paediatric hospitals and health centres in the USA and Canada (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). Eligible participants were children aged four to 16 years with sickle cell anaemia (HbSS, HbSβºthal, HbSO<sup>Arab</sup>) and abnormal transcranial Doppler (TCD) ultrasound velocities (≥ 200 cm per second) if they had received 12 months of chronic transfusions. A total of 121 participants were randomised: 60 to hydroxyurea starting at 20 mg/kg per day escalated to the MTD compared to standard treatment (transfusions) for 24 months. Children randomised to the standard treatment group received their usual chelation therapy or deferasirox to manage iron overload. Children randomised to the hydroxyurea group continued to receive transfusions until hydroxyurea was escalated to the MTD and following the discontinuation of transfusions, children received serial phlebotomy to manage iron overload. The primary aim of the study was to establish whether treatment with hydroxyurea could prevent primary stroke in these children. The study was terminated at the first interim analysis when non‐inferiority was demonstrated; the target sample size had been recruited by this point. </p> </section> <section id="CD002202-sec-0045"> <h5 class="title">Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </h5> <p>This comparison includes a single study, the SCATE (Sparing Conversion to Abnormal Transcranial doppler Elevation) study, which was a phase III multicentre, randomised, controlled study conducted in three centres in the USA, Jamaica and Brazil (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). The study was conducted in children with sickle cell anaemia (SS, Sβº, HbSO<sup>Arab</sup>, HbSD), HbSS or HbSβºthal and conditional TCD ultrasound velocities (170 cm to 199 cm per second). A total of 22 participants were randomised: 11 to hydroxyurea at 20 mg/kg with escalation to maximum dose of 35 mg/kg and 11 to standard treatment (observation). The primary aim of the study was to establish whether treatment with hydroxyurea could prevent conversion from conditional to abnormal time averaged mean velocity (TAMV) and subsequent stroke in these children. The planned length of follow‐up was 30 months but the study was terminated after 15 months of follow‐up due to slow participant accrual and the unlikelihood of meeting the trial recruitment target (100) and the primary endpoint. </p> </section> <section id="CD002202-sec-0046"> <h5 class="title">Hydroxyurea compared to no hydroxyurea for participants with SCD</h5> <p>This comparison includes a single randomised, multicentre, phase II, double‐blind, placebo‐controlled study with a 2x2 factorial design (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). Eligible participants were five years of age or older with HbSC and at least one vaso‐occlusive event in the previous 12 months (but none in the four weeks prior to study entry). A total of 44 participants were randomised equally across four treatment groups for 44 weeks: hydroxyurea (20 mg/kg per day) and magnesium (0.6 mmol/kg per day in two doses), hydroxyurea (20 mg/kg per day) and placebo, placebo and magnesium (0.6 mmol/kg per day in two doses), placebo and placebo. The study was not designed to measure efficacy and only measured laboratory measures. The study was terminated early due to low enrolment after 44 participants had been randomised (target 188). </p> </section> </section> <section id="CD002202-sec-0047"> <h4 class="title">Excluded studies</h4> <p>A total of 35 studies were excluded from the review.</p> <p>Nine studies were not randomised (<a href="./references#CD002202-bbs2-0012" title="Al-NoodHA , Al-KhawlaniMM , Al-AkwaA . Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin2011;35(1):13-21. ">Al‐Nood 2011</a>; <a href="./references#CD002202-bbs2-0017" title="deOliveiraEAM , deAssis BoyK , SantosAPP , da Silva MachadoC , Velloso-RodriguesC , GerheimPSAS , et al. Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease. Einstein (Sao Paulo)2019;17(4):eAO4742. [CENTRAL: CN-02174286] [CFGD REGISTER: SC394] ">de Oliveira 2019</a>; <a href="./references#CD002202-bbs2-0023" title="NCT00000602. Pediatric hydroxyurea in sickle cell anemia (PED HUG). www.ClinicalTrials.gov/show/NCT00000602 (first received 28 October 1999). ">NCT00000602</a>; <a href="./references#CD002202-bbs2-0024" title="NCT00001197. Hydroxyurea for the treatment of patients with sickle cell anemia. www.ClinicalTrials.gov/show/NCT00001197 (first received 4 November 1999). ">NCT00001197</a>; <a href="./references#CD002202-bbs2-0027" title="NCT00890396. Long- term effects of hydroxyurea in children with sickle cell anemia (the BABY HUG follow-up study). clinicaltrials.gov/ct2/show/NCT00890396 (first received 29 April 2009). ">NCT00890396</a>; <a href="./references#CD002202-bbs2-0036" title="PushiA . Hydroxyurea ameliorates importantly the clinical course of sickle cell disease reducing the frequency of painful crises. Hematology Journal2000;1(Suppl 1):34. [ABSTRACT NO.: 130] [CFGD REGISTER: SC282] ">Pushi 2000</a>; <a href="./references#CD002202-bbs2-0037" title="Silva-PintoAC , CarraraRC , OliveiraVC , PalmaPV , CamposAD , ZagoMA , et al. Hydroxyurea treatment of sickle cell diseases causes megaloblastic transformation of the bone marrow that is responsible for the increase of the mean corpuscular volume. Haematologica2007;Suppl 1:298. [CFGD REGISTER: SC201] ">Silva‐Pinto 2007</a>; <a href="./references#CD002202-bbs2-0038" title="Silva-PintoAC , Dias-CarlosC , Saldanha-AraujoF , FerreiraFI , PalmaPV , AraujoAG , et al. Hydroxycarbamide modulates components involved in the regulation of adenosine levels in blood cells from sickle-cell anemia patients. Annals of Hematology2014;93(9):1457-65. [CENTRAL: 1000846] [CFGDREGISTER: SC259] [JID:: 9107334] [PMID: 24696091]">Silva‐Pinto 2014</a>; <a href="./references#CD002202-bbs2-0044" title="VoskaridouE , TerposE , MargeliA , HantziE , MeletisJ , PapassotiriouI , et al. Renal dysfunction and osteodystrophy in patients with sickle cell thalassaemia under long-term treatment with hydroxyurea. In: 10th Congress of the European Hematology Association; 2005 June 2-5; Stockholm International Fairs, Sweden. 2005. [ABSTRACT NO: 0174] [CFGD REGISTER: SC168] ">Voskaridou 2005</a>), and two studies were terminated early due to problems recruiting participants (<a href="./references#CD002202-bbs2-0028" title="NCT02090296. Risk-based therapy for sickle cell anemia: a feasibility study. www.ClinicalTrials.gov/show/NCT02090296 (first received 18 March 2014). [CFGD REGISTER: SC291] ">NCT02090296</a>; <a href="./references#CD002202-bbs2-0031" title="NCT03825341. Hydroxyurea therapy: optimizing access in pediatric populations everywhere. clinicaltrials.gov/show/NCT03825341 (first received 31 January 2019). [CFGD REGISTER: SC432] ">NCT03825341</a>). Seven studies compared different doses of hydroxyurea (<a href="./references#CD002202-bbs2-0010" title="AbdullahiSU , SunusiSM , Sani AbbaM , SaniS , GaladanciA , InuwaH , et al. Low-versus moderate-dose hydroxyurea for secondary stroke prevention in children with sickle cell disease in sub-Saharan Africa: final results of a randomized controlled trial, sprint trial. Blood2020;136(Suppl 1):5-6. [CFGD REGISTER: SC280b] NCT02675790. Low dose hydroxyurea for secondary stroke prevention in children with sickle cell disease in Sub-Saharan Africa (SPRINT). www.clinicaltrials.gov/ct2/show/NCT02675790 (first received 8 January 2016). [CFGD REGISTER: SC280a] ">Abdullahi 2020a</a>; <a href="./references#CD002202-bbs2-0011" title="AbdullahiSU , JibirBW , Bello-MangaH , GamboS , InuwaH , TijjaniAG , et al. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. Lancet. Haematology2022;9(1):e26-e37. [CFGD REGISTER: SC293e] AbdullahiSU , JibirBW , Bello-MangaH , GamboS , InuwaH , TijjaniAG , et al. Randomized controlled trial of fixed low- vs moderate-dose hydroxyurea for primary stroke prevention in sub-Saharan Africa: final results of the spring trial. Blood2020;136(Suppl 1):4-5. [CFGD REGISTER: SC293d] AbdullahiSU , WudilBJ , Bello-MangaH , MusaAB , GamboS , GaladanciNA , et al. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial. Pediatric Hematology and Oncology2021;38(1):49-64. [CFGD REGISTER: SC293b] Bello-MangaH , GaladanciAA , AbdullahiS , AliS , JibirB , GamboS , et al. Low educational level of head of household, as a proxy for poverty, is associated with severe anaemia among children with sickle cell disease living in a low-resource setting: evidence from the SPRING trial. British Journal of Haematology2020;190(6):939-44. [CFGD REGISTER: SC293c] Bello-MangaH , HaliruL , TabariAM , FaroukB , SuleimanA , BahagoGY , et al. Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team. BMC Research Notes2022;15(1):1. [CFGD REGISTER: SC293f] NCT02560935. Primary prevention of stroke in children with SCD in Sub-Saharan Africa II (SPRING). www.clinicaltrials.gov/show/NCT02560935 (first received 02 September 2015). [CFGD REGISTER: SC293a] ">Abdullahi 2020b</a>; <a href="./references#CD002202-bbs2-0015" title="CTRI/2022/01/039317. Low dose hydroxyurea in sickle cell anemia [Efficacy, safety, and population pharmacokinetics of low-dose vs. standard dose hydroxyurea in paediatric patients suffering from sickle cell disease: a randomized double-blind active-control non-inferiority clinical trial]. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2022/01/039317 (first received 27 January 2022). ">CTRI/2022/01/039317</a>; <a href="./references#CD002202-bbs2-0020" title="FieldJJ , KassimA , BrandowA , EmburySH , MatsuiN , WilkersonK , et al.  Phase 2 trial of montelukast for prevention of pain in sickle cell disease. Blood Advances 2020;4(6):1159-65. [CFGD REGISTER: SC294b] NCT01960413. Phase 2 study of montelukast for the treatment of sickle cell anemia. www.clinicaltrials.gov/show/NCT01960413 (first received 10 October 2013). [CFGD REGISTER: SC294a] ">Field 2020</a>; <a href="./references#CD002202-bbs2-0021" title="MeierER , CrearySE , HeeneyMM , DongM , Appiah-KubiAO , NelsonSC , et al. Hydroxyurea optimization through precision study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Trials2020;21(1):983. [CFGD REGISTER: SC430b] [DOI: https://doi.org/10.1186/s13063-020-04912-z]NCT03789591. Hydroxyurea optimization through precision study (HOPS). clinicaltrials.gov/show/nct03789591 (first received 28 Dec 2018). [CFGD REGISTER: SC430a] ">Meier 2020</a>; <a href="./references#CD002202-bbs2-0034" title="GeorgeA , AygunB , MortierN , SparreboomA , WareR . A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in children with sickle cell anemia. Pediatric Blood &amp; Cancer2013;60(Suppl). [ABSTRACT NO: 588] [CENTRAL: 1007869] [CFGD REGISTER: SC283b] [EMBASE: 71047876]GeorgeA , DinuB , EstradaN , MinardC , HurwitzRL , MahoneyD , et al. NDEPTH: a randomized controlled trial of a novel dose-prediction equation to determine maximum tolerated dose for hydroxyurea therapy in pediatric patients with sickle cell anemia. Blood2019;134:2267. [CENTRAL: CN-02050621] [CFGD REGISTER: SC283c] [EMBASE: 630318481]GeorgeA , DinuB , EstradaN , MinardCG , HurwitzR , MahoneyDH , et al. Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): a randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology2020;95(9):E242-4. [CENTRAL: CN-02131373] [CFGD REGISTER: SC283d] [EMBASE: 631937641] [PMID: 32472611]GeorgeA , DinuBR , WareRE . Ndepth: novel dose escalation to predict treatment with hydroxyurea. Blood2015;126(23):3419. [CFGD REGISTER: SC283a] ">NDEPTH 2013</a>; <a href="./references#CD002202-bbs2-0035" title="JohnCC , OpokaR , LathamT , HumeH , NakafeeroM , KasiryeP , et al. Optimizing hydroxyurea dosing in sickle cell anemia: the Uganda MTD study. Blood2019;134:520. [CENTRAL: CN-02051498] [CFGD REGISTER: SC435b] [EMBASE: 630317942]JohnCC , OpokaRO , LathamTS , HumeHA , NabaggalaC , KasiryeP , et al. Hydroxyurea dose escalation for sickle cell anemia in Sub-Saharan Africa. New England Journal of Medicine2020;382(26):2524-33. [CENTRAL: CN-02133119] [CFGD REGISTER: SC435c] [PMID: 32579813]NCT03128515. Optimizing hydroxyurea therapy in children with SCA in malaria endemic areas [Optimizing hydroxyurea therapy in children with sickle cell anemia in malaria endemic areas: the NOHARM maximum tolerated dose (MTD) study]. www.clinicaltrials.gov/show/NCT03128515 (first received 25 April 2017). [CFGD REGISTER: SC435a] ">NOHARM 2020</a>). In 10 studies, all participants received hydroxyurea and were randomised to other additional treatments (<a href="./references#CD002202-bbs2-0013" title="CharnigoRJ , BeidlerD , RybinD , PittmanDD , TanB , HowardJ , et al. PF-04447943, a phosphodiesterase 9A inhibitor, in stable sickle cell disease patients: a phase Ib randomized, placebo-controlled study. Clinical and Translational Science2019;12(2):180-8. [CENTRAL: CN-01937374] [CFGD REGISTER: SC345b] [EMBASE: 626983905] [PMID: 30597771]CharnigoRJ , HowardJ , BeidlerD , RybinD , TanB , MichelsonAD , et al. A phase 1b, randomized, double-blind, placebo-controlled study of PF-04447943 in patients with stable sickle cell disease: changes in exploratory biomarkers. Blood2017;130(Suppl 1):974. [CENTRAL: CN-01616847] [CFGD REGISTER: SC345a] NCT02114203. Safety, tolerability, pharmacokinetics, and pharmacodynamics study of PF-04447943, co-administered with and without hydroxyurea, in subjects with stable sickle cell disease [A phase 1b, randomized, double-blind (sponsor open), placebo controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of pf 04447943, co-administered with and without hydroxyurea, in subjects with stable sickle cell disease]. www.clinicaltrials.gov/show/NCT02114203 (first received 15 April 2014). ">Charnigo 2019</a>; <a href="./references#CD002202-bbs2-0018" title="EleuterioRM , NascimentoFO , AraujoTG , CastroMF , FilhoTPA , FilhoPA , et al. Double-blind clinical trial of arginine supplementation in the treatment of adult patients with sickle cell anaemia. Advances in Hematology2019;eCollection 2019:4397150. [CENTRAL: CN-01916183] [CFGD REGISTER: SC383] [DOI: 10.1155/2019/4397150] [EMBASE: 626558583]">Eleuterio 2019</a>; <a href="./references#CD002202-bbs2-0019" title="EsteppJH , MelloniC , ThornburgCD , WiczlingP , RogersZ , RothmanJA , et al. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. Journal of Clinical Pharmacology2016;56(3):298-306. [CENTRAL: CN-01137410] [CFGD REGISTER: SC393] [EMBASE: 607382494]">Estepp 2016</a>; <a href="./references#CD002202-bbs2-0025" title="NCT00004492. Phase I/II randomized study of hydroxyurea with or without clotrimazole in patients with sickle cell anemia. www.clinicaltrials.gov/show/NCT00004492 (first received 19 October 1999). ">NCT00004492</a>;  <a href="./references#CD002202-bbs2-0033" title="A trial for prevention of recurrent ischemic priapism in men with sickle cell disease: a pilot study (PIN). www.clinicaltrials.gov/ct2/show/NCT05142254 (first received 2 December 2021). PACTR202105561969346. A randomized controlled double-blind trial for prevention of recurrent ischemic priapism in men with sickle cell disease: a pilot study. Priapism in Nigeria (PIN) trial. www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR2021055619693462021. ">NCT05142254</a>; <a href="./references#CD002202-bbs2-0039" title="McClishDK , SmithWR , OkhomiunaV , MouaffoDS , Lottenberg  R, ChenI , et al. The association of painful crises with patient reported outcomes in sickle cell disease: the SHIP-HU study. Blood2018;132(Suppl 1):3509. [CFGD REGISTER: SC413a] [DOI: 10.1182/blood-2018-99-114869]SmithWR , McClishDK , JohnsonS , LottenbergR , SislerI , SopD , et al. The effect of patient navigators on health-related quality of life in sickle cell anemia: the SHIP-HU study. Blood2019;134 Suppl 1:2168. [CFGD REGISTER: SC413c] SmithWR , McClishDK , LottenbergR , SislerI , SopD , JohnsonS , et al. The effect of patient navigators on laboratory parameters of hydroxyurea adherence in sickle cell anemia: the ship-hu study. Blood2019;134 Suppl 1:2309. [CFGD REGISTER: SC413b] SmithWR , McClishDK , LottenbergR , SislerIY , SopD , JohnsonS , et al. A randomised controlled provider-blinded trial of community health workers in sickle cell anaemia: effects on haematologic variables and hydroxyurea adherence. British Journal of Haematology2022;196(1):193-203. [CFGD REGISTER: SC413d] ">Smith 2022</a>; <a href="./references#CD002202-bbs2-0040" title="AbboudMR , HowardJ , CancadoR , SmithWR , GuvencB , EspurzN , et al. Crizanlizumab versus placebo, with or without hydroxyurea/hydroxycarbamide, in adolescent and adult patients with sickle cell disease and vaso-occlusive crises: a randomized, double-blind, phase III study (STAND). Blood2019;134:998. [CENTRAL: CN-02048780] [CFGD REGISTER: SC392] [EMBASE: 630316641]">STAND 2019</a>; <a href="./references#CD002202-bbs2-0041" title="AtagaKI , SarafSL , DerebailVK , SharpeCC , InatiA , LebensburgerJD , et al. The effect of crizanlizumab plus standard of care (Soc) versus soc alone on renal function in patients with sickle cell disease and chronic kidney disease: a randomized, multicenter, open-label, phase ii study (Steadfast). Blood2019;134:1018. [CENTRAL: CN-02050662] [CFGD REGISTER: SC391a] [EMBASE: 630319168]EUCTR2018-003608-38-GR. Study exploring the effect of crizanlizumab on kidney function in patients with chronic kidney disease caused by sickle cell disease [A phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients = 16 years with chronic kidney disease due to sickle cell nephropathy (STEADFAST) - STEADFAST]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-003608-38-GR (first received 2019). [CENTRAL: CN-02068279] [CFGD REGISTER: SC391b] ">STEADFAST 2019</a>; <a href="./references#CD002202-bbs2-0042" title="AtagaKI , KutlarA , CancadoR , LilesD , Velez-NandayapaL , LincyJ , et al. Crizanlizumab treatment is not associated with the development of proteinuria and hematuria in patients with sickle cell disease: a safety analysis from the sustain study. Hemasphere2018;2(S1):305-6. [CFGD REGISTER: SC287h] AtagaKI , KutlarA , DeBonnettL , LincyJ , KanterJ . Crizanlizumab treatment is associated with clinically significant reductions in hospitalization in patients with sickle cell disease: results from the sustain study. Blood2019;134:2289. [CENTRAL: CN-02052376] [CFGD REGISTER: SC287j] [EMBASE: 630317661]AtagaKI , KutlarA , KanterJ , LilesD , CancadoR , FriedrischJ , et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. New England Journal of Medicine2017;376(5):429-39. [CFGD REGISTER: SC287a] [DOI: 10.1056/NEJMoa1611770]AtagaKI , KutlarA , KanterJ , LilesD , CancadoR , FriedrischJ , et al. SUSTAIN: a multicenter, randomized, placebo-controlled, double-blind, 12-month study to assess safety and efficacy of selg1 with or without hydroxyurea therapy in sickle cell disease patients with sickle cell-related pain crises. Blood2016;128(22):1. [CFGD REGISTER: SC287f] KanterJ , KutlarA , LilesD , CancadoR , BruederleA , ShiM , et al. Crizanlizumab 5.0 mg/kg increased the time to first on-treatment sickle cell pain crisis: a subgroup analysis of the phase II sustain study. Blood2017;130(Suppl 1):613. [CFGD REGISTER: SC287c] KanterJ , LilesDK , Smith-WhitleyK , BrownC , KutlarA , ElliottB , et al. Crizanlizumab 5.0 mg/kg exhibits a favorable safety profile in patients with sickle cell disease: pooled data from two phase II studies. Blood2019;134(Suppl 1):991. [CENTRAL: CN-02093264] [CFGD REGISTER: SC287k] [EMBASE: 630316062]Kanter WashkoJ , KutlarA , LilesD , CancadoR , ShiM , ZhuZ , et al. Crizanlizumab 5.0mg/kg increased the time to first on-treatment Sickle Cell Pain Crisis (SCPC) and the likelihood of not experiencing SCPC while on treatment: subgroup analyses of the phase 2 sustain study. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S81. [CFGD REGISTER: SC287d] KutlarA , KanterJ , LilesD , CancadoR , BruederleA , ShiM , et al. Crizanlizumab, A P-selectin inhibitor, increases the likelihood of not experiencing a sickle cell-related pain crisis while on treatment: results from the phase II sustain study. Haematologica2017;102(Suppl 2):166. [ABSTRACT NO: S454] [CFGD REGISTER: SC287b] KutlarA , KanterJ , LilesDK , AlvarezOA , CancadoRD , FriedrischJR , et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. American Journal of Hematology2019;97(1):55-61. [CFGD REGISTER: SC287g] NCT01895361. Study to assess safety and impact of SelG1 with or without hydroxyurea therapy in sickle cell disease patients with pain crises. www.ClinicalTrials.gov/show/NCT01895361 (first received 10 July 2013). ShahN , BocciaR , KraftWK , HardestyBM , PauloseJ , LaineD , et al. Pro3 successor study: treatment and health care resource utilization by sickle cell patients who participated in the sustain study in the United States. Value in Health2019;22:S335. [CENTRAL: CN-01964014] [CFGD REGISTER: SC287i] [EMBASE: 2002156598]">SUSTAIN 2019</a>; <a href="./references#CD002202-bbs2-0043" title="VichinskyE , TorresM , GlassJ , MinnitiCP , BarretteS , HabrD , et al. A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2-year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy. Blood2011;118(21):1082. [ABSTRACT NO: 1082] [CFGD REGISTER: SC233a] VichinskyE , TorresM , MinnitiCP , BarretteS , HabrD , ZhangY , et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology2013;88(12):1068-73. [CFGD REGISTER: SC233b] [PMID: 23946212]">Vichinsky 2013</a>), and in three studies hydroxyurea was given for less than one month (<a href="./references#CD002202-bbs2-0014" title="ConranN , FertrinKY , MaximoCDA , OliveiraT , LoboC , CostaFF . Safe use of hydroxyurea in sickle cell disease patients hospitalized for painful vaso-occlusive episodes: results of the randomized, open-label helps study. Blood2019;134:2303. [CFGD REGISTER: SC431b] NCT03062501. Hydroxyurea in the emergency room to lessen pain in sickle cell crisis. www.ClinicalTrials.gov/show/NCT03062501 (first received 23 February 2017). [CFGD REGISTER: SC431a] ">Conran 2019</a>; <a href="./references#CD002202-bbs2-0016" title="De MontalembertM , BachirD , HulinA , GimenoL , MogenetA , BressonJL , et al. A phase 1 pharmacokinetics (PK) study of hydroxyurea (HU) 1,000 mg coated breakable tablets and 500mg capsules in pediatric and adult patients with sickle cell disease. Blood2005;106(11). [ABSTRACT NO: 3194] [CFGD REGISTER: SC193a] [DOI: 10.1182/blood.V106.11.3194.3194]deMontalembertM , BachirD , HulinA , GimenoL , MogenetA , BressonJL , et al. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. Haematologica2006;91(12):1685-8. ">De Montalembert 2006</a>; <a href="./references#CD002202-bbs2-0022" title="MisraH , BainbridgeJ , BerrymanJ , AbuchowskiA , GalvezKM , UribeLF , et al. A Phase Ib open label, randomized, safety study of SANGUINATETM in patients with sickle cell anemia. Revista Brasileira de Hematologia e Hemoterapia2017;39(1):20-7. [CFGD REGISTER: SC290b] NCT01848925. A phase I open-label, randomized, safety and efficacy study of SANGUINATE™ at two doses levels versus hydroxyurea in sickle cell disease (SCD) patients. www.clinicaltrials.gov/show/NCT01848925 (first received 8 May 2013). [CFGD REGISTER: SC290a] ">Misra 2017</a>). </p> <p>Two studies looked at measuring adherence to hydroxyurea (<a href="./references#CD002202-bbs2-0026" title="NCT00672789. Adherence to hydroxyurea in children with sickle cell anemia. clinicaltrials.gov/show/NCT00672789 (first received 6 May 2008). [CFGD REGISTER: SC422] ">NCT00672789</a>; <a href="./references#CD002202-bbs2-0032" title="NCT04675645. Adherence to HU and HRQOL in patients with sickle cell disease: an intervention study using hu-go app. clinicaltrials.gov/show/NCT04675645 (first received 19 December 2020). [CFGD REGISTER: SC415] ">NCT04675645</a>). One cross‐over study compared low‐dose hydroxyurea to no treatment to monitor those at increased risk of infection (<a href="./references#CD002202-bbs2-0029" title="NCT02149537. Risk stratification for clinical severity of sickle cell disease in Nigeria and assessment of efficacy and safety during treatment with hydroxyurea. www.clinicaltrials.gov/show/NCT02149537 (first received 24 May 2014). [CFGD REGISTER: SC289] ">NCT02149537</a>), and in one study participants were randomised to hydroxyurea plus a nutritional supplement or a nutritional supplement alone, so the effect of hydroxyurea could not be determined (<a href="./references#CD002202-bbs2-0030" title="NCT03634488. Management of severe acute malnutrition in SCD, in Northern Nigeria. www.ClinicalTrials.gov/show/NCT03634488 (first received 16 August 2018). ">NCT03634488</a>). </p> </section> <section id="CD002202-sec-0048"> <h4 class="title">Ongoing studies </h4> <p>There are two studies listed as ongoing, which we plan to assess in future updates of this review. One trial is assessing hydroxyurea in relation to preventing brain injury in people with SCD (HUPrevent). This is a randomised, double‐blind, parallel design, phase II study (hydroxyurea at 20 mg/kg/day increased by 5 mg/kg every eight weeks to maximum of 35 mg/kg/day versus placebo (sucrose) 0.2 mL/kg/day increased to max of 0.35 mL/kg/day) (<a href="./references#CD002202-bbs2-0045" title="NCT01389024. Hydroxyurea to prevent brain injury in sickle cell disease (HUPrevent). www.clinicaltrials.gov/ct2/show/NCT01389024 (first received 30 June 2011). ">NCT01389024</a>). The second trial is a multicentre, randomised, double‐blind, placebo‐controlled study evaluating the effect on albuminuria of treatment with hydroxyurea (Siklos®) (15 mg/kg/day) or placebo in adults with SCD (SIKAMIC) (<a href="./references#CD002202-bbs2-0046" title="NCT03806452. SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial). www.clinicaltrials.gov/ct2/show/NCT03806452 (first received 16 January 2019). ">NCT03806452</a>). See the relevant table for further details (<a href="./references#CD002202-sec-0129" title="">Characteristics of ongoing studies</a>). </p> </section> </section> <section id="CD002202-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD002202-fig-0002">Figure 2</a> and <a href="./references#CD002202-sec-0127" title="">Characteristics of included studies</a> for more information. </p> <div class="figure" id="CD002202-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002202-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002202-sec-0050"> <h4 class="title">Allocation</h4> <p>We judged four studies to have a low risk of bias (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). One study used an automated telephone response system to randomise participants using lists that had been produced by the medical co‐ordinating centre (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). The NOHARM, SCATE and TWiTCH studies used blocked randomisation and central allocation (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>).  </p> <p>Five studies had an unclear risk of bias (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). Three studies described adequate randomisation procedures (low risk of bias), but none of these studies clearly stated any method of allocation concealment so we judged there to be an unclear risk of allocation bias (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). The MSH study used computerised block randomisation, the Jain trial used random number tables and the CHAMPS study used a sequential allocation algorithm for randomisation (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). The Belgian study described the randomisation of participants as "drawing sealed envelopes, patients were randomly allocated to one of the following treatment sequences", therefore the generation and the allocation of the treatment sequence are not clear from this statement (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). The hospital pharmacy provided the treatment and placebo for each participant and both were described as "indistinguishable" (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). The SWiTCH trial did not discuss the method for randomisation or allocation concealment and therefore we have graded this as unclear (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). </p> </section> <section id="CD002202-sec-0051"> <h4 class="title">Blinding</h4> <p>We assessed six studies as having a low risk of both performance and detection bias (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). The BABY HUG study was described as "double blind"; the study paper stated that "participants, caregivers and medical coordinating centre staff were masked to treatment allocation"; the hydroxyurea and placebo powders were identical in terms of appearance and packaging and the liquid formulations had the same appearance and taste (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). In the Jain and NOHARM studies, participants, clinicians and outcome assessors were blinded to treatment allocation with placebo capsules of identical appearance (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>In three studies, the blinding of participants and personnel was also not possible due to the differences between the treatments (hydroxyurea and standard treatment) (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). However, given the objective nature of the primary assessments around the primary outcomes related to neurological events such as stroke judged by the blinded (partially masked) outcome assessors in these studies, we assessed these as having a low risk of  performance and detection bias. </p> <p>We assessed two studies as having a low risk of performance bias and an unclear risk of detection bias (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). In the CHAMPS study, treatment was assigned in combinations of identically appearing capsules and blinding was achieved by 'over‐capsulating' tablets (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>), while the MSH study was described as double‐blind (physician and participant) (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). It was not stated whether outcome assessors were blinded in either of these studies, so we judged these to have an unclear risk of detection bias.  </p> <p>The Belgian study had an unclear risk of both performance and detection bias (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). It was single‐blinded (the participant was unaware of the treatment schedule but the physician was aware of the treatment schedule) because of the difficulty of blinding the attending physician to the treatment received. It was not stated whether outcome assessors were blinded. </p> </section> <section id="CD002202-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>We judged seven studies in total to have a low risk of attrition bias (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>).  </p> <p>In five studies, withdrawals from treatment were documented, an intention‐to‐treat analysis approach in primary analyses was used and all randomised participants were included in the analysis (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). In the BABY HUG study, an intention‐to‐treat analysis was undertaken for primary outcomes (via multiple imputation methods to account for missing data) and for safety outcomes (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). Some of the secondary outcomes were reported for only the individuals who completed the study or had data recorded for specific measurements, but given that primary and important safety outcomes were reported using an intention‐to‐treat analysis, we judged this study to also be at a low risk of bias (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). In the SCATE study, due to the early termination of the study, two randomised participants did not receive their allocated treatment; however, the primary analysis of this study used an intention‐to‐treat approach and a sensitivity analysis considered the actual treatment received so this study was also assessed as having a low risk of bias (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). </p> <p>We judged the Belgian study to have an unclear risk of attrition bias (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). Three participants were excluded from the analysis due to their failure to attend their monthly evaluation at four to five months and there was no discussion of whether or not an intention‐to‐treat analysis was used. </p> <p>In the CHAMPS study, only participants who completed eight weeks (primary outcome) or 44 weeks (secondary outcomes) of follow‐up were included in the results (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). This is not an intention‐to‐treat approach so we judged this trial to be at high risk of bias. </p> </section> <section id="CD002202-sec-0053"> <h4 class="title">Selective reporting</h4> <p>We judged five studies to have a low risk of reporting bias (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). A published protocol was available for one study and all reported outcomes of the study were pre‐specified (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). Three studies defined outcomes in their methods sections, which were reported in the results (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). The CHAMPS study was not designed to measure efficacy and reported only laboratory‐based outcomes; all of these outcomes were well‐defined in the methods and reported in the results (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). </p> <p>We judged four studies to have a high risk of reporting bias (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). We are not able to include some results from two studies at this time, so we have judged these studies to be at a high risk of selective reporting bias. If these results can be included at a later date then this judgement will be reconsidered (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). The primary publication of the TWiTCH study stated that the secondary outcomes of neuropsychological status, quality of life and growth would be published at a later date (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). For the SWiTCH study, some outcomes (such as growth and development, functional evaluations, neurocognitive evaluations) do not yet seem to have been reported (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). The final two studies planned to measure outcomes that were not reported due to difficulty in collecting the information to inform these outcomes; these studies are also judged to be at a high risk of bias (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). </p> </section> <section id="CD002202-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>For six studies, we identified no other bias (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). </p> <p>Two studies were terminated early, which is a potential for bias but we do not regard either as being at a high risk of bias. One study was likely to be underpowered due to the early termination of the study with only 22% of the target sample size recruited (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). The second study to be terminated early at the first interim analysis had already recruited the target sample size at this point so we did not consider this study to be at a high risk of bias (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). A third study recruited only 23% of the target sample size; however, this study was not designed to measure efficacy and analyses were intended to be exploratory, so we did not consider this study to be at high risk of bias  (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). </p> </section> </section> <section id="CD002202-sec-0055"> <h3 class="title" id="CD002202-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD002202-tbl-0001"><b>Summary of findings 1</b> Summary of findings ‐ Hydroxyurea compared with placebo for sickle cell disease</a>; <a href="./full#CD002202-tbl-0002"><b>Summary of findings 2</b> Summary of findings ‐ Hydroxyurea and phlebotomy compared to transfusion and chelation for people with sickle cell disease and an increased risk of stroke</a>; <a href="./full#CD002202-tbl-0003"><b>Summary of findings 3</b> Summary of findings ‐ Hydroxyurea compared with observation for people with sickle cell disease and an increased risk of stroke</a>; <a href="./full#CD002202-tbl-0004"><b>Summary of findings 4</b> Summary of findings ‐ Hydroxyurea compared with no hydroxyurea for people with sickle cell disease</a> </p> <p>We graded the quality of the evidence for those outcomes included in the summary of findings tables. For the definitions of these gradings, please refer to the summary of findings tables (<a href="./full#CD002202-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD002202-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002202-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD002202-tbl-0004">summary of findings Table 4</a>). </p> <p>For the 2017 update of the review we included six new studies (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>), and at the 2022 update we included results from a single new study (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). Due to differences in the eligible populations and treatments in these new studies, we have made the following comparisons presented under each of our outcomes listed below. </p> <p> <ol id="CD002202-list-0007"> <li> <p>Hydroxyurea compared to placebo for participants with sickle cell disease (SCD): this comparison includes five studies with 784 randomised participants (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> </li> <li> <p>Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke: this comparison includes two studies with 254 randomised participants (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). </p> </li> <li> <p>Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke: this comparison includes a single study with 22 randomised participants (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). </p> </li> <li> <p>Hydroxyurea compared to no hydroxyurea for participants with SCD: this comparison includes a single study with 44 randomised participants (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). We note that this study recruits only individuals with HbSC; however, this comparison (and other comparisons) are worded to allow for future studies to be included in updates of this review which recruit individuals of all genotypes to contribute to this comparison. </p> </li> </ol> </p> <p>We have conducted meta‐analyses for comparisons 1 and 2 (above) where appropriate and presented results narratively or in additional tables (<a href="#CD002202-tbl-0005">Table 1</a>; <a href="#CD002202-tbl-0006">Table 2</a>; <a href="#CD002202-tbl-0007">Table 3</a>; <a href="#CD002202-tbl-0008">Table 4</a>). Data are not entered into analysis for the Belgian and CHAMPS studies due to the presentation of results from cross‐over and factorial designs, respectively; results are reported narratively (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). Long‐term follow‐up of the participants in the MSH study continued for up to 17 years and many publications presented results of long‐term follow‐up (see linked reference list of the MSH study) (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). After two years of double‐blind, placebo‐controlled therapy, all participants were offered hydroxyurea therapy, so any results reported after the MSH study period are uncontrolled. The long‐term results are not therefore analysed in this review. </p> <div class="table" id="CD002202-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Clinical events and markers of response in Jain 2012</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>18 months</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>18 months</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Clinical events (number of events per participant per year)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VOC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.13 (8.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.46 (3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 (3.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.43 (0.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13 (0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.13 (0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.98 (0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.13 (6.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.56 (2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.59 (2.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Haematological parameters</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.29 (0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.21 (0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.90 (0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbF(%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.8 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.21 (6.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.92 (5.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reticulocytes (x10⁵/mm³)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.83 (0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 (0.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.81 (0.67)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leucocytes (x10³/mm³)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.36 (6.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.54 (5.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.26 (4.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.38 (2.85)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelets (x10³/mm³)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.78 (0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.01 (0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.91 (0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.06 (0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RBC (x10⁶/mm³)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.89 (0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.98 (0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.84 (0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.11 (0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total bilirubin (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.32 (1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.27 (1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.71 (0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Values are mean (standard deviation); P values are calculated using independent t‐test.</p> <p>Hb: haemoglobin<br/>HbF: foetal haemoglobin<br/>RBC: red blood count<br/>VOC: vaso‐occlusive crises<br/>WBC: white blood count </p> </div> </div> <div class="table" id="CD002202-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Laboratory measurements from MSH 1995</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2 years</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2 years</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC (10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 (3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 (3.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3 (3.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2 (2.8)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutrophils (10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9 (2.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9 (2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7 (2.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (2.0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelets (10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>468 (147)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>399 (124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457 (130)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423 (122)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (1.3)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCV (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.9 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.2 (4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.1 (4.2)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCV (fl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (9)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reticulocytes (10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327 (98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325 (94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 (99)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbF (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (3.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6 (6.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 (3.3)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F cells (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (18)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F reticulocytes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (7)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0036</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense cells (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (7)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Creatinine (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (0.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (0.5)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total bilirubin (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7 (2.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2 (4.6)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Direct bilirubin (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (0.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7 (2.2)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspartate aminotransferase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (27)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alkaline phosphatase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (71)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Values are mean (standard deviation); P values are calculated using independent t‐test.</p> <p>Hb: haemoglobin<br/>HbF: foetal haemoglobin<br/>MCV: mean corpuscular volume<br/>PCV: packed cell volume<br/>WBC: white blood count </p> </div> </div> <div class="table" id="CD002202-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Laboratory evaluations from the SWiTCH trial</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea and</b> </p> <p><b>phlebotomy group (n = 67)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Transfusions and</b> </p> <p><b>chelation group (n = 66)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbF (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.9 (92 to 22.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.2 (‐0.8 to 0.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ANC (x10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.3 (‐5.1 to ‐1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (‐1.3 to 2.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 (‐0.7 to 0.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 (‐0.5 to 0.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.898</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐50.9 (‐66.8 to ‐33.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 (‐12.7 to 6.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbS (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.0 (21.7 to 46.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (‐7.5 to 12.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCV (fL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.5 (7.5 to 28.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 (‐2.0 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC (x10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.4 (‐8.1 to ‐2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 (‐2.0 to 2.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARC (x10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐149.1 (‐231.0 to ‐19.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.8 (‐88.2 to 93.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelets (x10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐83.0 (‐171.0 to ‐8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐28.0 (‐70.0 to 18.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total bilirubin (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1 (‐1.9 to ‐0.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (‐0.3 to 1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.2 (‐2.8 to 7.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.2 (‐5.5 to 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48888</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐966.0 (‐1629.0 to 49.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1159.5 (‐662.0 to 2724.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LDH (U/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐67.0 (‐143.0 to 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.5 (‐74.0 to 74.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ANC: absolute neutrophil count<br/>ARC: absolute reticulocyte count<br/>Hb: haemoglobin<br/>HbA: adult haemoglobin<br/>HbF: foetal haemoglobin<br/>HbS: sickle haemoglobin<br/>LDH: lactate dehydrogenase<br/>LIC: liver iron concentration<br/>MCV: mean corpuscular volume<br/>WBC: white blood count </p> <p>Values are median change from baseline and interquartile range. P values are calculated using Wilcoxon rank sum test. </p> </div> </div> <div class="table" id="CD002202-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Laboratory evaluations from the SCATE trial</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea (n = 11)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Observation (n = 11)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb (g/dL)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCV (fL)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARC (x10⁹/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐33.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC (x10⁹/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ANC (x10⁹/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelets (x10⁹/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐76</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbF (%)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight (kg)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Height (cm)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ANC: absolute neutrophil count<br/>ARC: absolute reticulocyte count<br/>Hb: haemoglobin<br/>HbF: foetal haemoglobin<br/>MCV: mean corpuscular volume<br/>WBC: white blood count </p> <p>Values are median change from baseline and P values are calculated using Wilcoxon rank sum test. </p> </div> </div> <section id="CD002202-sec-0056"> <h4 class="title">Primary outcomes</h4> <section id="CD002202-sec-0057"> <h5 class="title">1. Pain alteration</h5> <section id="CD002202-sec-0058"> <h6 class="title">Hydroxyurea compared to placebo for participants with SCD</h6> <p>The MSH study defined pain crisis as a visit to a medical facility, lasting four or more hours, requiring opiate analgesia (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). There was a statistically significant difference between the hydroxyurea group and placebo group in the mean annual crisis rate (all crises): mean difference (MD) ‐2.80 (95% confidence interval (CI) ‐4.74 to ‐0.86; P = 0.005) and for crises requiring hospitalisation: MD ‐1.50 (95% CI ‐2.58 to ‐0.42; P = 0.007; <a href="./references#CD002202-fig-0003" title="">Analysis 1.1</a>). </p> <p>The Jain study presented the number of clinical events (vaso‐occlusive crises) before and after intervention (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>). We could not calculate change from baseline in the number of clinical events so we have analysed between‐group data at 18 months and presented the before and after data in an additional table (<a href="#CD002202-tbl-0005">Table 1</a>). After 18 months of treatment, there was a statistically significant difference between the hydroxyurea group and placebo group: MD ‐9.60 (95% CI ‐10.86 to ‐8.34; P &lt; 0.00001; <a href="./references#CD002202-fig-0003" title="">Analysis 1.1</a>). </p> <p>The MSH study also showed a reduction in median time (Kaplan‐Meier life table estimate) from the initiation of treatment to first painful crisis (2.76 months in the hydroxyurea arm compared with 1.35 months on placebo (Cox regression P value = 0.014), second painful crisis (6.58 months in the hydroxyurea group compared with 4.13 months on placebo (Cox regression P value &lt; 0.0024), and third painful crisis (11.9 months in the hydroxyurea group compared with 7.04 months on placebo (Cox regression P value = 0.0002) (reported in <a href="./references#CD002202-bbs2-0060" title="CharacheS , TerrinTL , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia. New England Journal of Medicine1995;332:1317-22.">Charache 1995</a>). We note that the analysis of time‐to‐first, ‐second and ‐third painful crisis seems to treat crisis events independently, which is unlikely to be a realistic assumption. Furthermore, information relating to the analgesia used by participants in this study has been reported, but has not been presented according to the groups to which the participants were randomised (reported in <a href="./references#CD002202-bbs2-0049" title="BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63.">Ballas 1996</a>). </p> <p>The BABY HUG study showed a statistically significantly lower proportion of participants experiencing pain in the hydroxyurea group compared to the placebo group: risk ratio RR 0.68 (95% CI 0.5 to 0.92; <a href="./references#CD002202-fig-0004" title="">Analysis 1.2</a>) (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). Only one participant in the hydroxyurea group experienced a serious vaso‐occlusive crisis in the NOHARM trial and none in the placebo group, therefore it was very uncertain whether there was a difference between groups: RR 2.97 (95% CI 0.12 to 72.11; <a href="./references#CD002202-fig-0004" title="">Analysis 1.2</a>) (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>The Belgian study stated that "16 patients out of 22 (73%) did not require any hospitalisation for painful episodes when treated with hydroxyurea as compared with only 3 of 22 (14%) when treated with placebo" (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). In addition, it showed as reduction in mean hospital stay, with a stay of 5.3 days in the hydroxyurea group and 15.2 days in the placebo group. A planned outcome of "number of days in pain" was not reported in the trial publication due to difficulties in collecting this information from participants. </p> </section> <section id="CD002202-sec-0059"> <h6 class="title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </h6> <p>Both studies reported the number of participants experiencing 'serious' vaso‐occlusive or sickle cell anaemia‐related pain events (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>), and one study also reported the number of participants experiencing any vaso‐occlusive or sickle cell anaemia‐related pain event (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>) </p> <p>There was a statistically significantly higher proportion of participants experiencing serious vaso‐occlusive or sickle cell anaemia‐related pain in the hydroxyurea and phlebotomy group compared to the transfusion and chelation groups in the SWiTCH and TWiTCH studies: pooled RR 3.37 (95% CI 1.59 to 7.11; P = 0.001) (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>), but there was no significant difference between the groups in terms of all sickle cell anaemia pain events in the SWiTCH study: RR 1.03 (95% CI 0.81 to 1.30; P = 0.81; <a href="./references#CD002202-fig-0061" title="">Analysis 2.1</a>) (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). </p> </section> <section id="CD002202-sec-0060"> <h6 class="title">Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </h6> <p>No information was reported for this outcome in the SCATE study (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). </p> </section> <section id="CD002202-sec-0061"> <h6 class="title">Hydroxyurea compared to no hydroxyurea for participants with SCD</h6> <p>No information was reported for this outcome in the CHAMPS study (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). </p> </section> </section> <section id="CD002202-sec-0062"> <h5 class="title">2. Life‐threatening illness</h5> <section id="CD002202-sec-0063"> <h6 class="title">Hydroxyurea compared to placebo for participants with SCD</h6> <p>The BABY HUG, NOHARM and MSH studies provided data on the occurrence of acute chest syndrome and transfusions and the BABY HUG and MSH trials provided data on the occurrence of stroke (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). A statistically significantly fewer occurrences of the acute chest syndrome were observed in the hydroxyurea group: pooled RR 0.43 (95% CI 0.29 to 0.63; P &lt; 0.0001, I² = 0%), and also fewer participants on hydroxyurea underwent transfusions: pooled RR 0.66 (95% CI 0.53 to 0.82; P = 0.0002, I² = 0%). There was no statistically significant difference in terms of stroke: pooled RR 0.54 (95% CI 0.12 to 2.53; P = 0.44; <a href="./references#CD002202-fig-0005" title="">Analysis 1.3</a>). </p> <p>The MSH study reported data on hepatic sequestration and the BABY HUG and Opoka studies reported data on splenic sequestration (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>); the differences between the groups were not statistically significant: RR 0.32 (95% CI 0.03 to 3.06; P = 0.32) and RR 1.11 (95% CI 0.48 to 2.59; P = 0.80, I² = 13%), respectively (<a href="./references#CD002202-fig-0005" title="">Analysis 1.3</a>). </p> <p>The Opoka study also reported serious adverse events of bacteraemia or sepsis (six events in each group) and anaemia (one event in the placebo group); there was no statistically significant difference between groups (<a href="./references#CD002202-fig-0005" title="">Analysis 1.3</a>). </p> <p>The Jain study presented the number of clinical events (blood transfusions and hospitalisations) before and after intervention (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>). We could not calculate change from baseline for the number of clinical events so we have analysed between‐group data at 18 months and presented the before and after data in an additional table (<a href="#CD002202-tbl-0005">Table 1</a>). After 18 months of treatment, there was a statistically significant difference between the hydroxyurea group and placebo group in the number of blood transfusions: MD ‐1.85 (95% CI ‐2.18 to ‐1.52; P &lt; 0.00001) and in the number of hospitalisations: MD ‐8.89 (95% CI ‐10.04 to ‐7.74; P &lt; 0.00001). The duration of hospitalisation was also significantly less in the hydroxyurea group than the placebo group: MD ‐4.00 days (95% CI ‐4.87 to ‐3.13; P &lt; 0.00001; <a href="./references#CD002202-fig-0006" title="">Analysis 1.4</a>). </p> <p>No information was reported for this outcome in the Belgian study (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). </p> </section> <section id="CD002202-sec-0064"> <h6 class="title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </h6> <p>The primary aim of the TWiTCH study was to prevent primary stroke; 29 neurologic events occurred during the study, 17 in the hydroxyurea group and 12 in the standard treatment group, but none were deemed to be stroke or cerebral infarcts (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). Three events in each group were deemed to be transient ischaemic attacks and worsened vasculopathy developed in one participant in the standard treatment group. </p> <p>The aim of the SWiTCH study was to prevent secondary stroke; 91 new‐neurologic events were assessed for stroke and seven participants (all in the hydroxyurea treatment group) had positive stroke adjudication, one of which was fatal (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). There were also 20 transient ischaemic attack events in 15 participants (nine on transfusion and chelation and six on hydroxyurea and phlebotomy). </p> <p>There was no statistically significant difference in life‐threatening neurological events between the treatment groups in either study from the analysis conducted in this review (<a href="./references#CD002202-fig-0062" title="">Analysis 2.2</a>); however, following the seven events in the hydroxyurea and phlebotomy group, the SWiTCH study was terminated following an interim analysis demonstrating the inability of the primary outcome to reduce secondary stroke occurrence while managing iron overload "within the non‐inferiority stroke margin" (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). </p> <p>The SWiTCH and TWiTCH studies reported serious adverse events (including life‐threatening events) and other adverse events or toxicities separately (see Secondary outcomes for Adverse events) (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). Thirty‐eight participants experienced 81 serious adverse events in the SWiTCH study and 15 participants experienced 33 serious adverse events in the TWiTCH study (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). There were significantly more participants experiencing serious adverse events and SCD‐related adverse events in the hydroxyurea treatment groups compared to the transfusions groups: pooled RR 1.93 (95% CI 1.17 to 3.20; P = 0.01) and RR 3.10 (95% CI 1.42 to 6.75; P = 0.004), respectively (<a href="./references#CD002202-fig-0062" title="">Analysis 2.2</a>). There was no significant difference between groups in terms of hepatobiliary disease and splenic sequestration but serious acute chest syndrome and infections and infestations were significantly more common on hydroxyurea and phlebotomy treatment than on transfusion and chelation: pooled RR 2.84 (95% CI 1.25 to 6.42; P = 0.01) and pooled RR 3.65 (95% CI 1.05 to 12.76; P = 0.04), respectively (<a href="./references#CD002202-fig-0062" title="">Analysis 2.2</a>). </p> <p>As the control arm of the two studies in this comparison involved blood transfusions, we did not consider the number of participants requiring blood transfusion to be a life‐threatening event for this comparison. </p> </section> <section id="CD002202-sec-0065"> <h6 class="title">Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </h6> <p>The primary aim of the SCATE study was to prevent stroke and no strokes or transient ischaemic attacks occurred during the study. Vaso‐occlusive events (pain and acute chest syndrome) occurred more commonly in the observation arm than the hydroxyurea arm, but this was not statistically significant (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). There was also no statistically significant difference in cases of acute splenic sequestration or the number of participants requiring blood transfusion (<a href="./references#CD002202-fig-0078" title="">Analysis 3.1</a>). </p> </section> <section id="CD002202-sec-0066"> <h6 class="title">Hydroxyurea compared to no hydroxyurea for participants with SCD</h6> <p>No information was reported for this outcome in the CHAMPS study (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). </p> </section> </section> <section id="CD002202-sec-0067"> <h5 class="title">3. Death during the study</h5> <section id="CD002202-sec-0068"> <h6 class="title">Hydroxyurea compared to placebo for participants with SCD</h6> <p>The MSH study reported death and causes of death (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>); no deaths were reported to be related to hydroxyurea treatment. There were two deaths in the treated group and five in the placebo group including one homicide. Three deaths were reported in the <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a> study: one death in each group presumed to be related to sepsis and an additional sudden death in the hydroxyurea group, cause unknown. There was no statistically significant difference between treatment and control groups for this comparison (<a href="./references#CD002202-fig-0007" title="">Analysis 1.5</a>). </p> <p>There were no deaths in the remaining three studies (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>). </p> </section> <section id="CD002202-sec-0069"> <h6 class="title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </h6> <p>In the SWiTCH study, there was one death in the standard treatment arm (pulmonary embolism) and one death in the hydroxyurea treatment arm (fatal haemorrhagic stroke) (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). There were no deaths reported in the TWiTCH study (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). There was no statistically significant difference between treatment and control groups for this comparison (<a href="./references#CD002202-fig-0063" title="">Analysis 2.3</a>). </p> </section> <section id="CD002202-sec-0070"> <h6 class="title">Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </h6> <p>There were no deaths reported in the SCATE study (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). </p> </section> <section id="CD002202-sec-0071"> <h6 class="title">Hydroxyurea compared to no hydroxyurea for participants with SCD</h6> <p>There were no deaths reported in the CHAMPS study (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). </p> </section> </section> </section> <section id="CD002202-sec-0072"> <h4 class="title">Secondary outcomes</h4> <section id="CD002202-sec-0073"> <h5 class="title">1. Measures of HbF and neutrophil counts</h5> <section id="CD002202-sec-0074"> <h6 class="title">Hydroxyurea compared to placebo for participants with SCD</h6> <p>The BABY HUG and Opoka studies reported the change from baseline in HbF (%) and absolute neutrophil count (ANC) (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>); there was a statistically significant increase in HbF (%) in the hydroxyurea group compared to the placebo group: pooled MD 9.88 (95% CI 8.72 to 11.03, P &lt; 0.00001, I² = 94%; <a href="./references#CD002202-fig-0008" title="">Analysis 1.6</a>) and a statistically significant decrease in absolute neutrophil count (ANC) in the hydroxyurea group compared to the placebo group: pooled MD ‐1.70 (95% CI ‐2.38 to ‐1.02; P &lt; 0.00001, I²= 0%; <a href="./references#CD002202-fig-0009" title="">Analysis 1.7</a>). There was a very large amount of heterogeneity present in the analysis of HbF (%) (I² = 94%); when meta‐analysis is repeated using a random‐effects model, the pooled MD is similar but the CIs are substantially wider: pooled MD 9.20 (95% CI 4.40 to 14.00; P = 0.0002), indicating uncertainty in the pooled result due to the difference in the results of the two studies (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>The Jain and MSH studies presented results before and after intervention (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). We could not calculate change from baseline so we have analysed between‐group data at the end of the study and presented the before and after data in additional tables (<a href="#CD002202-tbl-0005">Table 1</a>; <a href="#CD002202-tbl-0006">Table 2</a>). The NOHARM study also presented results at the end of the study (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>), therefore we pooled data for the three studies for HbF (%) and present ANC at the different time points reported in the MSH and NOHARM studies (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>After the intervention, there was a statistically significant increase in HbF (%) in the hydroxyurea group compared to the placebo group in the three studies: pooled MD 6.24 (95% CI 5.28 to 7.20; P &lt; 0.0001; <a href="./references#CD002202-fig-0010" title="">Analysis 1.8</a>). There was a very large amount of heterogeneity present in the analysis of HbF (%) (I² = 96%); this appeared to originate from the <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a> study, which showed a much larger MD in HbF (around 12.5%) compared to the Jain and MSH studies (around 4% to 5%) (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). When meta‐analysis is repeated with a random‐effects model, the pooled MD is similar but the CIs are substantially wider: pooled MD 7.17 (95% CI 1.32 to 13.02; P = 0.02), indicating uncertainty in the pooled result due to the difference in the results of the three studies (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>The MSH and NOHARM studies reported the neutrophil response at the end of the study and the MSH study also reported the neutrophil response at 10 weeks (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>); at both time points there was a statistically significant decrease in neutrophil response in the hydroxyurea group compared to the placebo group: MD ‐1.90 (95% CI ‐2.51 to ‐1.29; P &lt; 0.0001) and pooled MD ‐1.47 (95% CI ‐1.87 to ‐1.06; P &lt; 0.0001, I² = 0%), respectively (<a href="./references#CD002202-fig-0011" title="">Analysis 1.9</a>). </p> <p>One study reported an increase in HbF and a decrease in ANC after six months of hydroxyurea treatment, but did not make a comparison to the placebo group (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). </p> </section> <section id="CD002202-sec-0075"> <h6 class="title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </h6> <p>The SWiTCH study reported the change from baseline in HbF (%) and ANC; there was a statistically significant difference between treatment groups for both of these measures (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). The results were presented as median and interquartile ranges and therefore could not be entered into a meta‐analysis; see an additional table for a summary of these results (<a href="#CD002202-tbl-0007">Table 3</a>). </p> <p>The TWiTCH study reported the change from baseline in HbF (%) and ANC; there was a statistically significant increase in HbF in the hydroxyurea group compared to the placebo group: MD 15.60 (95% CI 13.41 to 17.79; P &lt; 0.00001; <a href="./references#CD002202-fig-0064" title="">Analysis 2.4</a>) and a statistically significant decrease in ANC in the hydroxyurea group compared to the placebo group: MD ‐4.40 (95% CI ‐5.44 to ‐3.36; P &lt; 0.00001; <a href="./references#CD002202-fig-0065" title="">Analysis 2.5</a>) (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). </p> </section> <section id="CD002202-sec-0076"> <h6 class="title">Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </h6> <p>The SCATE study reported a significant increase in HbF and a significant decrease in ANC at last follow‐up in the hydroxyurea group compared to observation (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). Results were reported as median values so could not be included in analysis; see an additional table for a summary of these results (<a href="#CD002202-tbl-0008">Table 4</a>). </p> </section> <section id="CD002202-sec-0077"> <h6 class="title">Hydroxyurea compared to no hydroxyurea for participants with SCD</h6> <p>The CHAMPS study, which included participants with HbSC only, reported a statistically significant increase in HbF for hydroxyurea treatment compared to no hydroxyurea treatment at eight weeks and 24 weeks but no statistically significant difference was observed for ANC (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). Due to the presentation of results from the factorial design of the trial, the results cannot be entered into analysis. </p> </section> </section> <section id="CD002202-sec-0078"> <h5 class="title">2. Other surrogate markers of response</h5> <section id="CD002202-sec-0079"> <h6 class="title">Hydroxyurea compared to placebo for participants with SCD</h6> <p>The BABY HUG and NOHARM studies reported change from baseline in haemoglobin (Hb), mean corpuscular volume (MCV), white blood count (WBC), absolute reticulocyte count (ARC) and platelet count (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). The BABY HUG study also reported the change from baseline reticulocytes and total bilirubin (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>) and the NOHARM study also reported the change from baseline in creatinine and alanine transferase (ALT) (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>There was a statistically significant increase in Hb (<a href="./references#CD002202-fig-0012" title="">Analysis 1.10</a>), MCV (<a href="./references#CD002202-fig-0013" title="">Analysis 1.11</a>) and a statistically significant decrease in WBC (<a href="./references#CD002202-fig-0014" title="">Analysis 1.12</a>), ARC (<a href="./references#CD002202-fig-0015" title="">Analysis 1.13</a>), reticulocytes (<a href="./references#CD002202-fig-0016" title="">Analysis 1.14</a>) and total bilirubin (<a href="./references#CD002202-fig-0019" title="">Analysis 1.17</a>) in the hydroxyurea group compared to the placebo group. There was no statistically significant difference between groups in platelet count (<a href="./references#CD002202-fig-0017" title="">Analysis 1.15</a>), creatinine (<a href="./references#CD002202-fig-0018" title="">Analysis 1.16</a>) and ALT (<a href="./references#CD002202-fig-0019" title="">Analysis 1.17</a>). There was substantial heterogeneity (I² between 60% and 90%) for Hb, MCV and ARC, due to the differences in the results of the studies (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>The Jain and MSH studies presented results before and after intervention (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). We could not calculate change from baseline so we have analysed between‐group data at the end of the study and presented the before and after data in additional tables (<a href="#CD002202-tbl-0005">Table 1</a>; <a href="#CD002202-tbl-0006">Table 2</a>). The NOHARM study also presented results at the end of the study (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>), therefore we pooled data for these three studies, where reported. </p> <p>After the intervention, comparing hydroxyurea groups to the placebo groups, there was a statistically significant increase in Hb and MCV at 10 weeks and at the end of the studies (<a href="./references#CD002202-fig-0021" title="">Analysis 1.19</a>; <a href="./references#CD002202-fig-0022" title="">Analysis 1.20</a>) and there was also a statistically significant increase in WBC at the end of the studies (<a href="./references#CD002202-fig-0023" title="">Analysis 1.21</a>); however, there was substantial heterogeneity (I² between 64% and 87%, respectively) for Hb, MCV and WBC, due to the differences in the results of the studies. There was also a statistically significant decrease in reticulocytes at 10 weeks and at the end of the studies (<a href="./references#CD002202-fig-0024" title="">Analysis 1.22</a>; <a href="./references#CD002202-fig-0025" title="">Analysis 1.23</a>) and also in total bilirubin at the end of the studies (<a href="./references#CD002202-fig-0026" title="">Analysis 1.24</a>). A decrease in platelet count was also observed, which was not statistically significant at 10 weeks or 18 months, but when pooling the <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a> and the <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a> studies, with substantially different results, a statistically significant decrease was observed (<a href="./references#CD002202-fig-0027" title="">Analysis 1.25</a>; <a href="./references#CD002202-fig-0028" title="">Analysis 1.26</a>). </p> <p>In terms of other laboratory measures comparing hydroxyurea to placebo groups at the end of the studies, there was a statistically significant increase in packed cell volume (<a href="./references#CD002202-fig-0029" title="">Analysis 1.27</a>), F reticulocytes (<a href="./references#CD002202-fig-0030" title="">Analysis 1.28</a>) and F cells (<a href="./references#CD002202-fig-0031" title="">Analysis 1.29</a>), a statistically significant decrease in RBC count (<a href="./references#CD002202-fig-0032" title="">Analysis 1.30</a>), and dense cells (<a href="./references#CD002202-fig-0033" title="">Analysis 1.31</a>), and no difference between groups in leucocytes (<a href="./references#CD002202-fig-0034" title="">Analysis 1.32</a>), ALT (<a href="./references#CD002202-fig-0035" title="">Analysis 1.33</a>), creatinine (<a href="./references#CD002202-fig-0036" title="">Analysis 1.34</a>), aspartate aminotransferase (<a href="./references#CD002202-fig-0037" title="">Analysis 1.35</a>) and alkaline phosphatase (<a href="./references#CD002202-fig-0038" title="">Analysis 1.36</a>). </p> <p>One study reported differences in haematologic values after six months of treatment such as Hb, MCV (both significantly increased), platelet count and WBC (both significantly decreased) but only in the hydroxyurea group without comparison to the placebo group (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). </p> <p>The BABY HUG study reported change from baseline in growth: there were no significant differences between the groups in terms of height, weight or head circumference (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>) (<a href="./references#CD002202-fig-0039" title="">Analysis 1.37</a>). The MSH study reported on weight gain after two years as a mean rise of 3% in the hydroxyurea‐treated group and 6% in the placebo group, which was not statistically significant (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). </p> </section> <section id="CD002202-sec-0080"> <h6 class="title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </h6> <p>The SWiTCH study reported the change from baseline for several laboratory and haematologic measurements such as Hb, MCV, WBC, platelet count and total bilirubin (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). There was a statistically significant difference between treatment groups for most of the measurements (increase in HbF, HbS, MCV and decrease in ANC, HbA, WBC, ARC, platelets, serum ferritin and lactate dehydrogenase (LDH)), except for Hb and liver iron concentration; the results were presented as median and interquartile ranges and therefore could not be entered into a meta‐analysis; see an additional table for a summary of these results (<a href="#CD002202-tbl-0007">Table 3</a>). </p> <p>The TWiTCH study reported the change from baseline in Hb, MCV, WBC, ARC, platelet count, total bilirubin, sickle Hb, liver iron concentration, serum ferritin and LDH (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). There was a statistically significant increase in MCV (<a href="./references#CD002202-fig-0066" title="">Analysis 2.6</a>) and sickle Hb (<a href="./references#CD002202-fig-0067" title="">Analysis 2.7</a>), and a statistically significant decrease in Hb (<a href="./references#CD002202-fig-0068" title="">Analysis 2.8</a>), ARC (<a href="./references#CD002202-fig-0069" title="">Analysis 2.9</a>), WBC (<a href="./references#CD002202-fig-0070" title="">Analysis 2.10</a>), platelets (<a href="./references#CD002202-fig-0071" title="">Analysis 2.11</a>), total bilirubin (<a href="./references#CD002202-fig-0072" title="">Analysis 2.12</a>), liver iron concentration (<a href="./references#CD002202-fig-0073" title="">Analysis 2.13</a>), serum ferritin (<a href="./references#CD002202-fig-0074" title="">Analysis 2.14</a>) and LDH (<a href="./references#CD002202-fig-0075" title="">Analysis 2.15</a>) in the hydroxyurea and phlebotomy group compared to the transfusion and chelation group, </p> </section> <section id="CD002202-sec-0081"> <h6 class="title">Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </h6> <p>The SCATE study reported differences in haematologic values and growth values at last follow‐up (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). There was a statistically significant increase in Hb and MCV in the hydroxyurea group compared to the observation group. Other values were not statistically significantly different (differences the hydroxyurea group and observation group in Hb and MCV were statistically significant and other values were not significant (WBC, ANC, platelets, ARC, HbF, weight and height)). Results were reported as median values so could not be included in analysis; see an additional table for a summary of these results (<a href="#CD002202-tbl-0008">Table 4</a>). </p> </section> <section id="CD002202-sec-0082"> <h6 class="title">Hydroxyurea compared to no hydroxyurea for participants with SCD</h6> <p>The CHAMPS study reported statistically significant increases in MCV and Hb and a statistically significant decrease in WBC and platelets between hydroxyurea treatment and no hydroxyurea treatment at eight weeks and 24 weeks (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). No statistically significant difference was observed in RBC count, mean corpuscular Hb concentration (MCHC) and ARC. Due to the presentation of results from factorial design of the study, results cannot be entered into analysis. </p> </section> </section> <section id="CD002202-sec-0083"> <h5 class="title">3. Quality of life</h5> <section id="CD002202-sec-0084"> <h6 class="title">Hydroxyurea compared to placebo for participants with SCD</h6> <p>The MSH study has published in abstract a limited amount of quality of life data collected at six‐monthly intervals (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>, reported in <a href="./references#CD002202-bbs2-0104" title="TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161.">Terrin 1999</a> and <a href="./references#CD002202-bbs2-0050" title="BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59.">Ballas 2006</a>). Health‐related quality of life (HRQoL) was measured using three measures from the 'Health Status Survey' (nine scales), the 'Profile of Mood States' (four scales) and the 'Ladder of Life'. A lower score for each measure equated to a lower quality of life. </p> <p>Changes from baseline are presented for only three measures: General Health Perception,' 'Social Function' and 'Changes in Ladder of Life' and a four‐week score was reported for 'Pain Recall'. </p> <p>There was a statistically significant advantage to hydroxyurea compared to placebo in terms of general health perception at 18 months: MD 0.90 (95% CI 0.08 to 1.72; P = 0.03; <a href="./references#CD002202-fig-0040" title="">Analysis 1.38</a>) and pain recall at 18 months: MD 0.70 (95% CI 0.11 to 1.29; P = 0.02; <a href="./references#CD002202-fig-0041" title="">Analysis 1.39</a>), but not at any other measured time point for either measure. </p> <p>There were no statistically significant differences between the hydroxyurea and placebo groups at six months, one year, 18 months and two years for 'Social Function' and 'Changes in Ladder of Life' (<a href="./references#CD002202-fig-0042" title="">Analysis 1.40</a>; <a href="./references#CD002202-fig-0043" title="">Analysis 1.41</a>). </p> <p>For the MSH study, it was reported that there were no significant differences between groups in other measures of HRQoL (using a P value cut‐off for statistical significance of P &lt; 0.01 to allow for statistical testing of multiple HRQoL domains) (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a> reported in <a href="./references#CD002202-bbs2-0050" title="BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59.">Ballas 2006</a>). Results are presented as final scores rather than change from baseline so are not entered into analysis in this review. We encourage caution when interpreting the results of these quality of life scales as not all participants contributed data towards these analyses. </p> <p>No information was reported for this outcome in the remaining three studies (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>). </p> </section> <section id="CD002202-sec-0085"> <h6 class="title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </h6> <p>Quality of life was measured in the TWiTCH study, but results have not yet been published; if results are published at a later date, they will be included in an update of this review (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). No information was reported for this outcome in the remaining study (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). </p> </section> <section id="CD002202-sec-0086"> <h6 class="title">Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </h6> <p>HRQoL was a planned outcome in the SCATE study but was not reported due to difficulties in collecting information from participants at the early study termination date (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). </p> </section> <section id="CD002202-sec-0087"> <h6 class="title">Hydroxyurea compared to no hydroxyurea for participants with SCD</h6> <p>This outcome was not reported in the CHAMPS study (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). </p> </section> </section> <section id="CD002202-sec-0088"> <h5 class="title">4. Measure of chronic organ damage</h5> <section id="CD002202-sec-0089"> <h6 class="title">Hydroxyurea compared to placebo for participants with SCD</h6> <p>The MSH study reported similar rates of new leg ulcers in both groups: RR 0.85 (95% CI 0.44 to 1.64; P = 0.64) and avascular necrosis of femur and humerus: RR 0.97 (95% CI 0.39 to 2.37; P = 0.64) (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). The BABY HUG study reported more participants with decreased spleen function at exit in the placebo group than the hydroxyurea group but this was not statistically significant: RR 0.72 (95% CI 0.44 to 1.16; P = 0.18; <a href="./references#CD002202-fig-0044" title="">Analysis 1.42</a>) (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). </p> <p>The BABY HUG study reported several measures of:</p> <p> <ol id="CD002202-list-0008"> <li> <p>splenic function: diethylenetriaminepentaacetic acid glomerular filtration rate (<a href="./references#CD002202-fig-0045" title="">Analysis 1.43</a>); Howell‐Jolly body (HJB) (<a href="./references#CD002202-fig-0046" title="">Analysis 1.44</a>); pitted cells (<a href="./references#CD002202-fig-0047" title="">Analysis 1.45</a>); spleen to liver ratio of counts (<a href="./references#CD002202-fig-0048" title="">Analysis 1.46</a>); and spleen volume (<a href="./references#CD002202-fig-0049" title="">Analysis 1.47</a>); </p> </li> <li> <p>renal function: creatinine (<a href="./references#CD002202-fig-0050" title="">Analysis 1.48</a>); Schwartz glomerular filtration rate (GFR) (<a href="./references#CD002202-fig-0051" title="">Analysis 1.49</a>); cystatin C (<a href="./references#CD002202-fig-0052" title="">Analysis 1.50</a>); urine osmolality (<a href="./references#CD002202-fig-0053" title="">Analysis 1.51</a>); urine pH (<a href="./references#CD002202-fig-0054" title="">Analysis 1.52</a>); urine‐specific gravity (<a href="./references#CD002202-fig-0055" title="">Analysis 1.53</a>); and total kidney volume (<a href="./references#CD002202-fig-0056" title="">Analysis 1.54</a>); and </p> </li> <li> <p>central nervous system function: transcranial Doppler (TCD) velocity (<a href="./references#CD002202-fig-0057" title="">Analysis 1.55</a>); Bayley mental developmental index (MDI) and Bayley motor performance developmental index (PDI) (<a href="./references#CD002202-fig-0058" title="">Analysis 1.56</a>). </p> </li> </ol> </p> <p>Several of the outcomes showed significantly fewer indications of chronic organ damage on hydroxyurea compared to placebo (<a href="./references#CD002202-fig-0046" title="">Analysis 1.44</a>; <a href="./references#CD002202-fig-0047" title="">Analysis 1.45</a>; <a href="./references#CD002202-fig-0048" title="">Analysis 1.46</a>; <a href="./references#CD002202-fig-0050" title="">Analysis 1.48</a>; <a href="./references#CD002202-fig-0053" title="">Analysis 1.51</a>; <a href="./references#CD002202-fig-0055" title="">Analysis 1.53</a>, <a href="./references#CD002202-fig-0056" title="">Analysis 1.54</a>; <a href="./references#CD002202-fig-0057" title="">Analysis 1.55</a>); however, given the number of outcomes measured and the increased probability of type I statistical error and spurious results, the statistical significance of these secondary endpoint comparisons must be carefully interpreted (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). </p> <p>No information was reported for this outcome in the remaining two studies (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>). </p> </section> <section id="CD002202-sec-0090"> <h6 class="title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </h6> <p>The TWiTCH study reported a measure of central nervous system function (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). Eligible participants had abnormal TCD ultrasound velocities (&gt; 200 cm per second). The final TCD velocity was significantly lower in the hydroxyurea and phlebotomy group compared to the transfusion and chelation group: MD ‐5.00 (95% CI ‐9.16 to ‐0.84; P = 0.02; <a href="./references#CD002202-fig-0076" title="">Analysis 2.16</a>). This outcome was not reported in the SWiTCH study (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). </p> </section> <section id="CD002202-sec-0091"> <h6 class="title">Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </h6> <p>The aim of the SCATE study was to prevent conversion from conditional to abnormal time averaged mean velocity and subsequent stroke. One participant in the hydroxyurea group and five participants in the observation group converted; this difference between groups was not statistically significant (<a href="./references#CD002202-fig-0079" title="">Analysis 3.2</a>), but there was a significantly lower TAMV in the hydroxyurea group compared to the observation group: MD ‐25.70 (95% CI ‐45.38 to ‐6.02; P = 0.01; <a href="./references#CD002202-fig-0080" title="">Analysis 3.3</a>) (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). No strokes occurred during the study. </p> </section> <section id="CD002202-sec-0092"> <h6 class="title">Hydroxyurea compared to no hydroxyurea for participants with SCD</h6> <p>This outcome was not reported in the CHAMPS study (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). </p> </section> </section> <section id="CD002202-sec-0093"> <h5 class="title">5. Adverse effects or toxicity</h5> <p>As it is difficult to distinguish between adverse reactions (i.e. adverse events that are definitely drug‐related) and other adverse events that may be sickle‐ or transfusion‐related, we have reported all adverse events (or adverse effects) as they are reported in the study publications. Where possible, we have noted which adverse effects are defined as drug‐related, sickle‐related or transfusion‐related from the study publications. </p> <section id="CD002202-sec-0094"> <h6 class="title">Hydroxyurea compared to placebo for participants with SCD</h6> <p>The possible adverse effects reported in the MSH study were hair loss, skin rash, fever, gastro‐intestinal disturbance and 'other' reported events (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). There was no statistically significant difference between the groups with these measures (<a href="./references#CD002202-fig-0059" title="">Analysis 1.57</a>). In the MSH study, toxicity relating to the blood count was defined as less than 2500 x 10⁹ neutrophils/L, less than 95,000 x 10⁹ platelets/L, and Hb concentration less than 5.3 g/dL (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). Using these definitions, 120 of the hydroxyurea‐treated participants (79%) and 54 placebo participants (37%) became 'toxic' at least once, resulting in a dose modification. Importantly, no infections were related to neutropenia and no 'bleeding' episode could be related to thrombocytopenia. </p> <p>Pooled data from the BABY HUG and NOHARM studies showed that significantly fewer participants were hospitalised or experienced dactylitis, sepsis or bacteraemia, anaemia or gastroenteritis and significantly more participants experienced thrombocytopenia in the hydroxyurea groups compared to the placebo groups (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-fig-0059" title="">Analysis 1.57</a>). It should be noted that although the results are statistically significant, the individual study proportions of some adverse events were very different. There was no difference between groups in the number of participants with elevated bilirubin (<a href="./references#CD002202-fig-0059" title="">Analysis 1.57</a>). </p> <p>The BABY HUG study also reported no statistically significant differences in priapism, splenomegaly, ANC below 500, ALT over 150, skin and subcutaneous disorders and splenic sequestration, but there were significantly more participants with ANC 500 to 1250 in the hydroxyurea groups compared to the placebo groups (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-fig-0059" title="">Analysis 1.57</a>). The NOHARM study reported no statistically significant differences in neutropenia, acute chest syndrome, upper respiratory tract infection, other infections, reticulocytopenia and elevated aspartate aminotransferase (AST) or ALT (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-fig-0059" title="">Analysis 1.57</a>). </p> <p>Given the number of outcomes measured and the increased probability of type I statistical error and spurious group differences, statistical significance (or lack of) of any individual adverse event must be carefully interpreted. </p> <p>The NOHARM study also reported a composite outcome: statistically significantly fewer sickle cell anaemia‐related events (vaso‐occlusive pain crisis, dactylitis, acute chest syndrome, splenic sequestration or blood transfusion) occurred in the hydroxyurea group compared to the placebo group: RR 0.66 (95% CI 0.51 to 0.84; <a href="./references#CD002202-fig-0060" title="">Analysis 1.58</a>) (<a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>No major adverse events occurred in either group in the Jain study (<a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>); three participants in the hydroxyurea group experienced skin rash and two experienced nausea, but this was not a statistically significant difference compared to the placebo group (<a href="./references#CD002202-fig-0059" title="">Analysis 1.57</a>). No participants experienced alopecia, leucopenia, neutropenia, or renal or hepatic toxicity. </p> <p>It was stated that two children developed transient mild thrombocytopenia in the Belgian study but the treatment allocation of these children was not stated (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). </p> </section> <section id="CD002202-sec-0095"> <h6 class="title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and an increased risk of stroke </h6> <p>Life‐threatening adverse events are presented above in primary outcome 2 (<a href="./references#CD002202-fig-0062" title="">Analysis 2.2</a>). </p> <p>In the TWiTCH study it was stated that adverse events were balanced between the two groups: in the transfusion and chelation group there were 287 sickle‐related adverse events and 279 sickle‐related adverse events in the hydroxyurea and phlebotomy group (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). There were 19 adverse events related to chelation treatment in nine children in the control group (aminotransferases, gastrointestinal symptoms, increased serum creatinine, increased serum bilirubin, rash) and 18 adverse events related to phlebotomy in 14 children in the hydroxyurea treatment group (details not stated). No events related to hydroxyurea were reported. There was insufficient information to enter into the analysis: we hope to include any future information in an update. </p> <p>In the SWiTCH study, there were a total of 1253 non‐neurological adverse events in 128 individuals and there was no statistically significant difference between groups in the number of participants experiencing any adverse event: RR 0.99 (95% CI 0.92 to 1.05; P = 0.66; <a href="./references#CD002202-fig-0077" title="">Analysis 2.17</a>) (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). In terms of specific events, there was no statistically significant difference between treatment arms for most events. There was a statistically significant difference in terms of immune disorders (more in the transfusion and chelation group), reticulocytopenia, neutropenia and anaemia (more in the hydroxyurea and phlebotomy group) (<a href="./references#CD002202-fig-0077" title="">Analysis 2.17</a>); however, given the number of outcomes measured and the increased probability of type I statistical error and spurious group differences, the statistical significance must be carefully interpreted. </p> </section> <section id="CD002202-sec-0096"> <h6 class="title">Hydroxyurea compared to observation for participants with SCD and an increased risk of stroke </h6> <p>Adverse events reported in the SCATE study included transient neutropenia, reticulocytopenia, parasite infestation, headache and dizziness (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). There was no significant difference between treatment arms for any adverse event (<a href="./references#CD002202-fig-0081" title="">Analysis 3.4</a>) </p> </section> <section id="CD002202-sec-0097"> <h6 class="title">Hydroxyurea compared to no hydroxyurea for participants with SCD</h6> <p>In the CHAMPS study, adverse events and toxicity were only reported for all randomised participants and not by treatment group (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). A total of 22 serious adverse events were observed in 10 participants and 293 adverse events in 38 participants. It was reported that vaso‐occlusive pain crises, headache or migraine, upper respiratory infection, skin rash diarrhoea and abdominal pain were the most common adverse events during the trial and these events were evenly distributed across treatment groups. Two individuals, one receiving hydroxyurea and one not receiving hydroxyurea, experienced mild neutropenia. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002202-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002202-sec-0098"></div> <section id="CD002202-sec-0099"> <h3 class="title" id="CD002202-sec-0099">Summary of main results</h3> <p>Nine randomised controlled studies were eligible for inclusion in this review, with a total of 1104 children and adults with sickle cell disease (SCD) (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). The studies included in the review made the following comparisons: hydroxyurea compared to placebo (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>); hydroxyurea compared to no hydroxyurea (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>); hydroxyurea and phlebotomy compared to transfusion and chelation for the prevention of primary or secondary stroke (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>); and hydroxyurea compared to observation for participants at an increased risk of stroke (<a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>). </p> <p>The randomised studies comparing hydroxyurea with placebo showed a decrease in pain crises (albeit with slightly different criteria) in adults and children with sickle cell anaemia (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). The BABY HUG study also showed decreased rates of pain in the hydroxyurea group compared to placebo. This widening of inclusion criteria has had an important role in increasing indications for and use of hydroxyurea. Two studies comparing transfusion and hydroxyurea showed that transfusion was more effective in preventing 'serious' sickle‐related pain (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>), but there was no difference in all pain events between the two groups, as reported by one study (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). </p> <p>Rates of acute chest syndrome were decreased in those taking hydroxyurea when compared with those taking placebo and this was true in adults (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>) and children (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). Similar decreases were seen in transfusion rates, a surrogate for life‐threatening illness (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). Hydroxyurea did not prevent rates of hepatic or splenic sequestration when compared with placebo (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>The role of hydroxyurea compared with transfusion in the prevention of stroke has been investigated in two studies (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). The SWiTCH study included people with a previous stroke who had received at least 18 months of transfusion and randomised between ongoing transfusion therapy and hydroxyurea and phlebotomy (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). Treatment with hydroxyurea and phlebotomy was not expected to be as effective as transfusion in the reduction of secondary stroke but was expected to improve liver iron loads so a composite primary endpoint was used including stroke recurrence and liver iron concentration. In the 133 participants there were no strokes in the transfusion and chelation group but seven strokes (10%) in the hydroxyurea and phlebotomy group without concomitant improvement of liver iron concentration, leading to early trial closure. Hydroxyurea and phlebotomy were not as effective as transfusion for secondary stroke prevention. In the TWiTCH study, hydroxyurea was compared with transfusion in children with abnormal TCD velocities who had received transfusion for at least one year and had no evidence of vasculopathy on magnetic resonance angiogram (MRA) scan (<a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). Hydroxyurea was as effective as transfusion in preventing further stroke and final TCD velocity was lower in the hydroxyurea group. These findings are supported by observational data showing that in a non‐trial situation in children with abnormal TCDs who have normalised with transfusion, hydroxyurea can be used to maintain normal TCDs (<a href="./references#CD002202-bbs2-0055" title="BernaudinF , VerlhacS , ArnaudC , KamdemA , HauI , LeveilléE , et al. Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities. Blood2016;127(15):1814-22. [DOI: 10.1182/blood-2015-10-675231. Epub 2016 Feb 5.]">Bernaudin 2016</a>). </p> <p>In the randomised studies included in this analysis there was no statistically significant difference in mortality between any treatment and control group. Follow‐up from cohorts from the MSH study have been published at nine and 17.5 years (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>), although randomisation ceased after trial closure and participants could choose whether to take hydroxyurea or not (<a href="./references#CD002202-bbs2-0098" title="SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51.">Steinberg 2003</a>; <a href="./references#CD002202-bbs2-0099" title="SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8.">Steinberg 2010</a>). These follow‐up studies both confirmed reduced mortality in the group taking hydroxyurea, although the analysis was according to cumulative exposure to hydroxyurea and not the original randomisation. Further supporting evidence for reduced mortality with hydroxyurea comes from a prospective non‐randomised trial (LasHS) from Greece with 17 years of follow‐up, which showed improved probability of 10‐year survival in participants who were treated with hydroxyurea (<a href="./references#CD002202-bbs2-0108" title="VoskaridouE , ChristoulasD , BilalisA , PlataE , VarvagiannisK , StamatopoulosG , et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-centre trial (LaSHS). Blood2010;115:2354-63.">Voskaridou 2010</a>). These results should be treated cautiously as the participants were not randomised and the analysis of mortality in an observational study is more complex. </p> <p>In terms of chronic organ damage there were no statistically significant differences in renal and splenic function (the primary outcomes of <a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). Hydroxyurea had no significant effect on glomerular filtration rate over the two years of treatment, but it did improve urine concentrating ability and there was less renal enlargement in the hydroxyurea‐treated groups. </p> <p>Several of the randomised studies showed a statistically significant increase in foetal haemoglobin (HbF) levels in the groups treated with hydroxyurea, in keeping with the mechanism of action of the drug. This was seen both in participants treated with the maximum tolerated dose (MTD) of hydroxyurea (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>), and those treated with a standard dose (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>). A statistically significant increase in Hb level was seen in studies that compared hydroxyurea to placebo (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>; <a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>), and a decrease in haemolytic markers with hydroxyurea treatment was seen in some of the studies (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0004" title="JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. American Journal of Hematology2010;85(8):E42. [DOI: 10.1002/ajh.21763]JainD . Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute and Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. 2010:52. [ABSTRACT NO.: 076] [CENTRAL: CN-00746336] [CFGD REGISTER: SC211b] JainDL , SarathiV , DesaiS , BhatnagarM , LodhaA . Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin2012;36(4):323-32. [CENTRAL: 879848] [CFGD REGISTER: SC234] [PMID: 22734586]">Jain 2012</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0006" title="AnyanwuJN , WilliamsO , SautterCL , KasiryeP , HumeH , OpokaRO , et al. Novel use of hydroxyurea in an African region with malaria: protocol for a randomized controlled clinical trial. JMIR Research Protocols2016;5(2):e110. [CFGD REGISTER: SC286a] CarmanAS , SautterC , AnyanwuJN , SsemataAS , OpokaRO , WareRE , et al. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood &amp; Cancer2020;67(2):e27830. [CENTRAL: CN-02080753] [CFGD REGISTER: SC286k] [EMBASE: 628049884] [PMID: 31135090]DongM , MarahattaA , OpokaRO , McGannPT , JohnCC , WareRE , et al. PK/PD modeling of hydroxyurea treatment effects on fetal hemoglobin levels in young African children with sickle cell anemia. Journal of Pharmacokinetics and Pharmacodynamics2018;45(Suppl 1):S80. [CENTRAL: CN-01653655] [CFGD REGISTER: SC286j] [EMBASE: 624153366]MarahattaA , DongM , OpokaR , McElhinneyKE , LathamTS , JohnCC , et al. Pharmacokinetics of hydroxyurea therapy in African children with sickle cell anemia: a NOHARM ancillary PK study. Blood2017;130(Suppl 1):2252. [CENTRAL: CN-01450314] [CFGD REGISTER: SC286f] [DOI: /10.1182/blood.V130.Suppl_1.2252.2252] [EMBASE: 620385125]NCT01976416. Novel use of hydroxyurea in an African region with malaria. www.ClinicalTrials.gov/show/NCT01976416 (first received 5 November 2013). OpokaR , NdugwaC , LathamT , LaneA , HumeH , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): year 2 final results. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S104-5. [CFGD REGISTER: SC286e] OpokaR , NdugwaC , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a randomized controlled trial. Blood2017;130:Suppl 1. [CFGD REGISTER: SC286c] OpokaRO , HumeHA , LathamTS , LaneA , WilliamsO , TymonJ , et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica2020;105(6):E272-5. [CENTRAL: CN-02132252] [CFGD REGISTER: SC286l] [EMBASE: 2006098490] [PMID: 31649130]OpokaRO , NdugwaCM , LathamTS , LaneA , HumeHA , KasiryeP , et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood2017;130(24):2585-93. [CFGD REGISTER: SC286b] SiegertTF , CusickSE , WareRE , OpokaRO , JohnCC . Micronutrient levels in a pediatric Ugandan cohort with sickle cell anemia. American Journal of Tropical Medicine and Hygiene2018;99(4):158-9. [CENTRAL: CN-01935903] [CFGD REGISTER: SC286i] [EMBASE: 627539437]TymonJ , NakafeeroM , OpokaR , LaneA , LathamT , JohnC , et al. Novel use of hydroxyurea in an African region with malaria: effects of hydroxyurea treatment on transcranial doppler (TCD) velocities. Pediatric Blood &amp; Cancer2018;65(Suppl 1):S105-6. [CENTRAL: CN-01623446] [CFGD REGISTER: SC286h] [EMBASE: 621729104]">NOHARM 2017</a>). </p> <p>Those studies that used dose escalation to the MTD showed greater rates of cytopenias, which are expected as the dose of the drug is raised (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0007" title="HankinsJS , McCarvilleMB , Rankine-MullingsA , ReidME , LoboCL , MouraPG , et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. American Journal of Hematology2015;90(12):1099-105. [DOI: 10/1002/ajh.24198]NCT01531387. Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE). http://clinicaltrials.gov/show/NCT01531387 (first received 13 February 2012). ">SCATE 2015</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). The MSH study showed increased haematological toxicity resulting in a dose reduction in the hydroxyurea group as compared with placebo, but there were no infections related to neutropenia or bleeding episodes due to thrombocytopenia (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>). Similarly, the SWiTCH study showed significantly increased rates of reticulocytopenia, neutropenia and anaemia in the hydroxyurea group, compared with transfusion (<a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>). The BABY HUG study, which used a standard dose of 20 mg/kg of hydroxyurea, showed an increase in neutropenia (in terms of absolute neurophil count) in the hydroxyurea group but no increase in events of thrombocytopenia and no increase in the number of infections (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). There are no randomised studies comparing the effect of using a standard dose versus dose escalation to the MTD. Clearly, with careful laboratory monitoring and appropriate patient education, cytopenia should rarely represent a major issue as demonstrated. </p> <p>In the randomised studies comparing hydroxyurea with placebo there was no increase in adverse events related to hydroxyurea including hair loss, skin rash, fever and gastro‐intestinal disturbance. In addition, in the MSH study there was no increase in the incidence of leg ulcers and avascular necrosis in those treated with hydroxyurea. This is important as they have both been associated with hydroxyurea use in observational reports and leg ulcers are associated with hydroxyurea use in people with myeloproliferative disease. Furthermore, observational data looking at 15 years of hydroxyurea use from infancy has not shown any concerns about safety (<a href="./references#CD002202-bbs2-0071" title="HankinsJS , AygunB , NottageK , ThornburgC , SmeltzerMP , WareRE , et al. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine (Baltimore)2014;93(28):e215. [DOI: 10.1097/MD.0000000000000215]">Hankins 2014</a>), although as with the mortality data this is not based on randomised data and should be treated with caution. </p> </section> <section id="CD002202-sec-0100"> <h3 class="title" id="CD002202-sec-0100">Overall completeness and applicability of evidence</h3> <p>Evidence from the nine included studies is extensive and for four of the studies it is reported across many publications (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). Furthermore, as discussed in the <a href="#CD002202-sec-0099">Summary of main results</a>, evidence from these randomised studies is generally supported by longer‐term or observational evidence (or both). </p> <p>There are still questions about the impact of hydroxyurea on the chronic organ damage associated with SCD. Results from the BABY HUG study showed improved urine concentrating ability and less renal enlargement in the hydroxyurea‐treated groups. These results suggest that hydroxyurea may have some beneficial effect on renal function, but these results do not automatically translate into clinical benefit (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>). The long‐term effect of hydroxyurea, therefore, would benefit from further study, including effects on brain development, IQ, growth and development, as well as the prevention and management of chronic organ damage. </p> <p>As a chemotherapeutic agent, the cytostatic effects of hydroxyurea are different from those of radiation, alkylating agents and other anti‐cancer drugs, many of which are known to increase the risk of development of either leukaemia or cancer. Long‐term follow‐up of people taking hydroxyurea for other diagnoses, including polycythaemia rubra vera (<a href="./references#CD002202-bbs2-0054" title="BerkPD , WassermanLR , FruchtmanSM , GoldbergJD . Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LRBP , BerlinNI , editors(s). Polycythemia Vera and the Myeloproliferation Disorders. Philadelphia: WB Saunders, 1995:166-94.">Berk 1995</a>; <a href="./references#CD002202-bbs2-0064" title="FruchtmanSM , KaplanME , PetersonP , MackK , BerkPD , WassermanLR . Acute leukemia (AL), hydroxyurea (HU), and polycythemia vera (PV): an analysis of risk from the Polycythemia Vera Study Group. Blood1994;84(Suppl 1):518a.">Fruchtman 1994</a>; <a href="./references#CD002202-bbs2-0082" title="NajeanY , RainJD . Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood1997;90(9):3370-7.">Najean 1997</a>), essential thrombocythaemia (<a href="./references#CD002202-bbs2-0100" title="SterkersY , PreudhommeC , LaiJL , DemoryJL , CaulierMT , WattelE , et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood1998;91(2):616-22.">Sterkers 1998</a>) and cyanotic heart disease (<a href="./references#CD002202-bbs2-0105" title="TriadouP , Maier-RedelspergerM , KrishnamoortyR , DeschampsA , CasadevallN , DundaO , et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouvelle Revue Francaise d Hematologie1994;36(5):367-72.">Triadou 1994</a>), has shown no increase in malignancies in those with normal bone marrows and no significant increase in the other groups. There has been no evidence of malignancy in those with SCD treated with hydroxyurea in large observational studies (<a href="./references#CD002202-bbs2-0099" title="SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8.">Steinberg 2010</a>; <a href="./references#CD002202-bbs2-0108" title="VoskaridouE , ChristoulasD , BilalisA , PlataE , VarvagiannisK , StamatopoulosG , et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-centre trial (LaSHS). Blood2010;115:2354-63.">Voskaridou 2010</a>). Small numbers of case reports have reported myelodysplasia or acute leukaemia in people with SCD treated with hydroxyurea and two of these have been associated with 17p deletions. This is of interest as 17p deletions have also been associated with the development of myelodysplasia or acute leukaemia in people with myeloproliferative disease treated with hydroxyurea (<a href="./references#CD002202-bbs2-0048" title="AumontC , DrissF , LazureT , PicardV , CreidyR , De BottonS , et al. Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. American Journal of Hematology2015;90(7):E131-2.">Aumont 2015</a>; <a href="./references#CD002202-bbs2-0053" title="BazW , NajfeldV , YotsuyaM , TalwarJ , TerjanianT , ForteF . Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clinical Medicine Insights. Oncology2012;6:149-52.">Baz 2012</a>). In vitro work has not shown increased chromosome breakages or decreased repair in people with SCD on hydroxyurea (<a href="./references#CD002202-bbs2-0081" title="McGannPT , HowardTA , FlanaganJM , LahtiJM , WareRE . Chromosome damage and repair in children with sickle cell anaemia and long‐term hydroxycarbamide exposure. British Journal of Haematology2011;154(1):134-40.">McGann 2011</a>). </p> <p>Concerns have been raised about whether hydroxyurea is associated with abnormal spermatogenesis and teratogenic effects, but there are few data to confirm or refute that. There is a theoretical risk of hydroxyurea affecting sperm development and abnormal spermatogenesis has been shown in animals treated with hydroxyurea. Sperm abnormalities, including oligospermia and azoospermia, have been shown in males with SCD taking hydroxyurea, but it is not clear if these are due to the hydroxyurea as similar abnormalities have been described in males with SCD not taking hydroxyurea. One small study compared semen analysis before, during and after hydroxyurea treatment and showed semen parameters were affected whilst on hydroxyurea and did not seem to recover quickly (<a href="./references#CD002202-bbs2-0056" title="BerthautI , GuignedouxG , Kirsch-NoirF , deLarouziereV , RavelC , BachirD , et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica2008;93(7):988-93.">Berthaut 2008</a>). This included only small numbers of individuals and needs further investigation. </p> <p>Evidence of adverse outcomes and teratogenic effects in humans exposed to hydroxyurea in utero is limited. There is case report evidence of women with malignant disease taking hydroxyurea through pregnancy with no adverse effects on the foetus and 17‐year follow‐up of the MSH study has shown no adverse foetal outcomes in males or females taking hydroxyurea at conception (<a href="./references#CD002202-bbs2-0051" title="BallasSK , GuoN , DeCastroL , BellevueR . Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. JAMA2009;101(10):1046.">Ballas 2009</a>) (<a href="#CD002202-tbl-0009">Table 5</a>). An expert panel report evaluating the toxicity of hydroxyurea has led to recommendations that hydroxyurea is stopped in men and women who are trying to conceive and in breastfeeding women (<a href="./references#CD002202-bbs2-0083" title="National Toxicology Program. NTP-CERHR monograph on the potential human reproductive and developmental effects of hydroxyurea. NTP CERHR MON2008;Oct(21):vii-viii, v, ix-III1. [NIH PUBLICATION NO: 08-5993]">National Toxicology Program 2008</a>). The risks of stopping hydroxyurea whilst attempting conception should be carefully discussed with the individual. </p> <div class="table" id="CD002202-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Pregnancies in the MSH Study</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Pregnancy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal full‐term delivery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elective termination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Partners of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal full‐term delivery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spontaneous abortion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Still pregnant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>TOTAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> </tr> </tbody> </table> </div> <p>The CHAMPS study was the only study to include participants with HbSC (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>). It was not powered to measure efficacy and terminated early due to low enrolment so it is not possible to make conclusions about the efficacy of hydroxyurea in prevention of pain episodes in people with HbSC. Observational data suggest it may be safe and effective in selected individuals, but this needs further study with a phase III randomised study (<a href="./references#CD002202-bbs2-0079" title="Luchtman‐JonesL , PresselS , HilliardL , BrownRC , SmithMG , ThompsonAA , et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. American Journal of Hematology2016;91(2):238-42.">Luchtman‐Jones 2016</a>). A total of 165 people with HbS/B+thalassaemia were included in one observational study but only 44 received hydroxyurea and efficacy in this subgroup was not presented separately (<a href="./references#CD002202-bbs2-0108" title="VoskaridouE , ChristoulasD , BilalisA , PlataE , VarvagiannisK , StamatopoulosG , et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-centre trial (LaSHS). Blood2010;115:2354-63.">Voskaridou 2010</a>). </p> </section> <section id="CD002202-sec-0101"> <h3 class="title" id="CD002202-sec-0101">Quality of the evidence</h3> <p>We judged the quality of the evidence for the comparison 'Hydroxyurea compared to placebo' to be moderate for primary outcomes and low for HbF (%), quality of life and adverse events, where data were more limited and imprecise (<a href="./full#CD002202-tbl-0001">summary of findings Table 1</a>). </p> <p>Similarly, we judged the quality of the evidence for the comparison 'Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke' to be moderate‐quality (life‐threatening illness and measures of HbF and neutrophil counts) or low‐quality (pain alteration, deaths during the study and adverse events) where data were more limited and imprecise (<a href="./full#CD002202-tbl-0002">summary of findings Table 2</a>). </p> <p>The studies contributing the majority of the evidence to these comparison were large, generally well‐designed and at low risk of bias (<a href="./references#CD002202-bbs2-0001" title="AdamsRJ , BarredoJ , BondsDR , BrownC , CasellaJ , DanerL , et al. TCD in infants: a report from the BABY HUG trial. Blood2005;106(11):952. [ABSTRACT NO: 952] [CFGD REGISTER: SC180f] AdamsRJ , LudenJ , MillerS , WangW , ReesR , LiD , et al. TCD in infants: a report from the Baby Hug study. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:105. [CFGD REGISTER: SC180a] AlvarezO , MillerST , WangWC , LuoZ , McCarvilleMB , SchwartzGJ , et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(4):668-74. [CENTRAL: 848700] [CFGD REGISTER: SC180gg] [PMID: 22294512]ArmstrongFD , ElkinTD , BrownRC , GlassP , RanaS , CasellaJF , et al. Developmental function in toddlers with sickle cell anemia. Pediatrics2013;131(2):e406-14. [CENTRAL: 853612] [CFGD REGISTER: SC180mm] [PMID: 23296434]ArmstrongFD , ElkinTD , BrownRC , GlassP , ReesRC , WangWC , et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):713. [CFGD REGISTER: SC180p] ArmstrongFD , ReesRC , LiD , BonnerM , ElkinD , StrouseJJ , et al. Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug). In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:137. [CFGD REGISTER: SC180c] CasellaJF , WangWC , RogersZR , IyerRV , RanaS , DriscollMC , et al. Progress of the multicenter trial of hydroxyurea in infants with sickle cell anemia (BABY HUG) and assessment of baseline splenic and renal function. In: Pediatric Academic Societies Annual Meeting. Vol. 57. 2005:1111. [CFGD REGISTER: SC180pp] KalpatthiR , ThompsonB , LuM , WangWC , PatelN , KutlarA , et al. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clinical Biochemistry2013;46(3):278-81. [CENTRAL: 977455] [CFGD REGISTER: SC180kk] [PMID: 23123915]LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando. 2010. [ABSTRACT NO: 1631] [CFGD REGISTER: SC180aa] LebensburgerJD , MillerST , HowardTH , CasellaJF , BrownRC , LuM , et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood &amp; Cancer2012;59(4):675-8. [CENTRAL: 854381] [CFGD REGISTER: SC180hh] [PMID: 22190441]LedermanHM , ConnollyMA , KalpatthiR , WareRE , WangWC , Luchtman-JonesL , et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics2014;134(4):686-95. [CENTRAL: 1053679] [CFGD REGISTER: SC180oo] [PMID: 25180279]LedermanHM , ConnollyMA , WareRE , Luchtman-JonesL , GoldsmithJC . Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood2012;120(21):243. [ABSTRACT NO: 243] [CENTRAL: 977456] [CFGD REGISTER: SC180jj] ManwaniD . Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine2012;17(2):37-8. [CFGD REGISTER: SC180tt] [CFGD REGISTER: SC180tt] McCarvilleMB , LuoZ , HuangX , ReesRC , RogersZR , MillerST , et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. AJR American Journal of Roentgenology2011;196(6):1399-404. [CFGD REGISTER: SC180z] McCarvilleMB , ReesRC , RogersZR , KalpatthiR , MillerST , WangWC , et al. Abdominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 212] [CFGD REGISTER: SC180r] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 8] [CFGD REGISTER: SC180cc] McGannPT , FlanaganJM , HowardTA , DertingerSD , HeJ , KulharyaAS , et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatric Blood &amp; Cancer2012;59(2):254-7. [CENTRAL: 854422] [CFGD REGISTER: SC180ff] [PMID: 22012708]MillerST , BarredoJ , BrownC , BondsDR , CasellaJF , LiD , et al. Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006. [ABSTRACT NO: 141] [CFGD REGISTER: SC180d] MillerST , ReyK , HeJ , FlanaganJ , FishBJ , RogersZR , et al. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood &amp; Cancer2012;59(1):170-2. [CFGD REGISTER: SC180ee] MillerST , WangWC , IyerR , RanaS , LaneP , WareRE , et al. Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood &amp; Cancer2010;54(2):265-8. [CFGD REGISTER: SC180v] MillerST , WangWC , IyerRV , RanaSR , LanePA , WareRE , et al. Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood2008;112(11):1413. [CFGD REGISTER: SC180n] MillerST , WareRE , KutlarA , AlvarezOA , IyerRV , SarnaikSA , et al. Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):4791. [CFGD REGISTER: SC180i] NCT00006400. Hydroxyurea to prevent organ damage in children with sickle cell anemia. https://ClinicalTrials.gov/show/NCT00006400 (first received 13 October 2000). [CFGD REGISTER: SC180xx] PavlakisSG , ReesRC , HuangX , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):256-9. [CFGD REGISTER: SC180t] RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. [CFGD REGISTER: SC180rr] [PMID: 25157002]RanaS , HoustonPE , WangWC , IyerRV , GoldsmithJ , CasellaJF , et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics2014;134(3):465-72. Supplemental information. http://pediatrics.aappublications.org/content/134/3/465.supplemental. [CFGD REGISTER: SC180ss] RogersZ , AssmannS , LebensburgerJ , BrownRC , MajumdarS , CasellaJ , et al. Follow-up of hydroxyurea (hu) in infants with sickle cell anemia(sca): findings from baby hug studies. Pediatric Blood &amp; Cancer2020;67(Suppl 2):Paper Session # 2009. [CFGD REGISTER: SC180yy] [DOI: 10.1002/pbc.28321]RogersZR , CapparelliEV , ThompsonB , WareRE , WangWC , IyerRV , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial. In: 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006:157. [CFGD REGISTER: SC180e] RogersZR , FishB , LuoZ , IyerRV , ThornburgCD , SarnaikSA , et al. Hydroxyurea treatment of young children with sickle cell anemia: safety and efficacy of continued treatment-the BABY HUG follow-up study. Blood2011;118(21):Abstract 7. [CENTRAL: CN-01033070] [CFGD REGISTER: SC180ww] [DOI: 10.1182/blood.V118.21.7.7] [EMBASE: 70771818]RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1416. [CFGD REGISTER: SC180L] RogersZR , ReesRC , FilesB , IyerRV , ShulkinBL , Shalaby-RanaE , et al. Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 199] [CFGD REGISTER: SC180q] RogersZR , ReesRR , WangWC , LiD , IyerRV , RanaS , et al. Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial. In: 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio. 2005:106. [CFGD REGISTER: SC180b] RogersZR , ThompsonB , WareRE , WangWC , IyerRV , MillerST , et al. Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial. In: Blood. 2005. [ABSTRACT NO: 3184] [CFGD REGISTER: SC180g] SheehanVA , LuoZ , FlanaganJM , HowardTA , ThompsonBW , WangWC , et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology2013;88(7):571-6. [CENTRAL: 983421] [CFGD REGISTER: SC180nn] [PMID: 23606168]ThompsonBW , MillerST , RogersZR , ReesRC , WareRE , WaclawiwMA , et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatric Blood &amp; Cancer2010;54(2):250-5. [CFGD REGISTER: SC180s] ThompsonBW , WangWC , MillerST , RogersZR , WareRE , ThornburgCD , et al. The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA). In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 2134] [CFGD REGISTER: SC180dd] Thornburg CD,  CalatroniA ,  TelenM ,  Kemper AR . Adherence to hydroxyurea therapy in children with sickle cell anemia. Journal of Paediatrics2010;156(3):415-9. [CFGD REGISTER: SC180o] [DOI: 10.1016/j.jpeds.2009.09.044]ThornburgCD , FilesBA , LuoZ , MillerST , KalpatthiR , IyerR , et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood2012;120(22):4304-10; quiz 4448. [CENTRAL: 853818] [CFGD REGISTER: SC180ii] [PMID: 22915643]ThornburgCD , RogersZR , JengMR , RanaSR , IyerRV , FaughnanL , et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatric Blood &amp; Cancer2010;54(2):260-4. [CFGD REGISTER: SC180u] ThornburgCD , RogersZR , WangW , JengM , RanaSR , IyerRV , et al. Study drug and visit adherence: data from the Baby HUG trial. Blood2008;112(11):1275. [CFGD REGISTER: SC180o] WangW , LuoZ , AlvarezO , FixlerJ , MillerS , WareRE , et al. Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: analysis F from the BABY HUG trial. American Journal of Hematology2012;7:E20-1. [CFGD REGISTER: SC180uu] WangW , ReesRC , MillerST , BrownRC , CasellaJF , IyerRV , et al. Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1436. [CFGD REGISTER: SC180j] WangWC , OyekuSO , LuoZ , BouletSL , MillerST , CasellaJF , et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics2013;132(4):677-83. [CENTRAL: 962768] [CFGD REGISTER: SC180ll] [PMID: 23999955]WangWC , WareRE , MillerST , IyerRV , CasellaJF , MinnitiCP , et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet2011;377(9778):1663-72. [CFGD REGISTER: SC180y] WangWC , YekuSO , LuoZ , BouletSL , MillerST , FishB , et al. Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego. 2011. [ABSTRACT NO: 171] [CFGD REGISTER: SC180bb] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood2008;112(11):1414. [CFGD REGISTER: SC180m] WareRE , ReesRC , SarnaikSA , IyerRV , AlvarezOA , CasellaJF , et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics2010;156(1):66-70. [CFGD REGISTER: SC180w] WynnL , DebenhamE , FaughnanL , MartinB , KellyT , ReedC , et al. Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial. In: 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007:245. [CFGD REGISTER: SC180h] WynnL , MillerS , FaughnanL , LuoZ , DebenhamE , AdixL , et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemporary Clinical Trials2010;31(6):558-63. [CFGD REGISTER: SC180x] WynnLW , FaughnanL , LiD , WangW , MartinB , KellyT , et al. Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study. Blood2008;112(11):1429. [CFGD REGISTER: SC180k] ">BABY HUG 2011</a>; <a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>; <a href="./references#CD002202-bbs2-0008" title="AlvarezO , YovetichNA , ScottJP , OwenW , MillerST , SchultzW , et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. American Journal of Hematology2013;88(11):932-8. [CENTRAL: 963136] [PMID: 23861242]AygunB , MortierNA , KeslerK , LockhartA , SchultzWH , CohenAR , et al. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology2015;169(2):262-6. [CFGD REGISTER: SC220k] [PMID: 25612463]AygunB , MortierNA , KeslerK , SchultzWH , AlvarezOA , RogersZR , et al. Therapeutice phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience. In: 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [ABSTRACT NO: 1044] HeltonKJ , AdamsRJ , KeslerKL , LockhartA , AygunB , DriscollC , et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood2014;124(6):891-8. [CFGD REGISTER: SC220j] KwiatkowskiJL , CohenAR , GarroJ , AlvarezO , NagasubramanianR , SarnaikS , et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. American Journal of Hematology2012;87(2):221-3. [CENTRAL: 864015] [PMID: 22120913]NCT00122980. Stroke with transfusions changing to hydroxyurea. clinicaltrials.gov/show/NCT00122980 (first received 20 July 2005). NIH News Release. Stroke prevention study in children with sickle cell anemia, iron overload stopped early. www.nih.gov/news/health/jun2010/nhlbi-03.htm2010. [CFGD REGISTER: SC220l] SheehanVA , HowardTA , SaboA , NagasaswamyU , CrosbyJR , DavisB , et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood2012;120(21):241. [ABSTRACT NO: 241] [CENTRAL: 977454] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. American Journal of Hematology2011;86(11). [ABSTRACT: 844] [CFGD REGISTER: SC220m] WareRE , HelmsRW . Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia. In: 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida. 2010. [ABSTRACT NO: 844] WareRE , HelmsRW . Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood2012;119(17):3925-32. [CENTRAL: 849022] WareRE , McMurrayMA , SchultzWH , AlvarezOA , AygunB , CavalierME , et al. Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke. Blood2006;108(11):Abst 1213. WareRE , SchultzWH , YovetichN , MortierNA , AlvarezO , HilliardL , et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood &amp; Cancer2011;57(6):1011-7. [CENTRAL: 806683] ">SWiTCH 2012</a>; <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>). These studies recruited only individuals with the HbSS genotype or the HbSβºthal genotype, therefore the results are not applicable to those with the HbSC genotype. Furthermore, for the two most recently completed studies, results for secondary outcomes such as neuropsychological status, growth and development, functional evaluations and neurocognitive evaluations have not yet been reported. Any results relevant to this review from further publications will be included in updates of this review. </p> <p>For the other two comparisons in the review 'Hydroxyurea compared to observation for participants with SCD and risk of stroke' and 'Hydroxyurea compared to no hydroxyurea for participants with SCD', evidence was limited and of very low quality (<a href="./full#CD002202-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD002202-tbl-0004">summary of findings Table 4</a>). Only a single study contributed to each outcome and both of these studies are likely underpowered due to early termination after recruiting only around 20% of their target participants. Furthermore, due to the factorial design of one of the studies (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>), a direct comparison between hydroxyurea and a control treatment was not possible so all results for this comparison must be interpreted as indirect. </p> </section> <section id="CD002202-sec-0102"> <h3 class="title" id="CD002202-sec-0102">Potential biases in the review process</h3> <p>We applied a rigorous methodological approach to the review and employed a comprehensive search strategy as outlined in <a href="#CD002202-sec-0024">Electronic searches</a>, therefore we do not believe that our methodological approach has introduced any bias into the review. </p> <p>Given the designs of some of the studies included in this review (e.g. cross‐over, factorial) and differing study‐defined definitions of the outcomes of interest to this review, in many instances we felt it would be more appropriate to summarise results narratively or perform separate analyses rather than attempting to adjust original results in order to perform meta‐analysis. </p> <p>We encourage particular caution when interpreting the results of the outcome 'adverse events or toxicity', as it is difficult to distinguish between adverse reactions (i.e. adverse events that are definitely drug‐related) and other adverse events that may be sickle‐ or transfusion‐related. For completeness, we have reported all "adverse events" or "adverse effects" as they are reported in the study publications, regardless of any noted relationship to treatment. </p> </section> <section id="CD002202-sec-0103"> <h3 class="title" id="CD002202-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>As described earlier in this section, there have been several studies supporting the findings of this review. In addition to these, numerous reviews and other studies discussing the role of hydroxyurea in SCD are available but this is the only Cochrane Review of the topic. A report from the National Institutes of Health (NIH) reviewed 414 studies reporting on the role of hydroxyurea in SCD (published up until July 2014) and included five of the randomised studies included in this review (<a href="./references#CD002202-bbs2-0086" title="Evidence Based Management of Sickle Cell Disease. Expert Panel Report. National Institute of Health. 2014. www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/sickle-cell-disease-report%20020816.pdf (accessed 19 September 2016).">NIH 2014</a>). In some cases in the NIH review, where a literature search was not conducted or was insufficient, the panel relied on their cumulative expertise and knowledge to make consensus‐panel recommendations as outlined below. </p> <section id="CD002202-sec-0104"> <h4 class="title">Strong recommendations with high‐quality evidence</h4> <p> <ol id="CD002202-list-0009"> <li> <p>In adults with sickle cell anaemia who have three or more sickle cell‐associated moderate to severe pain crises in a 12‐month period, treat with hydroxyurea. </p> </li> <li> <p>In infants of nine to 42 months with sickle cell anaemia, offer treatment with hydroxyurea regardless of clinical severity to reduce SCD‐related complications (e.g. pain, dactylitis, acute chest syndrome, anaemia). </p> </li> <li> <p>To ensure proper use of hydroxyurea and maximise benefits and safety, use an established prescribing and monitoring protocol. </p> </li> </ol> </p> </section> <section id="CD002202-sec-0105"> <h4 class="title">Strong recommendations with moderate quality‐evidence</h4> <p> <ol id="CD002202-list-0010"> <li> <p>In adults with sickle cell anaemia who have sickle cell‐associated pain that interferes with daily activities and quality of life, treat with hydroxyurea. </p> </li> <li> <p>In adults with sickle cell anaemia who have a history of severe or recurrent acute chest syndrome (or both), treat with hydroxyurea. </p> </li> <li> <p>In adults with sickle cell anaemia who have severe symptomatic chronic anaemia that interferes with daily activities or quality of life, treat with hydroxyurea. </p> </li> </ol> </p> <p>The group also made an additional moderate recommendation with moderate‐quality evidence that children over 42 months and adolescents with sickle cell anaemia should be offered treatment with hydroxyurea regardless of clinical severity to reduce SCD‐related complications (e.g. pain, dactylitis, acute chest syndrome, anaemia). There were additional moderate and weak recommendations with low‐ and very low‐quality evidence and a consensus panel recommendation. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002202-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for this review (2022)" data-id="CD002202-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for this review (2022)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002202-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 1: Pain crises" data-id="CD002202-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 1: Pain crises </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 2: Proportion experiencing pain" data-id="CD002202-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 2: Proportion experiencing pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 3: Proportion experiencing life‐threatening events during study" data-id="CD002202-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 3: Proportion experiencing life‐threatening events during study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 4: Number of life‐threatening events during study" data-id="CD002202-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 4: Number of life‐threatening events during study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 5: Deaths during the study" data-id="CD002202-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 5: Deaths during the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 6: Change from baseline in foetal haemoglobin (HbF%)" data-id="CD002202-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 6: Change from baseline in foetal haemoglobin (HbF%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 7: Change from baseline in absolute neutrophil count (ANC, x10⁹/L)" data-id="CD002202-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 7: Change from baseline in absolute neutrophil count (ANC, x10⁹/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 8: Foetal haemoglobin (HbF%) after treatment" data-id="CD002202-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 8: Foetal haemoglobin (HbF%) after treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 9: Neutrophil response (x10⁹/L) after treatment" data-id="CD002202-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 9: Neutrophil response (x10⁹/L) after treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 10: Change from baseline in haemoglobin (g/L)" data-id="CD002202-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 10: Change from baseline in haemoglobin (g/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 11: Change from baseline in mean corpuscular volume (fL)" data-id="CD002202-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 11: Change from baseline in mean corpuscular volume (fL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 12: Change from baseline in white blood cell (WBC) count (x10⁹/L)" data-id="CD002202-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 12: Change from baseline in white blood cell (WBC) count (x10⁹/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 13: Change from baseline in absolute reticulocyte count (x10⁹/L)" data-id="CD002202-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 13: Change from baseline in absolute reticulocyte count (x10⁹/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 14: Change from baseline in reticulocytes (%)" data-id="CD002202-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 14: Change from baseline in reticulocytes (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 15: Change from baseline in platelet count (10⁹/L)" data-id="CD002202-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 15: Change from baseline in platelet count (10⁹/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 16: Change from baseline in creatinine (mg/dL)" data-id="CD002202-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 16: Change from baseline in creatinine (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 17: Change from baseline in total bilirubin (mg/L)" data-id="CD002202-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 17: Change from baseline in total bilirubin (mg/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 18: Change from baseline in alanine transferase (ALT) (U/L)" data-id="CD002202-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 18: Change from baseline in alanine transferase (ALT) (U/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 19: Haemoglobin (g/dL)" data-id="CD002202-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 19: Haemoglobin (g/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 20: Mean corpuscular volume (fL)" data-id="CD002202-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 20: Mean corpuscular volume (fL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 21: White blood cells (WBC) count at the end of the study" data-id="CD002202-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 21: White blood cells (WBC) count at the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 22: Reticulocytes (10⁹/L)" data-id="CD002202-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 22: Reticulocytes (10⁹/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 23: Reticulocytes (10⁵/mm³) at 18 months" data-id="CD002202-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 23: Reticulocytes (10⁵/mm³) at 18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 24: Total bilirubin (mg/L)" data-id="CD002202-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 24: Total bilirubin (mg/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 25: Platelet count (10⁹/L)" data-id="CD002202-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 25: Platelet count (10⁹/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 26: Platelet count (10³/mm³) at 18 months" data-id="CD002202-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 26: Platelet count (10³/mm³) at 18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 27: Packed cell volume" data-id="CD002202-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 27: Packed cell volume </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 28: F reticulocytes" data-id="CD002202-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 28: F reticulocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 29: F cells" data-id="CD002202-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 29: F cells </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 30: Red blood count" data-id="CD002202-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 30: Red blood count </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 31: Dense cells" data-id="CD002202-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 31: Dense cells </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 32: Leucocytes" data-id="CD002202-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 32: Leucocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 33: Alanine transferase (ALT) (U/L)" data-id="CD002202-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 33: Alanine transferase (ALT) (U/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 34: Creatinine (mg/dL) at the end of the study" data-id="CD002202-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 34: Creatinine (mg/dL) at the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 35: Aspartate aminotransferase" data-id="CD002202-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 35: Aspartate aminotransferase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 36: Alkaline phosphatase" data-id="CD002202-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 36: Alkaline phosphatase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 37: Change from baseline in growth" data-id="CD002202-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 37: Change from baseline in growth </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 38: Quality of life: general health perception" data-id="CD002202-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 38: Quality of life: general health perception </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 39: Quality of life: pain recall" data-id="CD002202-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 39: Quality of life: pain recall </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 40: Quality of life: social function" data-id="CD002202-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 40: Quality of life: social function </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 41: Changes in 'Ladder of Life'" data-id="CD002202-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 41: Changes in 'Ladder of Life' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.41.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.42" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 42: Proportion of participants with signs of organ damage" data-id="CD002202-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.42.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.42.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 42: Proportion of participants with signs of organ damage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.42.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.43" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 43: Signs of organ damage ‐ change from baseline in DTPA GFR" data-id="CD002202-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.43.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.43.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 43: Signs of organ damage ‐ change from baseline in DTPA GFR </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.43.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.44" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 44: Signs of organ damage ‐ change from baseline in Howell‐Jolley body (per 106 red blood cells)" data-id="CD002202-fig-0046" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.44.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.44.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 44: Signs of organ damage ‐ change from baseline in Howell‐Jolley body (per 10<sup>6</sup> red blood cells) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.44.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.45" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 45: Signs of organ damage ‐ change from baseline in pitted cells (%)" data-id="CD002202-fig-0047" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.45.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.45.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 45: Signs of organ damage ‐ change from baseline in pitted cells (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.45.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.46" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 46: Signs of organ damage ‐ change from baseline in spleen: liver ratio of counts" data-id="CD002202-fig-0048" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.46.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.46.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 46: Signs of organ damage ‐ change from baseline in spleen: liver ratio of counts </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.46.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.47" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 47: Signs of organ damage ‐ change from baseline in spleen volume (cm3)" data-id="CD002202-fig-0049" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.47.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.47.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 47: Signs of organ damage ‐ change from baseline in spleen volume (cm<sup>3</sup>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.47.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.48" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 48: Signs of organ damage ‐ change from baseline in creatinine (mg/L)" data-id="CD002202-fig-0050" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.48.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.48.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 48: Signs of organ damage ‐ change from baseline in creatinine (mg/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.48.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.49" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 49: Signs of organ damage ‐ change from baseline in Schwartz GFR" data-id="CD002202-fig-0051" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.49.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.49.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 49: Signs of organ damage ‐ change from baseline in Schwartz GFR </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.49.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.50" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 50: Signs of organ damage ‐ change from baseline in cystatin C" data-id="CD002202-fig-0052" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.50.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.50.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.50</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 50: Signs of organ damage ‐ change from baseline in cystatin C </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.50.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.51" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 51: Signs of organ damage ‐ change from baseline in urine osmolality" data-id="CD002202-fig-0053" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.51.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.51.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.51</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 51: Signs of organ damage ‐ change from baseline in urine osmolality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.51.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.52" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 52: Signs of organ damage ‐ change from baseline in urine pH" data-id="CD002202-fig-0054" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.52.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.52.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.52</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 52: Signs of organ damage ‐ change from baseline in urine pH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.52.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.53" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 53: Signs of organ damage ‐ change from baseline in urine‐specific gravity" data-id="CD002202-fig-0055" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.53.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.53.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.53</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 53: Signs of organ damage ‐ change from baseline in urine‐specific gravity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.53.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.54" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 54: Signs of organ damage ‐ change from baseline in total kidney volume" data-id="CD002202-fig-0056" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.54.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.54.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.54</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 54: Signs of organ damage ‐ change from baseline in total kidney volume </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.54.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.55" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 55: Signs of organ damage ‐ change from baseline in TCD ultrasound velocity (time‐averaged mean maximum velocity)" data-id="CD002202-fig-0057" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.55.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.55.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.55</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 55: Signs of organ damage ‐ change from baseline in TCD ultrasound velocity (time‐averaged mean maximum velocity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.55.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.56" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 56: Signs of organ damage ‐ change from baseline in CNS measures" data-id="CD002202-fig-0058" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.56.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.56.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.56</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 56: Signs of organ damage ‐ change from baseline in CNS measures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.56.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.57" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 57: Proportion of participants experiencing adverse events and toxicity" data-id="CD002202-fig-0059" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.57.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.57.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.57</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 57: Proportion of participants experiencing adverse events and toxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.57.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-001.58" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 58: Proportion with SCA‐related events (composite outcome)" data-id="CD002202-fig-0060" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.58.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-001.58.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.58</div> <div class="figure-caption"> <p>Comparison 1: Hydroxyurea versus placebo for participants with sickle cell disease, Outcome 58: Proportion with SCA‐related events (composite outcome) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-001.58.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 1: Proportion experiencing pain" data-id="CD002202-fig-0061" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 1: Proportion experiencing pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 2: Proportion experiencing life‐threatening events during study" data-id="CD002202-fig-0062" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 2: Proportion experiencing life‐threatening events during study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 3: Deaths during the study" data-id="CD002202-fig-0063" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 3: Deaths during the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 4: Change from baseline in foetal haemoglobin (HbF %)" data-id="CD002202-fig-0064" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 4: Change from baseline in foetal haemoglobin (HbF %) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 5: Change from baseline in absolute neutrophil count (x10⁹/L)" data-id="CD002202-fig-0065" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 5: Change from baseline in absolute neutrophil count (x10⁹/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 6: Change from baseline in mean corpuscular volume (fL)" data-id="CD002202-fig-0066" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 6: Change from baseline in mean corpuscular volume (fL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 7: Change from baseline in sickle haemoglobin (%)" data-id="CD002202-fig-0067" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 7: Change from baseline in sickle haemoglobin (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 8: Change from baseline in haemoglobin (g/L)" data-id="CD002202-fig-0068" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 8: Change from baseline in haemoglobin (g/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 9: Change from baseline in absolute reticulocyte count (10⁹ / L)" data-id="CD002202-fig-0069" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 9: Change from baseline in absolute reticulocyte count (10⁹ / L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 10: Change from baseline in white blood count (10⁹ / L)" data-id="CD002202-fig-0070" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 10: Change from baseline in white blood count (10⁹ / L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 11: Change from baseline in platelets (10⁹/L)" data-id="CD002202-fig-0071" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 11: Change from baseline in platelets (10⁹/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 12: Change from baseline in total bilirubin (mg/L)" data-id="CD002202-fig-0072" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 12: Change from baseline in total bilirubin (mg/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 13: Change from baseline in liver iron concentration" data-id="CD002202-fig-0073" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 13: Change from baseline in liver iron concentration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 14: Change from baseline in serum ferritin (ng/mL)" data-id="CD002202-fig-0074" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 14: Change from baseline in serum ferritin (ng/mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 15: Change from baseline in lactate dehydrogenase (U/L)" data-id="CD002202-fig-0075" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 15: Change from baseline in lactate dehydrogenase (U/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 16: Signs of organ damage ‐ CNS measures at the end of the study" data-id="CD002202-fig-0076" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 16: Signs of organ damage ‐ CNS measures at the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 17: Proportion of participants experiencing non‐neurological adverse events and toxicity" data-id="CD002202-fig-0077" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke, Outcome 17: Proportion of participants experiencing non‐neurological adverse events and toxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hydroxyurea compared to observation for participants with SCD and risk of stroke, Outcome 1: Proportion experiencing life‐threatening events during the study" data-id="CD002202-fig-0078" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Hydroxyurea compared to observation for participants with SCD and risk of stroke, Outcome 1: Proportion experiencing life‐threatening events during the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hydroxyurea compared to observation for participants with SCD and risk of stroke, Outcome 2: Signs of organ damage ‐ proportion of participants with a change in CNS measures" data-id="CD002202-fig-0079" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Hydroxyurea compared to observation for participants with SCD and risk of stroke, Outcome 2: Signs of organ damage ‐ proportion of participants with a change in CNS measures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hydroxyurea compared to observation for participants with SCD and risk of stroke, Outcome 3: Signs of organ damage ‐ change from baseline in CNS measures" data-id="CD002202-fig-0080" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Hydroxyurea compared to observation for participants with SCD and risk of stroke, Outcome 3: Signs of organ damage ‐ change from baseline in CNS measures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002202-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/urn:x-wiley:14651858:media:CD002202:CD002202-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Hydroxyurea compared to observation for participants with SCD and risk of stroke, Outcome 4: Adverse events and toxicity" data-id="CD002202-fig-0081" src="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_t/tCD002202-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Hydroxyurea compared to observation for participants with SCD and risk of stroke, Outcome 4: Adverse events and toxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/media/CDSR/CD002202/image_n/nCD002202-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002202-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea compared with placebo for sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Hydroxyurea compared with placebo for sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population</b>: adults and children with sickle cell disease </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: hydroxyurea </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain alteration<sup>a</sup> </b> </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All studies showed a significant advantage to hydroxyurea compared to placebo (different measures of pain alteration presented)<b><sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>784</p> <p>(5 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life‐threatening illness</b> </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Significantly fewer occurrences of ACS (3 studies) and transfusions (4 studies) on hydroxyurea compared to placebo. No significant differences in terms of stroke, hepatic or splenic sequestration (2 studies). </p> <p>In 1 study, 6 serious adverse events of bacteraemia/sepsis were reported in each of the hydroxyurea and placebo groups and 1 serious adverse event of anaemia was reported in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>759</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during the study</b> (all deaths) </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> <p>(3 to 36 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65 (0.19 to 2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>784</p> <p>(5 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was also no significant difference between groups in terms of deaths related to SCD. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of HbF</b> (%) </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant increase in HbF(%) in the hydroxyurea group compared to the placebo group in all studies (different measures presented).<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>784</p> <p>(5 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>e,f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of ANC</b> </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant decrease in ANC in the hydroxyurea group compared to the placebo group in all studies (different measures presented).<b><sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724</p> <p>(4 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b>: 'Health Status Survey', the 'Profile of Mood States' and the 'Ladder of Life' </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant difference in terms of any domain of any scale except for pain recall at 18 months (MD 0.70, 95% CI 0.11 to 1.29, P = 0.02).<b><sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 277</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>e,g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events or toxicity</b>: differences in rates of specific adverse events </p> <p>Follow‐up: 6 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Significantly fewer events of hospitalisation, dactylitis, sepsis or bacteraemia, anaemia and gastroenteritis, and significantly more events of thrombocytopenia and ANC raised to between 500 to 1250 in the hydroxyurea compared to the placebo group. </p> <p>No significant differences between groups in terms of all other events.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>784</p> <p>(5 studies)<b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>e,h</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study also reported statistically significantly fewer composite SCA‐related events (vaso‐occlusive pain crisis, dactylitis, acute chest syndrome, splenic sequestration or blood transfusion) in the hydroxyurea group compared to the placebo group: RR 0.66 (95% CI 0.51 to 0.84). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>The basis for the <b>assumed risk</b> is the event rate in the control group unless otherwise stated in the comments and footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ACS</b> : acute chest syndrome; <b>ANC</b> : absolute neutrophil counts; <b>CI</b> : confidence interval; <b>HbF</b> : foetal haemoglobin; <b>MD</b> : mean difference;<b>NA</b> : not applicable; <b>RR</b> : risk ratio; <b>SCA</b> : sickle cell anaemia; <b>SCD</b>: sickle cell disease. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b><sup>a</sup> </b>Pain alteration measured by mean annual pain crisis rate, time from initiation of treatment to first, second or third crisis, number of vaso‐occlusive crises, proportion of participants experiencing pain, proportion of hospitalisations for painful episodes. </p> <p><b><sup>b</sup> </b>One study of 25 participants is of a cross‐over design and participants are counted only once in this total (<a href="./references#CD002202-bbs2-0002" title="FersterA , VermylenC , CornuG , BuyseM , CorazzaF , DevalckC , et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996;88(6):1960-4. ">Belgian Study 1996</a>). These results are not included in the meta‐analysis, but they provide relevant information and so contribute to the outcome. </p> <p><b><sup>c</sup> </b>Different measures presented ‐ change from baseline or post intervention measures ‐ therefore, data from all studies could not be pooled. </p> <p><b><sup>d</sup> </b>Within the study (<a href="./references#CD002202-bbs2-0005" title="ArmstrongFD , SteinbergMH , BallasSK , AtagaKI , WaclawiwMA , KutlarA , et al. Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea. Blood2009;(22). [ABSTRACT NO: 1543] BallasSK , BartonF , CastroO , BellevueR , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Narcotic analgesia use among adult patients with sickle cell anemia. Blood1995;86(10 Suppl 1):642a. BallasSK , BartonF , CastroO , KoshyM , BellevueR . Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia. In: National Sickle Cell Disease Program 21st Annual Meeting; 1996 Mar. 1996:63. BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59. BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA , Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management2010;40(6):870-82. [CENTRAL: 779191] [PMID: 20864308]BallasSK , BausermanRL , McCarthyWF , CastroOL , SmithWR , WaclawiwMA . Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex,age, and geographical location. American Journal of Hematology2010;85(8):613-6. BallasSK , BausermanRL , McCarthyWF , WaclawiwMA , BartonBA . Impact of hydroxyurea on employment among patients with sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2485] BallasSK , BausermanRL , McCarthyWF , WaclawiwMA . The impact of hydroxyurea on career and employment of patients with sickle cell anemia. JAMA2010;102(11):993-9. BallasSK , ConnesP . Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and alpha-thalassemia. European Journal of Haematology2018;101:798-803. [CENTRAL: CN-01922310] [CFGD REGISTER: SC9yy] [EMBASE: 624300746]BallasSK , MarcolinaMJ , DoverGJ , BartonFB . Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology1999;105(2):491-6. BallasSK , MarcolinaMJ , Investigators of the multicenter study of hydroxyurea in sickle cell anemia. In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea. Blood1995;86(10 Suppl 1):140a. BallasSK , McCarthyWF , BausemanRI , CastroOL , SwerdlowPS , SmithW , et al. Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH). Blood2009;114(22). [ABSTRACT NO: 2577] BallasSK , McCarthyWF , BausermanRL , CastroOL , WaclawiwMA , BartonBA . Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia. Blood2009;114(22). [ABSTRACT NO: 2582] BallasSK , McCarthyWF , BausermanRL , ValafarF , WaclawiwM , BartonBA , et al. Definition of the responder to hydroxyurea therapy: revisited. Blood2009;114(22):1513. [ABSTRACT NO: 1513] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. American Journal of Hematology2010;85(8):E16. [CENTRAL: CN-01032746] [CFGD REGISTER: SC9xx] [EMBASE: 70787265]BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanR , et al. Early detection of responders to hydroxyurea therapy. In: 4th Annual Sickle Cell Disease Research and Educational Symposium &amp; Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida. Vol. 26. 2010. [ABSTRACT NO: 030] [CFGD REGISTER: SC9pp] BallasSK , McCarthyWF , GuoN , BrugnaraC , KlingG , BausermanRL , et al. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin2010;34(5):424-9. [CENTRAL: CN-00768857] [CFGD REGISTER: SC9ww] [PMID: 20854115]BallasSK , McCarthyWF , GuoN , DeCastroL , BellevueR , BartonBA , et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. Journal of the National Medical Association2009;101(10):1046-51. [CENTRAL: 730469] [PMID: 19860305]BartonF , TerrinM , MooreR , McMahonRP , CharacheS . Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in sickle cell anemia (MSH). The MSH Investigators. Controlled Clinical Trials1996;17(2 Suppl):67S. BrandonAE , McCarthyWF , BartonFB , TerrinML . Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study. Clinical Trials2004;2:209. CharacheS , BartonFB , MooreRD , TerrinML , SteinbergMH , DoverGJ , et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive &quot;switching&quot; agent. Medicine1996;75(6):300-26. CharacheS , TerrinM , MooreRD , DoverGJ , BartonFB , EckertSV , et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. New England Journal of Medicine1995;332(20):1317-22. CharacheS , TerrinML , MooreRD , DoverGJ , McMahonRP , BartonFB , et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Controlled Clinical Trials1995;16(6):432-46. CharacheS . Effects of hydroxyurea therapy in patients with sickle cell anemia. Australian and New Zealand Journal of Medicine1996;26:326. CharacheS . Experimental therapy of sickle cell disease. Use of hydroxyurea. American Journal of Pediatric Hematology/Oncology1994;16(1):62-6. CharacheS . Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology1997;34(3 Suppl 3):15-21. CharacheS . Preventing pain in sickle cell anemia (HB SS): baseline data from patients in a hydroxyurea trial. Blood1993;82(10 Suppl):356a. DrawzP , AyyappanS , NouraieM , SarafS , GordeukV , HostetterT , et al. Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American Society of Nephrology2016;11(2):207-15. [CFGD REGISTER: SC246j / SC9uu] HackneyAC , HeizerW , HoffmanE , JonesS , StrayhornD , OrringerEP . Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia. Blood1995;86(10 Suppl 1):141a. HackneyAC , HezierW , GulledgeTP , JonesS , StrayhornD , BusbyM , et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clinical Science1997;92(5):481-6. HandyC , BartonF , MooreR , McMahonR , EckertS , TerrinM . Dose titration in the multicentre study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1996;17(Suppl 2):92S. HeizerWD , HackneyAC , BusbyM , GulledgeT , JonesS , StrayhornG , et al. The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): an ancillary study to the multicentre study of hydroxyurea (MSH). In: National Sickle Cell Disease Program 18th Annual Meeting; 1993 May. 1993:117a. KutlarA , BartonF , TerrinM , SteinbergMH . Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: the MSH at 7-8 years follow-up. In: National Sickle Cell Disease Program 25th Annual Meeting; 2001 Apr. 2001. [ABSTRACT NO: #126] McCarthyWF , BausermanRL , BartonBA , GuoN , BallasSK , SmithW . Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial. Blood2006;11:3807. [ABSTRACT NO: 3807] McMahonRP , WaclawiwMA , GellerNL , BartonFB , TerrinML , BondsDR . An extension of stochastic curtailment for incompletely reported events: the multicenter study of hydroxyurea in sickle cell anemia (MSH). Controlled Clinical Trials1997;18(5):420-30. MooreRD , CharacheS , TerrinM , BartonFB , BallasSK . Cost-effectiveness of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Meeting; 1999 Mar. 1999:210. MooreRD , CharacheS , TerrinML , BartonFB , BallasSK , and the investigators of the MSH study of hydroxyurea in sickle cell anemia. Cost-effectiveness of hydroxyurea in sickle cell anemia. American Journal of Hematology2000;64(1):26-31. NCT00000586. Multicenter study of hydroxyurea in patients with sickle cell anemia (MSH). https://ClinicalTrials.gov/show/NCT00000586 (first received 28 October 1999). OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergC . The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS). In: National Sickle Cell Disease Program 21st Meeting; 1996 Mar. 1996:131. OrringerEP , JonesS , StrayhornD , HoffmanE , ParkerJ , GreenbergCS . The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia. Blood1996;88(10 Suppl 1):496a. PeckerLH , HussainS , ChristiansonMS , LanzkronS . Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology2020;191(5):880-7. [CENTRAL: CN-02142742] [CFGD REGISTER: SC9aaa] [EMBASE: 2005676164] [PMID: 32712966]PeckerLH , SalzbergE , ChaturvediS , ZhaoN , ChristiansonMS , LanzkronSM . Anti-mullerian hormone, a measure of ovarian reserve, is low in female subjects in the multi-center study of hydroxyurea. Blood2019;134:890. [CENTRAL: CN-02048864] [CFGD REGISTER: SC9zz] [EMBASE: 630318098]SmithWR , BallasSK , McCarthyWF , BausermanRL , SwerdlowPS , SteinbergMH . The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine2011;12(5):697-705. SmithWR , BausemanRL , McCarthyWF , BartonBA , BallasSK . Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia. In: 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009. [ABSTRACT NO: 253] SteinbergMH , BallasS , BartonF , TerrinM , theMSH . Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH). Blood1997;90(10 Suppl 1 Pt 1):444a. SteinbergMH , BartonF , CastroO , KoshyM , EckmanJ , TerrinM . Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years. Blood1999;94(10 Suppl 1 Pt 1):644a-5a. SteinbergMH , BartonF , CastroO , PegelowCH , BallasSK , KutlarA , et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;289(13):1645-51. SteinbergMH , BartonF , CastroO , RamirezG , BellevueR , TerrinM , et al. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood2000;96(11 Pt 1):485a. SteinbergMH , CastroO , BallasSK , BartonF , TerrinM . The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years. Blood1998;92(10 Suppl 1 Pt 1):496a. SteinbergMH , LuZH , BartonFB , TerrinML , CharacheS , DoverGJ . Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood1997;89(3):1078-8. SteinbergMH , LuZH , BartonM , TerrinS , CharacheS , DoverG , et al. Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU). Blood1995;86(10 Suppl 1):418a. SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematolology2010;85(6):403-8. SteinbergMH . Determinants of fetal hemoglobin response to hydroxyurea. Seminars in Hematology1997;3(Suppl 3):8-14. SteinbergMH . Mortality at 3-5 years: the multicenter study of hydroxyurea in sickle cell anemia (MSH). In: National Sickle Cell Disease Program Annual Meeting; 1997 Sep. 1997:68. TerrinML , BartonFB , BondsD , BallasSK , SwerdlowP , PegelowCH , et al. Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia. In: National Sickle Cell Disease Program 23rd Annual Meeting; 1999 Mar. 1999:161. ">MSH 1995</a>, reported in <a href="./references#CD002202-bbs2-0050" title="BallasSK , BartonFB , WaclawiwMA , SwerdlowP , EckmanJR , PegelowCH , et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes2006;4:59.">Ballas 2006</a>), to allow for multiple statistical testing of the quality of life domains, a P value &lt; 0.01 was considered significant. Therefore this result is not interpreted as significant in the study publication. </p> <p><b><sup>e</sup> </b>Downgraded once due to applicability: only individuals with HbSS or HbSβº‐thalassaemia genotypes were included therefore the results are not applicable to individuals with the HbSC genotype. </p> <p><b><sup>f</sup> </b>Downgraded once due to inconsistency: substantial heterogeneity present in the analyses of HbF (%) (I² &gt; 90%), indicating uncertainty in the pooled result due to the difference in the results of the individual studies. </p> <p><b><sup>g</sup> </b>Downgraded once due to imprecision/uncertainty: caution is encouraged regarding the interpretation of these results as not all participants contributed data to all quality of life domains and the study publication defines statistical significance differently to this review. </p> <p><b><sup>h</sup> </b>Downgraded once due to imprecision/uncertainty: caution is encouraged regarding the interpretation of these results due to the number of separate outcomes considered in analysis and the increased probability of a statistical type I error. Also, where data were pooled, the individual study proportions of some adverse events were very different. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea compared with placebo for sickle cell disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002202-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea and phlebotomy compared to transfusion and chelation for people with sickle cell disease and an increased risk of stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Hydroxyurea and phlebotomy compared to transfusion and chelation for people with sickle cell disease and an increased risk of stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population</b>: adults and children with sickle cell disease and an increased risk of stroke </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: hydroxyurea and phlebotomy </p> <p><b>Comparison</b>: transfusion and chelation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Transfusion and chelation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea and phlebotomy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain alteration</b>: proportion experiencing serious VOC or sickle‐related pain events </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>718 per 1000</p> <p>(339 to 1000 per 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.37 (95% CI 1.59 to 7.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>d,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference between treatment groups in terms of all pain events (serious and non‐serious) in 1 study (RR 1.03, 95% CI 0.81 to 1.30). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life‐threatening illness</b> </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant difference between groups in life‐threatening neurological events, hepatobiliary disease and splenic sequestration; significantly more ACS and infections and infestations in the hydroxyurea and phlebotomy compared to the transfusion and chelation group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during the study</b> (all deaths) </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 death occurred in the transfusion and chelation group of 1 study<b><sup>a</sup> </b>. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 death occurred in the hydroxyurea and phlebotomy group of 1 study<b><sup>a</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99 (95% CI 0.06 to 15.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>d,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of HbF</b> (%) </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant increase in HbF(%) in the hydroxyurea and phlebotomy group compared to the transfusion and chelation group for both studies (different measures presented)<b><sup>b</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of ANC</b> </p> <p>Follow‐up: 24 to 30 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant decrease in ANC in the hydroxyurea and phlebotomy group compared to the transfusion and chelation group for both studies (different measures presented)<b><sup>b</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported<b><sup>c</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events or toxicity</b>: differences in rates of specific adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a statistically significant difference in terms of immune disorders (more in transfusion and chelation group), reticulocytopenia, neutropenia and anaemia (more in hydroxyurea and phlebotomy group) in 1 study and the rate of adverse events was balanced across groups in the other study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>d,f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>The basis for the <b>assumed risk</b> is the event rate in the control group unless otherwise stated in the comments and footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ACS</b> : acute chest syndrome; <b>ANC</b> : absolute neutrophil counts; <b>CI</b> : confidence interval; <b>HbF</b> : foetal haemoglobin; <b>NA</b> : not applicable; <b>RR</b> : risk ratio; <b>VOC</b>: vaso‐occlusive crisis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b><sup>a</sup> </b> Absolute data presented for number of deaths as the confidence interval of the relative effect is very large due to the small number of events.<br/><b><sup>b</sup> </b> Different measures presented ‐ mean or median change from baseline ‐ therefore data from all studies could not be pooled.<br/><b><sup>c</sup> </b>Quality of life data were collected in <a href="./references#CD002202-bbs2-0009" title="AygunB ,  WruckLM ,  SchultzWH ,  MuellerBU ,  BrownC ,  Luchtman-JonesL ,  et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology2012;87(4):428-30. AygunB , MortierN , RogersZR , OwenW , FuhB , GeorgeA , et al. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the twitch experience. Blood2016;128(22):1018. [CFGD REGISTER: SC276i] De MontalembertM , BenkerrouM , GrosseR , KordesU , BrousseV , PondarreC , et al. Assessment of hematological data in a cohort of European children with sickle cell anemia treated with hydroxyurea: can European centers apply today the lessons from the twitch study?Blood2016;128(22):2494. [CFGD REGISTER: SC276k] HeltonKJ , RobertsD , SchultzWH , DavisBR , KalfaTA , PresselSL , et al. Effects of chronic transfusion therapy on MRI and MRA in children with sickle cell anemia. Blood2014;124(21):4052. [CENTRAL: 1261883] ImranH , AygunB , DavisBR , PresselSL , Herbert SchultzW , JacksonSM , et al. Effects of chronic transfusion therapy on transcranial doppler ultrasonography velocities in children with sickle cell anemia at risk for primary stroke: baseline findings from the Twitch trial. Blood2014;124(21):87. [CENTRAL: 1261882] NCT01425307. Transcranial doppler (TCD) with transfusions changing to hydroxyurea (TWiTCH). www.clinicaltrials.gov/ct2/show/nct014253072011. WareRE , DavisBR , SchultzWH , BrownC , AygunB , SarnaikSA , et al. TCD with transfusions changing to hydroxyurea (TWITCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Blood2015;126(23):3. [CFGD REGISTER: SC276e] WareRE , DavisBR , SchultzWH , BrownRC , AygunB , SarnaikS , et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet2016;387:661-70. WareRE , LaneA , SchultzWH , ImranH , LeeMT , HeeneyMM , et al. Variation in serial TCD velocity measurements in the TCD with transfusions changing to hydroxyurea (TWiTCH) trial. Blood2016;128(22):1019. [CFGD REGISTER: SC276n] WoodJC , CohenA , AygunB , ImranH , Luchtman-JonesL , Thompson. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia - baseline findings from the Twitch trial. Blood2013;122(21):2238. [CENTRAL: 1261881] WoodJC , CohenAR , PresselSL , AygunB , ImranH , Luchtman‐JonesL . Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. British Journal of Haematology2016;172(1):122-30. [CFGD REGISTER: SC276c] WoodJC , OfeliaA , HeeneyMM , GeorgeA , GaugerC , FuhB , et al. Changes in extrahepatic iron load in response to iron chelation versus phlebotomy: observations from the twitch trial. Blood2016;128(22):202. [CFGD REGISTER: SC276j] WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , LeeMT , et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. [CENTRAL: 1090263] [EMBASE: 2015311270] [CRS: 5500050000000271]WoodJC , PresselS , RogersZR , OdameI , KwiatkowskiJL , Lee MT et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology2015;90(9):806-10. WoodJC , St PierreT , AygunB , MortierN , SchultzWH , PicconeCM , et al. Agreement between R2 and R2* liver iron estimates is independent of the type of iron removal therapy: results from the twitch trial. Blood2016;128(22):1274. [CFGD REGISTER: SC276l] ">TWiTCH 2016</a>; to date, the primary results of this study have been published but not the quality of life data. When available, quality of life data will be included in an update of this review.<br/><b><sup>d</sup> </b> Downgraded once due to applicability: only children with HbSS or HbSβº‐thalassaemia were included therefore the results are not applicable to adults or individuals with the HbSC genotype.<br/><b><sup>e</sup> </b> Downgraded once due to imprecision: small number of events and large CI around the relative effect.<br/><b><sup>f</sup> </b>Downgraded once due to imprecision/uncertainty: caution is encouraged regarding the interpretation of these results due to the number of separate outcomes considered in analysis and the increased probability of a statistical type I error. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea and phlebotomy compared to transfusion and chelation for people with sickle cell disease and an increased risk of stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002202-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea compared with observation for people with sickle cell disease and an increased risk of stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Hydroxyurea compared with observation for people with sickle cell disease and an increased risk of stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population</b>: adults and children with sickle cell disease and an increased risk of stroke </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: hydroxyurea </p> <p><b>Comparison</b>: observation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Observation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain alteration</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life‐threatening illness</b> </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant differences between groups in terms of ACS, blood transfusions required or acute splenic sequestration. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during the study</b> </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of HbF</b> </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant increase in HbF in the hydroxyurea group compared to the observation group<b><sup>a</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of ANC</b> </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant decrease in ANC in the hydroxyurea group compared to the observation group<b><sup>a</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported<b><sup>b</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events or toxicity:</b> differences in rates of specific adverse events </p> <p>Follow‐up: 15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant differences between groups in terms of transient neutropenia, reticulocytopenia, parasite infestation, headache and dizziness. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>The basis for the <b>assumed risk</b> is the event rate in the control group unless otherwise stated in the comments and footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ACS</b> : acute chest syndrome; <b>ANC</b> : absolute neutrophil counts; <b>CI</b> : confidence interval; <b>HbF</b> : foetal haemoglobin; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Median values reported so data cannot be entered into analysis.<br/><sup>b</sup>Outcome was not collected or presented due to early termination of study.<br/><sup>c</sup>Downgraded twice due to serious imprecision: study terminated early with only 22 of target 100 participants recruited. Small number of participants included in final analyses, which are likely to be underpowered.<br/><sup>d</sup>Downgraded once due to applicability: only children with HbSS or HbSβº‐thalassaemia were included therefore the results are not applicable to adults or individuals with HbSC genotype. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea compared with observation for people with sickle cell disease and an increased risk of stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002202-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea compared with no hydroxyurea for people with sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Hydroxyurea compared with no hydroxyurea for sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population</b>: adults and children with sickle cell disease </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: hydroxyurea </p> <p><b>Comparison</b>: no hydroxyurea </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No hydroxyurea</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain alteration</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Life‐threatening illness</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death during the study</b> </p> <p>Follow‐up: 11 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths occurred.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 44</p> <p>(1 study)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of HbF</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a significant increase in HbF in the hydroxyurea group compared to the no hydroxyurea group<sup>1</sup>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 44</p> <p>(1 study)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of ANC</b> </p> <p>Follow‐up: 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no significant difference in ANC between treatment groups<b><sup>a</sup> </b>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 44</p> <p>(1 study)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>Follow‐up: NA</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events or toxicity</b> </p> <p>Follow‐up: 11 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Vaso‐occlusive pain crises, headache/migraine, upper respiratory infection, skin rash diarrhoea and abdominal pain were the most common adverse events during the trial and these events were evenly distributed across treatment groups (not separated by group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 44</p> <p>(1 study)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>The basis for the <b>assumed risk</b> is the event rate in the control group unless otherwise stated in the comments and footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ANC</b> : absolute neutrophil counts; <b>CI</b> : confidence interval; <b>HbF</b> : foetal haemoglobin; <b>NA</b> : not applicable; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence.<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b><sup>a</sup> </b>Due to the factorial design of the study (22 participants randomised to a treatment arm including hydroxyurea and 22 randomised to a treatment arm without hydroxyurea), the results are not entered into analysis. All results of this trial are considered exploratory (<a href="./references#CD002202-bbs2-0003" title='NCT00532883. Hydroxyurea and magnesium pidolate to treat people with hemoglobin sickle cell disease. https://ClinicalTrials.gov/show/NCT00532883 (first received 21 September 2007). WangW , BrugnaraC , SnyderC , WynnL , RogersZ , KalinyakK , et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. British Journal of Haematology2011;152(6):771-6. [CENTRAL: 801819] [PMID: 21275961]WangWC , SnyderC , BrugnaraC , TelenMJ , SteinbergMH , WynnLW , et al. Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the "CHAMPS" trial. Blood2009;22. [ABSTRACT NO: 819] '>CHAMPS 2011</a>).<br/><b><sup>b</sup> </b> Downgraded once due to indirectness: the factorial design of the study makes comparison of hydroxyurea to no hydroxyurea indirect.<br/><b><sup>c</sup> </b> Downgraded once due to imprecision and risk of bias: the study was terminated early with only 44 out of 188 participants recruited and outcome data are presented for only those who completed each follow‐up time.<br/><b><sup>d</sup> </b>Downgraded once due to applicability: participants with HbSC were included therefore the results are not applicable to individuals with HbSS or HbSβº‐thalassaemia genotypes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings ‐ Hydroxyurea compared with no hydroxyurea for people with sickle cell disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002202-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Clinical events and markers of response in Jain 2012</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>18 months</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>18 months</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Clinical events (number of events per participant per year)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VOC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.13 (8.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.46 (3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 (3.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.43 (0.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13 (0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.13 (0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.98 (0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.13 (6.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.56 (2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.59 (2.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Haematological parameters</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.29 (0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.21 (0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.90 (0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbF(%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.8 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.21 (6.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.92 (5.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reticulocytes (x10⁵/mm³)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.83 (0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 (0.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.81 (0.67)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leucocytes (x10³/mm³)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.36 (6.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.54 (5.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.26 (4.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.38 (2.85)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelets (x10³/mm³)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.78 (0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.01 (0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.91 (0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.06 (0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RBC (x10⁶/mm³)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.89 (0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.98 (0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.84 (0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.11 (0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total bilirubin (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.32 (1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.27 (1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.71 (0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Values are mean (standard deviation); P values are calculated using independent t‐test.</p> <p>Hb: haemoglobin<br/>HbF: foetal haemoglobin<br/>RBC: red blood count<br/>VOC: vaso‐occlusive crises<br/>WBC: white blood count </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Clinical events and markers of response in Jain 2012</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002202-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Laboratory measurements from MSH 1995</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2 years</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>2 years</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC (10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 (3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 (3.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3 (3.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.2 (2.8)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutrophils (10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9 (2.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9 (2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7 (2.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (2.0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelets (10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>468 (147)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>399 (124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457 (130)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423 (122)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.5 (1.3)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCV (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.9 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.2 (4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.1 (4.2)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCV (fl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (9)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reticulocytes (10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327 (98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 (100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325 (94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 (99)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbF (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (3.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6 (6.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 (3.3)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F cells (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (18)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F reticulocytes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (7)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0036</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dense cells (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (7)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Creatinine (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (0.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (0.5)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total bilirubin (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7 (2.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2 (4.6)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Direct bilirubin (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (0.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7 (2.2)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspartate aminotransferase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (27)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alkaline phosphatase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119 (71)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Values are mean (standard deviation); P values are calculated using independent t‐test.</p> <p>Hb: haemoglobin<br/>HbF: foetal haemoglobin<br/>MCV: mean corpuscular volume<br/>PCV: packed cell volume<br/>WBC: white blood count </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Laboratory measurements from MSH 1995</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002202-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Laboratory evaluations from the SWiTCH trial</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea and</b> </p> <p><b>phlebotomy group (n = 67)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Transfusions and</b> </p> <p><b>chelation group (n = 66)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbF (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.9 (92 to 22.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.2 (‐0.8 to 0.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ANC (x10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.3 (‐5.1 to ‐1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (‐1.3 to 2.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 (‐0.7 to 0.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 (‐0.5 to 0.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.898</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐50.9 (‐66.8 to ‐33.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 (‐12.7 to 6.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbS (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.0 (21.7 to 46.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (‐7.5 to 12.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCV (fL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.5 (7.5 to 28.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 (‐2.0 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC (x10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.4 (‐8.1 to ‐2.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 (‐2.0 to 2.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARC (x10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐149.1 (‐231.0 to ‐19.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.8 (‐88.2 to 93.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelets (x10⁹/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐83.0 (‐171.0 to ‐8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐28.0 (‐70.0 to 18.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total bilirubin (mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1 (‐1.9 to ‐0.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (‐0.3 to 1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LIC (mg Fe/g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.2 (‐2.8 to 7.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.2 (‐5.5 to 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48888</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum ferritin (ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐966.0 (‐1629.0 to 49.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1159.5 (‐662.0 to 2724.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LDH (U/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐67.0 (‐143.0 to 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.5 (‐74.0 to 74.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ANC: absolute neutrophil count<br/>ARC: absolute reticulocyte count<br/>Hb: haemoglobin<br/>HbA: adult haemoglobin<br/>HbF: foetal haemoglobin<br/>HbS: sickle haemoglobin<br/>LDH: lactate dehydrogenase<br/>LIC: liver iron concentration<br/>MCV: mean corpuscular volume<br/>WBC: white blood count </p> <p>Values are median change from baseline and interquartile range. P values are calculated using Wilcoxon rank sum test. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Laboratory evaluations from the SWiTCH trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002202-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Laboratory evaluations from the SCATE trial</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea (n = 11)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Observation (n = 11)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb (g/dL)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCV (fL)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARC (x10⁹/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐33.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC (x10⁹/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ANC (x10⁹/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Platelets (x10⁹/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐76</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbF (%)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight (kg)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Height (cm)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ANC: absolute neutrophil count<br/>ARC: absolute reticulocyte count<br/>Hb: haemoglobin<br/>HbF: foetal haemoglobin<br/>MCV: mean corpuscular volume<br/>WBC: white blood count </p> <p>Values are median change from baseline and P values are calculated using Wilcoxon rank sum test. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Laboratory evaluations from the SCATE trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002202-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Pregnancies in the MSH Study</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Pregnancy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hydroxyurea</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal full‐term delivery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elective termination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Partners of patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normal full‐term delivery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spontaneous abortion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Still pregnant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>TOTAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Pregnancies in the MSH Study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/full#CD002202-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002202-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hydroxyurea versus placebo for participants with sickle cell disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Pain crises <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Mean annual crisis rate at 2 years (all crises)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Mean annual crisis rate at 2 years (all crises requiring hospitalisation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Number of vaso‐occlusive crises after 18 months of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Proportion experiencing pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Proportion experiencing pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Proportion with serious vaso‐occlusive crisis (SAE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Proportion experiencing life‐threatening events during study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Acute chest syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.29, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Hepatic sequestration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.12, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Patients transfused</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.53, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Splenic sequestration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.48, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 Bacteremia or sepsis (SAE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.33, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.7 Anaemia (SAE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Number of life‐threatening events during study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Blood transfusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Hospitalisations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Duration of hospitalisation (days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Deaths during the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 All deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.19, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Deaths related to SCD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.09, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Change from baseline in foetal haemoglobin (HbF%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.88 [8.72, 11.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Change from baseline in absolute neutrophil count (ANC, x10⁹/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.38, ‐1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Foetal haemoglobin (HbF%) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.24 [5.28, 7.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Neutrophil response (x10⁹/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Neutrophils (x10⁹/L) at 10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐2.51, ‐1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Neutrophils (x10⁹/L) at the end of the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.47 [‐1.87, ‐1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Change from baseline in haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.09, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Change from baseline in mean corpuscular volume (fL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.91 [5.71, 8.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Change from baseline in white blood cell (WBC) count (x10⁹/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.37 [‐5.65, ‐3.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Change from baseline in absolute reticulocyte count (x10⁹/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐117.38 [‐141.47, ‐93.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Change from baseline in reticulocytes (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Change from baseline in platelet count (10⁹/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐23.14 [‐58.14, 11.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Change from baseline in creatinine (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Change from baseline in total bilirubin (mg/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Change from baseline in alanine transferase (ALT) (U/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Haemoglobin (g/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 At 10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.19, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 At the end of the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.94, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Mean corpuscular volume (fL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 At 10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.30 [9.69, 14.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 At the end of the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.30 [6.55, 10.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 White blood cells (WBC) count at the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.68 [‐3.28, ‐2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Reticulocytes (10⁹/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 Reticulocytes (10⁹/L) at 10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 Reticulocytes (10⁹/L) at the end of the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Reticulocytes (10⁵/mm³) at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐0.90, ‐0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Total bilirubin (mg/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 At the end of the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.56 [‐1.90, ‐1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Platelet count (10⁹/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.1 Platelet count (x10⁹/L) at 10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐35.00 [‐75.19, 5.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.2 Platelet count (x10⁹/L) at the end of the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐39.50 [‐62.77, ‐16.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Platelet count (10³/mm³) at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.16, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Packed cell volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.1 Packed cell volume (%) at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 F reticulocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.1 F reticulocytes at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 F cells <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.1 F cells (%) at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Red blood count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.1 Red blood count (10⁶/mm³) at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Dense cells <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.1 Dense cells (%) at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Leucocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.1 Leucocytes (10³/mm³) at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Alanine transferase (ALT) (U/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Creatinine (mg/dL) at the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Aspartate aminotransferase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.1 Aspartate aminotransferase at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.36 Alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.36.1 Alkaline phosphatase at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.37 Change from baseline in growth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.37.1 Height (cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.37.2 Weight (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.37.3 Head circumference (cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.38 Quality of life: general health perception <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.38.1 General health perception at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.38.2 General health perception at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.38.3 General health perception at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.38.4 General health perception at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.39 Quality of life: pain recall <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.1 Pain recall at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.2 Pain recall at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.3 Pain recall at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.4 Pain recall at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.40 Quality of life: social function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.1 Social function at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.2 Social function at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.3 Social function at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.4 Social function at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.41 Changes in 'Ladder of Life' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.1 Changes in 'Ladder of Life' at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.2 Changes in 'Ladder of Life' at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.3 Changes in 'Ladder of Life' at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.4 Changes in 'Ladder of Life' at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.42 Proportion of participants with signs of organ damage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.1 New leg ulcers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.2 Aseptic necrosis (humerus or femur)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.3 Decreased spleen function at exit (compared to baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.43 Signs of organ damage ‐ change from baseline in DTPA GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.44 Signs of organ damage ‐ change from baseline in Howell‐Jolley body (per 10<sup>6</sup> red blood cells) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.45 Signs of organ damage ‐ change from baseline in pitted cells (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.46 Signs of organ damage ‐ change from baseline in spleen: liver ratio of counts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.47 Signs of organ damage ‐ change from baseline in spleen volume (cm<sup>3</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.48 Signs of organ damage ‐ change from baseline in creatinine (mg/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.49 Signs of organ damage ‐ change from baseline in Schwartz GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.1 Schwartz glomerular filtration rate (mL/min per 1.73m2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.50 Signs of organ damage ‐ change from baseline in cystatin C <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.51 Signs of organ damage ‐ change from baseline in urine osmolality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.52 Signs of organ damage ‐ change from baseline in urine pH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.53 Signs of organ damage ‐ change from baseline in urine‐specific gravity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.54 Signs of organ damage ‐ change from baseline in total kidney volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.55 Signs of organ damage ‐ change from baseline in TCD ultrasound velocity (time‐averaged mean maximum velocity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.56 Signs of organ damage ‐ change from baseline in CNS measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.56.1 Bayley Mental Development Index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.56.2 Bayley motor performance development index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.57 Proportion of participants experiencing adverse events and toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.1 Hair loss at 1 or 2 visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.69, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.2 Hair loss at 3 or more visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.31, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.3 Skin rash at 1 or 2 visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.62, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.4 Skin rash at 3 or more visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.58, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.5 Fever at 1 or 2 visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.55, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.6 Fever at 3 or more visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.7 Gastrointestinal disturbance at 1 or 2 visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.50, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.8 Gastrointestinal disturbance at 3 or more visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.9 Other abnormalities at 1 or 2 visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.33, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.10 Other abnormalities at 3 or more visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.83, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.11 Hospitalisation (for any reason)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.62, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.12 Dactylitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.39, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.13 Sepsis or bacteraemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.20, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.14 Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.15 Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.44, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.16 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [1.00, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.17 Elevated bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.18 Priapism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.26, 8.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.19 Splenomegaly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.61, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.20 Absolute neutrophil count &lt; 500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.50, 12.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.21 Absolute neutrophil 500 to 1250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [1.58, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.22 Alanine transaminase &gt; 150 U/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.19, 21.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.23 Skin and subcutaneous disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.75, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.24 Splenic sequestration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.36, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.25 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 99.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.26 Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.38, 129.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.27 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.95 [0.24, 101.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.28 Acute chest syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.52, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.29 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.30 Infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.21, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.31 Reticulocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.15, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.57.32 Elevated AST/ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.58 Proportion with SCA‐related events (composite outcome) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hydroxyurea versus placebo for participants with sickle cell disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002202-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Proportion experiencing pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Vaso‐occlusive or sickle cell‐related pain (all)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Vaso‐occlusive or sickle cell‐related pain (serious)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [1.59, 7.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion experiencing life‐threatening events during study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Stroke (secondary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.78 [0.86, 253.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Transient ischaemic attack (primary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.21, 4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Transient ischaemic attack (secondary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.25, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Other neurological event (primary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.07, 15.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Acute chest syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [1.25, 6.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.6 Infections and infestations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.65 [1.05, 12.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.7 Splenic sequestration or splenectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.8 Hepatobiliary disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.07, 15.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.9 Total with serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.17, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.10 Total with sickle cell related, non‐neurological adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [1.42, 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Deaths during the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Change from baseline in foetal haemoglobin (HbF %) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Change from baseline in absolute neutrophil count (x10⁹/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Change from baseline in mean corpuscular volume (fL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Change from baseline in sickle haemoglobin (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Change from baseline in haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Change from baseline in absolute reticulocyte count (10⁹ / L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Change from baseline in white blood count (10⁹ / L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Change from baseline in platelets (10⁹/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Change from baseline in total bilirubin (mg/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Change from baseline in liver iron concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Change from baseline in serum ferritin (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Change from baseline in lactate dehydrogenase (U/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Signs of organ damage ‐ CNS measures at the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 Final TCD ultrasound velocity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Proportion of participants experiencing non‐neurological adverse events and toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 Infections and infestations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.3 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.4 Musculoskeletal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.5 Immune system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.6 Cholelithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.7 Cholecystitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.8 Asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.9 Acute chest syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.10 Renal or urinary disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.11 Priapism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.12 Catheter‐related complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.13 Cardiac disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.14 Hyperbilirubinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.15 Alanine transaminase increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.16 Aspartate transaminase increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.17 Serum creatinine increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.18 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.19 Reticuloctopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.20 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.21 Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.22 Sickle cell pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.23 Sickle cell‐related events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.24 All adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hydroxyurea and phlebotomy compared to transfusion and chelation for participants with SCD and risk of stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002202-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Hydroxyurea compared to observation for participants with SCD and risk of stroke</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Proportion experiencing life‐threatening events during the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Vaso‐occlusive events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Acute splenic sequestration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Blood transfusions required</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Signs of organ damage ‐ proportion of participants with a change in CNS measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Participants converting from conditional to abnormal TCD ultrasound velocity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Signs of organ damage ‐ change from baseline in CNS measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 TCD ultrasound velocity (time‐averaged mean maximum velocity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Adverse events and toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Headaches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 Transient neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.4 Reticulocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.5 Parasite infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Hydroxyurea compared to observation for participants with SCD and risk of stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002202.pub3/references#CD002202-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002202.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002202-note-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002202-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002202-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002202-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD002202-note-0014">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD002202-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002202-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002202-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002202\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002202\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002202\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002202\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002202\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002202.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002202.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002202.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002202.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002202.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718217374"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002202.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718217378"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002202.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dcaed2cd1f3fd',t:'MTc0MDcxODIxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 